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Abstract
This thesis describes an investigation of the andmalarial activity of a number of 
novel 10-phenylflavin analogues and includes a study of the structure activity 
relationships between several distinct series. This work was undertaken in order to 
define the structural features required for activity and to find analogues with improved 
activity and reduced toxicity.
One series of flavins was prepared to help identify the substitution profile in the 
10-phenyl moiety associated with the highest biological activity. Another series of 
compounds was prepared in which the substituents at the 3-N position were varied. This 
group of flavins gave some insight into the role that lipophility played in activity.
Altering the benzenoid ring-3 of the flavin to produce a series of 7,8,9-substituted 
3-methyl-10-(substituted phenyl)flavins and 10-(4'-chlorophenyl)-3-methyl-6,8- 
diazaflavin showed that changes to the ring-3 were not well tolerated.
Removing the ring-3 of the flavin to produce a series of 3-methyl-8-(substituted 
phenyl)pteridine-2,4(3//,8//)-diones showed that the 3-membered ring structure of the 
flavin was required for in vivo activity.
All of the above compounds were tested for antimalarial activity and the results 
discussed. Some of the above compounds were tested for antibabesial and anti-HTV 
activity and found to be inactive. The compound 3-ethyl-10-(3'-trifluoromethyl)flavin 
was tested for anticoccidial activity and found to be active.
The synthesis and some of the spectral properties of the above compounds are 
described and discussed.
The possibility that these flavins might exert their antimalarial action via the 
inhibition of host glutathione reductase was investigated and discounted.
Publications arising from this thesis
Manuscripts
Halladay PK, Hunt NH, Butcher GA, Cowden WB. Antimalarial action of flavin 
analogues seems not to be due to inhibition of glutathione reductase of host erythrocytes. 
Biochem Pharmacol 1990; 39: 1063-1065.
Halladay PK, Cowden WB. 3-Methyl-8-(substituted phenyl)pteridine-2,4(3//,8//)- 
diones as potential antimalarials. Aust J Chem 1990; 43: 1449-1454.
Abstracts
Halladay P, Hunt NH, Clark LA, Cowden WB. Identification of analogues of 
10-(substituted phenyl)-3-methylflavin with increased antimalarial activity. (SP12). 
Proceedings of the Australian Biochemical Society, Vol. 20, 1988.
Halladay P, Hunt NH, Clark LA, Cowden WB. Identification of analogues of 
10-(substituted phenyl)-3-methylflavin with increased antimalarial activity. (Abstract 
431). Chemistry International Conference RACI, 1989.
Nomenclature
In this thesis the following common names have been used; primary 
benzenamines are referred to as anilines, pyrimidine-2,4( l//,3//)-diones 
are referred to as uracils and benzo[g]pteridine-2,4(3//,10//)-diones are 
referred to as flavins.
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1CHAPTER 1 Introduction
1-1 Malaria
1-1.1 The importance of malaria
Malaria is one of the world's major health problems. This is due to the wide 
distribution of the disease, the severity of its pathology and the resulting hindrance to 
socioeconomic development.
Malaria is distributed over approximately 100 countries, mostly in the tropical and 
highly populated areas of Africa, Asia, Central and South America. This means nearly 
45% of the world's population live in malaria endemic or potentially endemic areas [1,2]. 
In 1988 five million cases of malaria were reported world-wide (excluding Africa), 
though the actual number is probably much higher as many cases go unreported. 
According to the World Health Organization (WHO) 100 million people are clinically ill 
with malaria at any given time and around one million die from it each year [2-4].
Malaria is not only a problem confined to countries in which its infected vector is 
present. The greatly increased amount of travel to infected areas due to tourism or 
business from malaria free areas has lead to many cases of "imported" malaria in 
countries such as Britain, the United States, France and Australia [4-6].
1-1.2 Malaria - the disease
Malaria is an infectious disease caused by parasites belonging to the genus 
Plasmodium. The large number of species in this genus have a great variety of hosts 
including mammals, reptiles and birds. Malaria parasites, to a large extent, are host 
specific and are only known to parasitize other species when they are closely related to 
the normal host [7].
Human malaria is caused by four plasmodial species, these are Plasmodium 
ovale, P. malariae, P. vivax and P. falciparum. P. vivax and P. falciparum are the 
species of greatest epidemiological importance as they are responsible for most human
malaria. P .falciparum is the cause of malignant tertian malaria which often produces a 
sudden intense disease in the non-immune patient. If untreated the infection may rapidly 
progress to fatal termination, this is frequently the result of cerebral malaria. P. vivax, 
the cause of benign tertian malaria, is responsible for much debilitating illness though 
very few deaths. It is the human malaria best known for relapses after treatment.
P. ovale and P. malariae, broadly speaking, are less of a problem as they have a smaller 
distribution, are usually not fatal and have milder clinical symptoms.
The clinical symptoms of malaria may assume protean forms and a worthwhile 
review of the clinical features of malaria are given by Harinasuta and Bunnag [5].
Typical textbook cases of malaria involve a series of chronologically regular attacks. 
Briefly, the attack consists of firstly a feeling of chilliness and shivering followed by a 
feeling of intense heat. Both these stages of the disease are associated with a rise in 
temperature. The paroxysm can last for 2 to 6 hours and ends with profuse sweating and 
a gradual drop in temperature [4,8]. Between each attack patients may be asymptomatic. 
The periodicity of attacks is dependent upon the species of malaria. The intervals 
between attacks are less than 48 hours for P. falciparum, 48 hours for P. vivax and 
P. ovale, and 72 hours for P. malariae. Some of the prominent pathological features of 
the disease are enlargement of the liver and spleen, varying degrees of anaemia, and 
deposition of malarial pigment (the parasitic digestive residue of haemoglobin) in various 
organs and tissues of the body.
1-1.3 Life cycle of the parasite
Malaria parasites undergo a complex life cycle alternating between vertebrate and 
arthropod host. Figure 1-1 displays the life cycle of plasmodia in primates. What 
follows is a brief description of the generalized life cycle of the parasite in primates. 
More precise and exhaustive reviews of this subject are given in books by Peters [9a], 
Gamham [10a], and Peters and Richards [11].
The female Anopheles mosquito is the vector for malaria. Sporozoites are 
injected into the vertebrate host via the saliva during the blood feed of an infected vector.
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Fig 1-1 Life cycle of plasmodia in primates
2Once in the blood stream the sporozoites invade the parenchyma cells of the liver.
In this tissue phase the sporozoite becomes rounded as it develops into a 
schizont. The schizont's nucleus then undergoes repeated divisions. Once this is 
complete the cytoplasm segregates to form many merozoites inside the schizont. The 
now fully developed schizont and liver cell walls rupture to release large numbers of 
merozoites into the blood stream. This tissue phase of asexual reproduction is known as 
tissue or exoerythrocytic schizogony. In mammalian malaria only a single generation of 
exoerythrocytic schizogony occurs. In some species of plasmodia (eg P. vivax) not only 
do the sporozoites undergo tissue schizogony but some also form a latent stage, called 
hypnozoites, which lie dormant for varying time periods before undergoing 
exoerythrocytic schizogony. This latter event accounts for the "recurring" nature of 
P. vivax infections.
The blood phase starts with the invasion of erythrocytes by merozoites released 
from the tissue phase. After entering the cell the invading merozoite feeds on the 
haemoglobin of the cell. This uninuclear feeding form of the parasite is termed a 
trophozoite. The parasite now begins to go through another cycle of asexual 
multiplication. The nuclear material of the parasite increases and undergoes several 
divisions resulting in a number of nuclei which are situated in the cytoplasmic 
syncytium. At this stage the parasite is referred to as a preschizont. The preschizont 
becomes a mature schizont when the cytoplasmic syncytium divides to form completely 
differentiated merozoites. When the mature schizont bursts it liberates the merozoites 
(the number of merozoites released is species dependent) into the blood. These 
merozoites quickly infect other erythrocytes. This cycle of asexual reproduction is 
known as blood schizogony and is associated with disease symptoms.
After infecting a new erythrocyte the merozoite can either initiate a new cycle of 
blood schizogony or transform into either a micro (male) gametocyte or macro (female) 
gametocyte. Blood schizogony continues until either the parasite is completely eradicated 
by drug treatment, the host's immune system or the death of the host.
The sexual phase in the parasite's life cycle begins when the gametocytes are 
taken up by a suitable arthropod. In the insect's midgut the gametocytes shed the
4erythrocyte membrane and mature into gametes. The macrogametocyte quickly forms the 
macrogamete with few evident morphological changes, retaining its rounded structure. 
The micro game tocyte on the other hand undergoes a dramatic maturation process termed 
exflagellation. In this process the nucleus divides three times, forming usually eight 
nuclei which combine with the cytoplasm to form microgametes. These microgametes 
move through the mid-gut, with the aid of a flagellum, in search of a macrogamete.
Once a microgamete reaches a macrogamete fertilization takes place. The newly formed 
zygote remains quiescent for a period before it becomes mobile. The latter form, known 
as an ookinete, actively invades the intestinal ephithelium of the arthropod and lodges 
itself beneath the basal lamina, forming an oocyst. The diploid nucleus of the oocyst 
undergoes meiotic division, followed by intensive mitotic divisions, while the cytoplasm 
maintains its syncytial structure. Finally the cytoplasm divides to form sporozoites. The 
elongated and mobile sporozoites migrate from the oocyst to the salivary glands of the 
arthropod host, where they are ready to infect a new vertebrate host.
1-1.4 Chemotherapy of malaria
The chemotherapy of malaria is determined by the therapeutic objective of the 
treatment and the effectiveness of drugs against different species, strains and life cycle 
stages of the parasite.
As could be expected by the many forms that the parasite goes through in its life 
cycle, existing antimalarial drugs have differing levels of effectiveness on different stages 
in the parasite's life cycle. This has lead to the classification of drugs in terms of the 
section of the life cycle they effect. The following terms have been used:
Blood schizontocide - refers to a drug which acts upon asexual parasites in the blood; 
Tissue schizontocide - refers to a drug which acts upon asexual parasites in the tissues. 
This includes drugs active against hypnozoites, more specifically referred to as 
hypnozoitocides;
Gametocytocide - refers to a drug which acts upon the sexual forms of the parasite in the 
blood; and
Table 1-1: Action of some antimalarial drugs against different life
cycle stages of the malaria parasites a
Activity status against different life cycle stages of the human malaria parasites b’c
Antimalarial
Erythrocyctic 
asexual phase
Tissue phase
(excluding
hypnozoites)
Hypnozoites Gametoeytes
Chloroquine active and fast 
acting
not active not active active for P. vivax and 
P. malariae, not active for 
P. falciparum
Primaquine weak activity weak activity high activity high activity
Mefloquine active and fast 
acting
probably not 
active
probably not 
active
active for P. vivax and 
P. malariae, not active for 
P. falciparum
Proguanil active but slow 
acting
active against 
P. falciparum  
and P. ovale
not active highly active
Pyrimethamine active but slow 
acting
active some activity 
for P. vivax
uncertain
Sulfones and 
Sulfonamides
weak activity possible action uncertain uncertain
Tetracycline active but slow 
acting ( only 
known for 
P . fa lc iparum )
active ( only 
known for 
P. fa lciparum )
not active for 
P. vivax
not active ( only known for 
P. fa lciparum )
a Information for this table was obtained mostly from reference [16,16a]. b The sporozoites are not 
included in this table as none of these antimalarials is known to be active against them. c As more 
research in this area is conducted the information in this table is subject to change.
5Sporontocide - refers to a drug which acts upon the sporogonic forms in the mosquito 
after it has fed on the treated host
In Table 1-1 the differences in activities among some antimalarials against life cycle 
stages as well as between species are demonstrated
The interplay between the parasite life cycle and symptomatology of malaria 
needs to be understood when using drugs to treat malaria. The attacks of malaria occur 
during blood schizogony whereas no symptoms are noticeable in the tissue schizogony 
phase. To alleviate symptoms effective blood schizontocides should be used. The 
relapse phenomenon, in which months or even years after the initial infection has been 
cleared malaria reappears, is due to the dormant hypnozoites which is characteristic in the 
human plasmodia species P. vivax and P. ovale. In infections of this kind the use of 
hypnozoitocides must be considered.
Treatment regimens for malaria have different therapeutic goals which are related 
to the species of infecting plasmodia, the chances of reinfection, the severity of the 
infection and the toxicity of the drug to the individual. The development of drug 
resistance by plasmodia has lead to further complications in treatment. This means that 
not only the species of the infecting Plasmodium but also its likely drug resistant status 
should be known before treatment regimens are decided. Different treatment aims have 
been classified as follows:
Causal prophylaxis - this refers to the use of drugs that exert a lethal effect on malaria 
parasites during the pre-erythrocytic stages, i.e. the sporozoites and/or the tissue stages. 
In this way prevention of acute attacks of malaria is effected. This treatment is usually 
over long periods and accordingly the drug must be well tolerated.
Suppressive treatment - this refers to the use of blood schizontocides to prevent the 
clinical manifestation of the disease by elimination of asexual parasites from the blood. 
The treatment as for causal prophylaxis usually occurs over long periods so the drug 
used should be well tolerated.
Clinical cure - this refers to the termination of a clinical attack of malaria by interrupting 
blood schizogony with blood schizontocides. Drugs of choice here should be fast acting 
as the progress of the disease to fatality is often very rapid.
6Radical Cure - refers to treatment with drugs that eradicate all asexual stages from the 
body. There is little point trying to effect a radical cure while still in an endemic area 
because of possible reinfection.
Suppressive cure - refers to complete elimination of all asexual stages of the parasite by 
continued suppressive treatment
Gametocytocidal therapy - refers to agents which destroy the sexual forms of malarial 
parasites in human blood and thereby reduce the reservoir of infection.
1-1.5 Currently used antimalarial drugs 
(i) The 4-aminoquinolines
Chloroquine is a member of this group and is the most commonly used and well 
known of all the antimalarial drugs. Other compounds in this series include 
hydroxychloroquine and amodiaquine, the structure of chloroquine is shown in Fig 1-2. 
Chloroquine, the best example of the series, is very effective against the asexual 
erythrocytic forms of all human plasmodia. It is the drug of choice in the treatment of an 
acute malarial attack as it rapidly controls parasitemia and thus, clinical symptoms. The 
good blood schizontocidal activity coupled with chloroquine's low toxicity means it is 
commonly used for suppressive treatment It is not, however, effective against hepatic 
forms of the parasite and is only used to obtain suppressive cures usually in the case of 
P. falciparum where the tissue stage of the parasite does not persist. The spread of 
chloroquine-resistant plasmodia, especially P. falciparum, is increasing dramatically, 
making this drug less reliable as an effective treatment than it once was.
7F ig  1-2 C h em ica l s tru c tu re s  o f c u r re n t ly  u sed  a n tim a la r ia ls
CH3
I
NH*CH(CH2)3N(C2H5)2
Chloroquine
Primaquine
CH-NH
Proguanil Cycloguanil
NH--
Pyrimethamine
8The mechanism of action is as yet uncertain but it appears, in part, to be a result 
of preferential accumulation in parasitized erythrocytes. Two of the present theories on 
its mode of action are [12];
(1) chloroquine concentrates inside the parasite’s food vacuole and raises the 
intralysosomal pH, thereby inhibiting digestion of host protein, and
(2) ferriprotoporphyrin IX, a product of the malaria parasite's digestion of haemoglobin, 
tightly binds chloroquine forming a toxic chloroquine-ferriprotoporphyrin complex.
(ii) The 8-aminoquinolines
Primaquine is the only example of an 8-aminoquinoline in common current 
clinical use; its structure is shown in Fig 1-2. Other members of this series include 
pamaquine and quinocide. Primaquine, unlike chloroquine has weak blood 
schizontocidal activity but is highly active against the exoerythrocytic forms of P. vivax 
and P .falciparum. Its great clinical value lies in its hynozoitocidal activity which allows 
radical cures in the case of P. vivax. Primaquine has to be administered with care as it 
can cause haemolytic anaemia in a significant proportion of the population which are 
genetically glucose-6-phosphate dehydrogenase deficient. Primaquine is also noted for 
its good gametocytocidal activity against all human malarias. This is probably 
responsible for the infrequent observation of primaquine resistance [13]. This is 
fortunate since the 8-aminoquinolines are the best antimalarial agents for elimination of 
the latent tissue stages of relapsing malaria. Little is known of the mode of action of the 
8-aminoquinolines.
(iii) The 4-quinolinemethanols
The two drugs of major interest from this series are quinine and mefloquine 
(structures shown in Fig 1-2). The alkaloid quinine was first used as an antimalarial in 
the sixteen hundreds in the form of a crude extract of the bark of the cinchona tree. Later 
it was isolated and used directly until early this century when synthetic antimalarials 
became available.
Although, quinine was superseded by newer less toxic synthetic drugs the advent
9and increase of multi-drug resistant strains of malaria has seen it brought back into use as 
an important alternate treatment Its primary action is as a rapid blood schizontocide for 
all human malarias and a gametocytocide for P. vivax and P. malariae.
Mefloquine is a relatively new derivative (clinical trials began in 1972) of quinine 
which has been found to be an effective, reasonably well tolerated and safe antimalarial 
drug. It is highly active against blood forms, with its major use as a treatment for 
chloroquine-resistant P . falciparum. Presently its use is being rigidly controlled in order 
to prevent the rapid occurrence of mefloquine resistance.
(iv) The biguanides
These drugs of which proguanil (shown in Fig 1-2) is representative, differ 
considerably in their structure from the already discussed antimalarials. It has been 
shown that biguanides act as a prodrug and the active form is a dihydrotriazine formed 
during the metabolism of the biguanides. These dihydrotriazines have themselves been 
made and used directly as antimalarials, an example of one of these is cycloguanil shown 
in Fig 1-2. The discovery of proguanil represents an important advance made in the 
chemotherapy of malaria. It is an effective blood schizontocide for all four human 
plasmodia and is one of the most innocuous of the antimalarials. These properties make 
it highly suitable for suppressive treatment Its use in achieving clinical cures is limited 
by a slow onset of action compared to the 4-aminoquinolines. Proguanil has 
gametocytocidal activity against P. falciparum and P. vivax and has activity against the 
tissue stages of P. falciparum and P. ovale but not against the hypnozoites of P. vivax. 
The biguanides exert their antimalarial activity by selectively inhibiting parasitic 
dihydrofolate reductase, a key enzyme in the folic acid cycle which is necessary for the 
synthesis of methionine, glycine, thymidine and the purines. The spread of proguanil 
resistance has been reported in all species of malaria except P. ovale [14]. To overcome 
this resistance potentiating combinations of drugs were introduced. The biguanicides are 
used in association with sulphones (usually dapsone) and sulphonamides (such as 
sulfadoxine) themselves mild antimalarials. The sulphones and sulphonamides inhibit 
another stage of the folic acid cycle of the parasite. Unlike man, plasmodia must
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synthesise folic acid de novo, the sulphones and sulphonamides inhibit this biosynthesis. 
These inhibitors of two different steps in the same biochemical pathway when used in 
combination have a strong synergistic effect.
(v) The diaminopyrimidines
Pyrimethamine (shown in Fig 1-2) and trimethoprim are the two compounds of 
this group used as antimalarials. Like the biguanides, they function by inhibition of 
parasitic dihydrofolate reductase and as such have many similar pharmacological 
properties. Pyrimethamine is active against blood forms of plasmodia generally and as 
such is used mainly in suppressive treatment. Like proguanil, pyrimethamine is slow 
acting and well tolerated. Resistance to pyrimethamine developed quickly in many areas 
of the world [14] and cross resistance to other antifolates meant that pyrimethamine, like 
the biguanides, is normally used in combination with sulfones or sulphonamides to 
increase its antimalarial activity. Maloprim, which contains pyrimethamine and dapsone, 
and Fansidar, which contains pyrimethamine and sulfadoxine, are two widely used 
examples of such pharmaceutical preparations.
A more complete and extensive review of the chemistry and pharmacology of 
antimalarials can be found in monographs by Thompson and Werbel [15], and Bruce- 
Chwatt etal. [16].
1-1.6 Drug resistance
A major threat to the effective control of malaria has been the development of 
drug resistance. Table 1-2 shows when some of the common antimalarials were first 
introduced and when resistance developed to them. P. falciparum has been most prone 
to develop drug resistance especially to chloroquine. This type of resistance is increasing 
at an astounding rate both in its intensity and geographically [17,18]. Chloroquine 
resistance is well established over large parts of South East Asia and the Amazon basin 
and is now spreading over Africa [18,19].
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Table 1-2: The occurrence of drug resistance to common antimalarials a
Antimalarial drug Year in which clinical use began Year and location in which resistance 
was reported for P. falciparum
Quinine ca 1630 1910 Brazil
Primaquine 1951 1963 Colombia
Chloroquine 1945 1960 Venezuela
Proguanil 1948 1949 Liverpool
Pyrimethamine 1951 1952 Gambia
Sulfadoxine 1964 1968 Cambodia
Dapsone 1965 1968 Cambodia
a Information obtained from reference [9b].
Furthermore, the appearance of strains of P. falciparum which are resistant to 
other drugs and even combinations of drugs have compounded the problems of increased 
virulence and drug resistance. Drug resistance has occurred as a result of wide-spread, 
indiscriminate, inappropriate or incomplete treatment and failure to combat transmission. 
These conditions are favourable for the occurrence of genetic changes in the parasite 
which allow it to develop tolerance to particular compounds [20].
A number of strategies have been introduced to overcome and slow the spread of 
resistance. These include developing new antimalarial agents, using combinations of 
drugs in treatment and more thoughtful dispensing practices for existing drugs.
The development of new drugs effective against malaria is a long slow process, 
only a few have become available over the last twenty years. The most valuable of the 
new compounds are those that have a unique mode of action; these avoid problems of 
cross resistance with the existing antimalarials.
In an endeavour to find new drugs to treat malaria some useful candidates have 
been identified including mefloquine, halofantrine, artemisinin and some antibiotics.
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Mefloquine (discussed in section l-1.5(iii)) has been made available for clinical use and 
acts as a potent blood schizontocide and is active against multi-drug resistant falciparum 
malaria. Mefloquine's structural similarity to quinine lead to concerns about the 
possibility of cross resistance occurring. This was borne out by reports of mefloquine 
resistance occurring in areas where mefloquine had not yet been used. The first of these 
were from Thailand where quinine-resistant strains were already wide-spread [21]. 
Halofantrine (structure shown below), though not at the same stage of development as 
mefloquine, has schizontocidal activity against chloroquine-resistant strains of 
P. falciparum [21]. Even though it is based on the phenanthrene ring, and not the 
quinoline ring structure, it is suspected that it has a similar mode of action to quinine and 
mefloquine, again raising the strong possibility of cross resistance occurring.
OH
I
HC— CH2CH2N[(CH2)3CH3]2
Halofantrine
Some antibiotics such as chloramphenicol and tetracycline have been shown to be 
antimalarials and have been used mostly to treat drug-resistant strains of malaria. 
Tetracycline has been shown to have some activity against liver stages and marked 
activity against blood stages of the parasite [9c]. The onset of activity of the antibiotics is 
slow so they are often used in combination with other fast acting antimalarials. The 
advantages of these antibiotics are that they probably have a different mode of action 
from other antimalarials and they are already in clinical use, thus reducing the need for 
extensive pretesting. The most exciting of the new antimalarials are compounds based 
on artemisinin (qinghaosu), a natural product first isolated and characterised in 1972 
from the wormwood, Artemisia annua Linnaeus. Extracts of this plant were used
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historically as a Chinese folk remedy to treat malaria and other fever-associated diseases, 
references to it date back to the middle of the fourth century [22]. Artemisinin has a 
structure (shown below) unlike all presently used antimalarial drugs. It is a 
sesquiterpene lactone consisting of four rings and contains a peroxide bridge. This novel 
compound has been shown to have a different mechanism of action from both 
chloroquine and the antifolate drugs [22]. The necessity of the endoperoxide bridge for 
activity [22] and the apparent interference to membrane structures of the parasite [23] 
have lead some authors to suggest that the mode of action may be due to free oxygen 
radical-induced stress [22,24,25]. Artemisinin and its derivatives are quick acting blood 
schizontocides with low toxicity, and low cross resistance to chloroquine and other 
antimalarials. Two reviews on artemisinin have been published by Luo and Shen [22], 
and Anand et al. [26].
Artemisinin
The use of appropriately selected drug combinations is a necessary practise in the 
treatment of malaria to retard the spread of drug resistance. Use of a single compound 
may lead to resistance by causing genetic alteration of some aspect of the parasite. The 
basis of combination drug therapy in overcoming drug resistance is that the development 
of genetic changes in the parasite allowing it to combat two or more drugs at once is far 
less likely.
It is possible with different combinations of the existing antimalarials to produce 
different effects. There are combinations of drugs which have complementary, additive 
and potentiating effects. Complementary combinations are those which may act on 
different stages of the parasite's life cycle such as a combination of chloroquine and
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primaquine. Chloroquine acts on the blood schizonts whereas primaquine eliminates the 
hypnozoites and the gametocytes. Combinations such as chloroquine and pyrimethamine 
have an additive effect when used together whereas the combination of antifolates in 
Maloprim and Fansidar are found to be synergistic. The use of combination drug 
therapy has been applied to slow the development of mefloquine resistance by the triple 
combination of mefloquine, sulfadoxine and pyrimethamine know collectively as 
Fansimef. Care must be taken not to use a drug combination in areas where malaria 
resistance to one of the drugs in the combination already exists, as this lessens the 
antimalarial activity of the combination and defeats the purpose of the combination 
therapy in slowing the development of resistance [27].
The realization that drug resistance is still likely to grow, even with the advent of 
new antimalarials and drug combinations, has prompted careful dispensing practices to 
be undertaken. These practices were stated by WHO [28 a] and include;
1) the cessation of mass distribution of antimalarial drugs and chemotherapeutic 
targeting to defined high risk groups or the control of epidemics,
2) use of new antimalarials should be tightly controlled and limited to cases involving 
drug resistant malaria,
3) knowledge of the drug resistant status of the parasite to allow the appropriate use of 
existing, new and combinations of antimalarials to minimize development of resistance, 
and
4) that a complete course of therapy be used to effect a successful treatment and prevent 
transmission.
The above points aim to reduce drug resistance by lowering the rate of contact or 
sub-therapeutic contact between the plasmodia and antimalarials or by lowering the 
chances of transmission of parasite populations which have been exposed to drugs.
A complete work on drug resistance in malaria has been written by Peters [9].
A recent review by Björkman and Phillips-Howard [29] deals with the current 
epidemiology of drug resistant malaria.
a Originally from, Advances in malaria chemotherapy, WHO Technical report series No. 711, WHO, 
Geneva, 1984.
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1-1.7 Malaria control and vaccine
Other methods of combating malaria besides the use of chemotherapy include the 
traditional method of vector control and the revived hope of a malaria vaccine. Vector 
control includes among other methods the use of insecticides, destruction of mosquito 
breeding areas, bed nets impregnated with insecticides, house screening and introduction 
of specific mosquito pathogens [4].
The hope first generated by the idea of a malaria vaccine was high, however, it 
has become apparent in the last few years that the high degree of antigenic polymorphism 
of the parasite makes vaccine development difficult [3,30]. This has been reflected in the 
disappointing trails of candidate vaccines against sporozoite and asexual blood stages of 
malaria [31].
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1-2 Flavins
1-2.1 Structure and nomenclature
The trivial though common names of benzo[g]pteridine-2,4(3//,10//)-dione are 
isoalloxazine and flavin. The new LU.P.A.C. numbering system of benzo[g]pteridine- 
2,4(3//, 10//)-dione, shown below in structure 1.1 replaces the original German 
numbering system shown in structure 1.2. For brevity benzo[g]pteridine-2,4(3//,10//)- 
dione will be referred to as flavin throughout the rest of this work and the numbering 
system in formula 1.1 will be used.
0  5
R N ^ 4 \ - ^ N\ 7
1 R 9
1? 10 5
7
1 R 8
1.1 1 .2
1-2.2 The history of flavins as antimalarials
The association between flavins and malaria began in 1944 with the observation 
of Seeler and Ott [32] that riboflavin deficiency in chicks infected with Plasmodium 
lophurae had the effect of depressing parasitemia during the course of the disease.
Thirty-nine years later this phenomenon was renoted by Thumham et al. [33] 
who found there was a relationship between riboflavin status in Papua New Guinean 
infants and their susceptibility to malaria. It was found that the number of infants with 
malaria and normal riboflavin levels was significantly higher than would be expected 
statistically compared to those infants with riboflavin deficiency. This suggested 
riboflavin deficiency may be malaria protective. To confirm this finding a similar 
experiment to that of Seeler and Ott was conducted by Kaikai and Thumham [34]. 
Using Plasmodium berghei in rats they showed that riboflavin deficiency depressed 
parasite counts and that the depression was inversely related to the riboflavin status.
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In an effort to determine the minimal nutritional requirements of P .falciparum in 
culture Divo et al. [35] found that the supply of exogenous riboflavin was not necessary 
for normal parasite growth over a 96 hour period This is a similar finding to that of 
Siddiqui and colleagues [36] who, in an in vitro study, found no effect on the growth of 
P. knowlesi after 24 hours of riboflavin deficiency. These findings seemingly conflict 
with the in vivo results above. However, the nutrients necessary for parasite success 
cannot always be identified by depleting them from the culture medium as there may be 
intraerythrocytic stores of nutrients that are sufficient for parasite viability. Divo et al. 
admits this in their paper and to quote William Träger [37], one of the pioneers in in vitro 
parasitology, "Only in such medium (an axenic parasite culture in which the host is 
excluded) can all of the nutritional requirements of an organism be determined
Geary, Divo and Jenson [38] undertook an antimalarial screen of antimetabolite 
drugs based on analogues of riboflavin, nicotinamide, pyridoxine and thiamin using the 
minimal medium developed by Divo et al. [35] in order to enhance any parasiticidal 
activity. This study showed P. falciparum growth inhibition was most profound for 
riboflavin analogues (antagonists) over 96 hours in the minimal medium.
Dutta et al. [39] in 1985 put forward the hypothesis that interference with 
riboflavin metabolism could possibly provide protection against malaria. They suggest 
that metabolic inhibitors of riboflavin metabolism should be investigated for their 
therapeutic potential as antimalarial agents. They state [40] "investigation of the possible 
chemotherapeutic efficacy of metabolic inhibitors of riboflavin which may have selective 
antagonistic effects on Plasmodium is vital".
Cowden et al. [41] reported the results of an in vivo antimalarial screen using a 
range of riboflavin analogues. In that work they found 10-(4'-chlorophenyl)-3- 
methylflavin (Fig 1-3) to have significant activity against P. vinckei vinckei in mice and 
against P. falciparum in culture. They also showed that 10-(4'-chlorophenyl)-3- 
methylflavin was well tolerated at the doses needed to obtain cures. In a continuation of 
this work a number of analogues based on 10-(4'-chlorophenyl)-3-methylflavin were 
synthesised and tested by Cowden et al. [42]. In that paper they were able to undertake a 
limited structure activity relationship (S AR) study, the main conclusions of which were;
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(1) for compounds with 4'-halo substituents the order of antimalarial activity 
was Br > Cl > F,
(2) 2'-substituents lowered or abolished activity,
(3) the 3-methyl group was required for activity, and
(4) the halophenyl group had to be directly attached to the N-10 position to maintain 
activity.
Fig 1-3 Chemical structures of riboflavin and its antimalarial
analogue 10-(4'-chlorophenyl)-3-methylflavin
O O
C H 3N
hnA ^ n^ ^ ch
A 1c h 21H C - O HV
Cl
H C - O H
H C - O H
C H 2O H
10-(4,-chlorophenyl)-3-methylflavin riboflavin
1-3 Scope of this thesis
10-(4,-Chlorophenyl)-3-methylflavin represents a structurally novel antimalarial 
compound. The spread of drug resistance has heightened the need for new malarial 
drugs. With this in mind the present study was undertaken, primarily to investigate the 
structure activity relationship between analogues of the lead compound and their 
antimalarial activity. This was done to define the structural features required for activity 
and to find analogues with improved activity and reduced toxicity. Other aspects dealt 
with and discussed are the syntheses and some of the physical characteristics of these 
compounds, the electrophilic substitution of the parent structure (10-phenylflavin) and an 
investigation of a possible mode of action of these compounds.
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In Chapters 2 and 3 the effects of varying the substituents on the 10-phenyl ring, 
and at the 3-N position and the 10-phenyl ring together are examined.
In Chapters 4 and 5 the effect of altering ring-3 of the flavin moiety by adding 
substituents, making a 6,8-diaza analogue and removing the ring to produce a series of 
pteridine-2,4(3//,8//)-diones are examined.
In these chapters the results of andmalarial testing in the P. vinckei vinckei mouse 
model were the main measure of andmalarial activity. A number of the compounds were 
also tested for activity against chloroquine-sensitive and chloroquine-resistant 
P. falciparum in culture as well as for anti-HIV, anticoccodial and antibabesial activity.
In Chapter 6 the possibility that these flavins may be exerting their antimalarial 
action via the inhibition of host glutathione reductase is investigated and discounted.
Finally, the experimental details of the organic syntheses and most of biological 
testing of the earlier chapters are collated in Chapter 7.
CHAPTER 2
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CHAPTER 2 Syntheses and antimalarial activity of some 3-methyI-10- 
(substituted phenyl)flavins
2-1 Introduction
In view of the antimalarial activity of the lead compound 10-(4'-chlorophenyl)-3- 
methylflavin and the highly variable response achieved by alterations made on the 10-N- 
phenyl ring [42] it was decided to undertake a systematic study of substituents in this 
position (including a quantitative structure-activity relationship study). In this chapter the 
synthesis and antimalarial activity of the 3-methyl-10-(substituted phenyl)flavins are 
discussed. The *H n.m.r., 13C n.m.r. and ultraviolet and visible (UV) spectra of this 
class of compounds are described and discussed. Some of the compounds produced 
were screened for activity against, drug resistant P. falciparum, Babesia microti and HTV 
and the results discussed. Additionally some of the compounds were submitted for in 
vitro testing against Giardia intestinalis and a number of human tumour cell lines.
Scheme 2-1
N-substituted alloxan
H3BO3
Other pyrimidines that have been used instead of alloxan
dialuric acid 5-halobarbituric acid
z cc
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2-2 Syntheses
2- 2.1 Introduction
The large number of synthetic routes known for the production of the flavin ring 
system has mainly stemmed from the interest in the production of the important vitamin 
riboflavin and closely related derivatives. Kuhn and co-workers reported the first flavin 
synthesis in 1934 as part of the effort to characterise the structure of riboflavin [43,44]. 
The synthesis involved the condensation of 4,5-dimethyl-N-methyl-1,2-benzenediamine 
and alloxan to produce 7,8,10-trimethylflavin (lumiflavin).
The synthesis and chemistry of flavins are reviewed by Lambooy [43], and Ohta, 
Wrigglesworth and Wood [45]. A brief review of several methods of flavin synthesis 
found in the literature and their potential usefulness in regard to the aim of producing
3- methyl-10-(substituted phenyl)flavins is outlined in the following sections.
2-2.2 Literature methods
(i) The condensation of N-substituted 1,2-benzenediamine with various pyrimidines as 
depicted in Scheme 2-1 involves the formation of the central pyrazine ring and has been 
the most commonly used synthesis of flavins [43,46,47]. The various pyrimidines that 
can be used in this condensation include alloxan, N-substituted alloxans, alloxantin, 
dialuric acid, 5-halo and 5,5-dihalobarbituric acids. Varying degrees of success have 
been obtained with all of these pyrimidines though the most favoured seems to be 
alloxan. Boric acid has been found to catalyse this reaction. The major difficulty 
associated with this reaction is preparing the desired 1,2-benzenediamine starting 
material.
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(ii) The reaction of 2-arylazobenzenamine with barbituric acid illustrated in Scheme 2-2 
was shown by Tishler et al. [48] to be a convenient high yielding method of producing 
flavins, not requiring the less accessible and unstable 1,2-benzenediamine starting 
material used in method (i) above.
The production of the 2-arylazobenzenamine starting material is achieved by the 
coupling of an aryl diazonium salt to an N-substituted benzenamine. It is necessary to 
block the activated 4-position of the N-substituted benzenamine with a substituent to 
ensure the electrophilic aromatic substitution occurs at the 2-position. Experience has 
shown that 3,4-substituted N-substituted benzenamines usually give the best yields in 
this reaction [43]. The practical implication of this limitation in preparing the starting 
material for this synthetic route is that it is restricted to producing 7,8-disubstituted 
flavins.
Scheme 2-2
Scheme 2-4
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(iii) The condensation of 5-nitrosobarbituric acid (violuric acid) with an N-substituted 
benzenamine is a method of producing flavins from very readily available starting 
materials. Since this condensation shown in Scheme 2-3 can take place via either the 2 or 
6 position of the N-substituted benzenamine the possibility exists for the formation of 
two isomers, depending upon the pattem of substitution in the benzene ring of the 
N-substituted benzenamine.
Scheme 2-3
Ac-
R
(iv) The preparation of flavins from quinoxalines involves the construction of the 
pyrimidine ring. There are only a few reports in the literature using this method of 
producing flavins. A novel route (Scheme 2-4a) used by Clerin et al. [49] involved the 
preparation of a 10-substituted 3-phenylflavin from the intermediate methyl l-alkyl-2- 
amino-l,5,6,7-tetrahydro-3-quinoxaline carboxylate by reaction with phenylisocyanate, 
followed by cyclization in the presence of triethylamine and subsequent dehydrogenation. 
Smith and Bruice [50] showed that the alkaline hydrolysis of a flavin (Scheme 2-4b) lead 
to the formation of a 2-(N-methylureido)-l-substituted quinoxaline-3-carboxylic acid. 
This reaction was reversible under acidic anaerobic conditions. This reaction shows that 
the appropriate quinoxaline intermediate for the synthesis of flavins would probably 
require a 3-carboxylic acid functionality. The synthesis of such quinoxalines usually 
involves a 1,2-benzenediamine starting material [51].
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(v) Birch and Moye [52] found they could produce flavins by reacting 5-amino-6-(N- 
substituted amino)uracil with the biacetyl dimer as its hemiacetal. This, as shown in 
Scheme 2-5a, leads to the formation of a pteridine-2,4(3//,8//)-dione intermediate that 
readily undergoes cyclization to give the corresponding flavin. A variation on this 
procedure, depicted in Scheme 2-5b, involves the condensation of monomeric biacetyl 
with a 6,7-dimethylpteridine-2,4(3//,8//)-dione to form a 7,8-dimethylflavin [43,53].
Scheme 2-5 
(a) o
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(vi) The condensation of 5-amino-6-(N-substituted amino)uracils with the dimer of 
3,4-dimethyl-1,2-benzoquinone has produced flavins in reasonable yields [54].
However, this reaction, shown in Scheme 2-6, seems to be restricted to the production of 
7,8-disubstituted flavins as 1,2-benzoquinone is reported [43,55] not to react with 
5,6-diaminouracils to form flavins. This could possibly be due to oxidation of the 
diaminouracils by the monomeric 1,2-benzoquinone [43,56].
Scheme 2-6
O O
dimer
(vii) Yoneda et al. [57] have shown that 6-(N-substituted anilino)uracils, upon 
nitrosation or nitration of the 5 position and subsequent cyclization, give 10-substituted 
flavin 5-N-oxides which are easily reduced to the corresponding flavins (Scheme 2-7a). 
Sakuma et al. [58], using a similar method, unsuccessfully attempted to produce 
3-methyl-10-phenylflavin by cyclization of 3-methyl-5-nitro-6-diphenylaminouracil. 
However, the expected flavin was obtained by reduction of the 5-nitro group to 5-amino 
followed by autoxidation (Scheme 2-7b). The 3-methyl-5-nitro-6-diphenylaminouracil 
used in this reaction was produced by condensation of 6-chloro-3-methyl-5-nitrouracil 
with N-phenylbenzenamine. This route was used probably as a consequence of the 
reported failure of the nucleophilic substitution of the less reactive 6-chlorouracils by 
N-phenylbenzenamines [59,60].
Z
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(viii) A procedure pioneered by Yoneda et al. [60,61] specifically designed for the 
production of 10-arylflavins, involves the condensation of a 6-anilino-3-methyluracil with 
nitrosobenzene. The mechanism of the reaction suggested by Yoneda et al. [60] is shown 
in Scheme 2-8. It involves the formation of a 5-hydroxylamino intermediate followed by 
dehydration and cyclization to a 1,5-dihydroflavin, which is dehydrogenated with excess 
nitrosobenzene to the corresponding flavin.
(ix) The most recent new synthesis of flavins is reported by Sako et al. [62]. It involves 
the oxidative cyclization of 6-(substituted amino)-5-anilinouracils by heating in the 
presence of oxygen as seen in Scheme 2-9. The virtue of this method lies in the fact that 
the 10-N substituents and ring-3 of the flavin are introduced into the molecule in the form 
of primary amines and anilines, respectively, of which many substituted forms are 
commercially available. This allows a great variety of substituents to be introduced into 
these positions.
Scheme 2-9
O O
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2- 2.3 L iterature summary
The overall synthetic goal outlined in this chapter was to produce a large number of
3- methyl-10-(substituted phenyl)flavins. Of the literature methods discussed above, 
methods (ii), (v) and (vi) were deemed unsuitable as they are apparently restricted to the 
production of 7,8-disubstituted flavins. For 10-(substituted phenyl)flavin synthesis, 
methods (iii) and (vii) would require the often difficult to make N-(substituted 
phenyl)benzenamine starting material. Here, the appropriately substituted benzene is 
required to form the 10-phenyl ring of the flavin while the unsubstituted benzene ring 
forms the ring-3 of the flavin, however, the reverse of this can also occur, generating 
isomers for both routes. These two methods, therefore, were deemed not worthy of 
pursuit Methods (i) and (iv) would require the difficult and time consuming synthesis of 
N-(substituted phenyl)-1,2-benzenediamine starting materials for each 10-(substituted 
phenyl)flavin produced. Methods (i) and (iv) were therefore considered impractical 
because of the large number of flavins planned for synthesis. From Schemes 2-8 and 2-9 
it can be seen the remaining two methods (viii) and (ix) would use the common 
intermediate 6-(substituted anilino)-3-methyluracil. Method (viii) was considered 
superior to method (ix) for the present series because method (ix) has an additional two 
synthetic steps in the production of the flavins. Furthermore, method (viii) was 
considered the most appropriate reaction for the following reasons:
1) This reaction has been proven to be reliable in the production of 3-methyl-10- 
(substituted phenyl)flavins in reasonable yields [42].
2) The 10-substituted phenyl group can be introduced into the reaction sequence 
usually in the form of a commercially available aniline.
3) The site of variation in the molecule is added at the second last synthetic step 
allowing the use of a common starting material until late in the reaction sequence.
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2-2.4 Synthesis description
The majority of the 3-methyl- 10-(substituted phenyl)flavins (2.5) described in this 
chapter were formed by the condensation of 6-(substituted anilino)-3-methyluracil (2.4) 
with three equivalents of nitrosobenzene in the presence of acetic anhydride, essentially 
according to the method of Yoneda et al. [60]. The starting materials, methylurea, 
malonic acid, substituted anilines (excepting 2.3u and 2.3w) and nitrosobenzene, for 
the four step sequence outlined in Schemes 2-10 and 2-11 are commercially available.
Methylurea and malonic acid were cyclized to N-methylbarbituric acid (2.1) by the 
slow addition of the condensing agent, acetic anhydride, at 60° as described by Stein et al. 
[63]. This method was used in preference to the more common preparation of barbituric 
acids of condensation of malonic esters with urea or alkylated urea in the presence of 
sodium alkoxide. As this latter method has been reported to be less satisfactory in the 
preparation of N-methylbarbituric acid [63,64 a].
The monochlorination at the 6-position of N-methylbarbituric acid (2.1) was 
achieved by refluxing the barbituric acid in a mixture of phosphorus oxychloride and 
water [65,66].
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CH
3^ nh
0 ^ n h 2
0  0  
H C r N  AcjO CH3N - ^ N
H O - ^ O
H
O
p o c l 3 JL
H20  ^  CH3N |j
H
methylurea malonic 2 . 1
acid
2 .2
Cl
a Dr W. Cowden personal communication.
Scheme 2-11
NH
method A) 3 equiv. of 2.3
CH3Nx^ j |  +
H
7 ^
------ (X)n
method B) 1 equiv. of 2.3 and 
2 equiv. of N,N-diethylaniline
2 .2 2 .3
; h 3n ^ > i
1
C ' V' ' N ^  ^NH
3 equiv. of
CH
3A ^ n
X
(X )n
r
2 .4
3 5’
4 '
2 .5
(X)n
2.3 - 2 .5 1 (X)n 2.3 - 2.5 (X)„ 2.3 - 2.5 (X)„
a H k 4-Et gg 3,5-(OMe)2
b 2-Me t 3-Cl,4-Me hh 4-OH
c 3-Me u 3-Cl,5-Me 11 4-CF3
e 2,4-Me2 w 4-Cl,3-Me nn 3-SMe
f 3,4-Me2 X 4-Cl,2-F oo 4-SMe
1
2-Et dd 3,4-F2 qq 4-CN
29
Initially some of the 6-(substituted anilino)-3-methyluracils were prepared by 
heating three equivalents of the appropriate aniline with 6-chloro-3-methyluracil (2.2). 
This method, which was described previously [42,60,67,68], called for an excess of the 
aniline to be used. This procedure, in synthetic terms is satisfactory, however some of 
the aniline starting materials were either expensive or less readily available synthetically, 
therefore a new method was devised to conserve them. The latter consisted of reacting 
molar equivalents of the chlorouracil 2.2 and the appropriate aniline nucleophile 2.3 in 
the presence of two molar equivalents of N,N-diethylaniline. This method proved 
satisfactory, giving equivalent yields and fewer coloured by-products than the original 
method.
4-Chloro-3-methylaniline (2.3w) and 3-chloro-5-methylaniline (2.3u) were 
required reagents that were not available commercially. The 4-chloro-3-methylaniline 
was prepared according to a literature procedure [69] in which 2-methyl-4-nitroaniline is 
converted, via the Sandmeyer reaction to 2-chloro-5-nitrotoluene and the latter chemically 
reduced to the desired aniline. The 3-chloro-5-methylaniline was prepared according to 
the method of Browne and Dyson [70]. In that paper the starting material is misnamed as
5- nitro-o-toluidine instead of 4-nitro-o-toluidine (2-methyl-4-nitroaniline). The method 
of preparation involved the chlorination of 2-methyl-4-nitroaniline with potassium 
chlorate to give 2-chloro-6-methyl-4-nitroaniline. The latter was converted to the 
diazonium salt, the diazonium group was replaced with hydrogen by the action of sulfuric 
acid to give 3-nitro-5-chlorotoluene which was then chemically reduced to give the 
required aniline.
A number of the 3-methyl-10-(substituted phenyl)flavins were not synthesized by 
the method above. These were the 4'-NMe2 (2.5jj), 2',6'-Me2 (2.5h), 3'-NC>2 
(2.5ii), 4*-CC>2H (2.5rr) and 4'-SC>2Me (2.5pp) substituted compounds.
Attempts to condense 6-(4'-dimethylaminoanilino)-3-methyluracil with 
nitrosobenzene failed to give the expected product, possibly due to the activation of the
6- anilino ring to electrophilic substitution by the N,N-dimethylamino substituent. An 
alternate route (see sections 2-2.2(i), 3-2 and Scheme 2-12) involving the reaction of the 
N-^'-aminophenyty-N'jN’-dimethyl-M-benzenediamine and alloxan with boric acid as
Scheme 2-12
N(CH3)2 N(CH3)2
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a catalyst was undertaken. This gave the 10-(4'-dimethylaminophenyl)flavin which was 
then methylated with methyl iodide to give 10-(4'-dimethylaminophenyl)-3-methylflavin 
(2.5jj).
The 4'-C02H (2.5rr), 4'-SC>2Me (2.5pp) and 3'-N02 (2.5ii) substituted 
10-phenylflavins were derived from existing flavins. The 4'-carboxylate 2.5rr was 
prepared in good yield by acid hydrolysis of the corresponding nitrile 2.5qq. The 
4'-methylsulfonyl analogue 2.5pp was readily prepared by the action of peroxyacetic 
acid on the 4'-methylthio compound 2.5oo. The 3'-nitro compound 2.5ii was prepared 
from 10-phenylflavin by nitration with a mixture of nitric and sulfuric acid (nitronium 
ion) to give the 10-(3’-nitrophenyl)flavin. Methylation of this flavin gave 3-methyl-10- 
(3'-nitrophenyl)flavin (2.5ii). The electrophilic substitution of 10-phenylflavin is 
discussed in more detail in section 3-3.
The nucleophilic substitution of 6-chloro-3-methyluracil by 2,6-dimethylaniline 
failed to occur under the conditions used. This may be due to the steric hindrance 
occasioned by the two methyl groups ortho to the attracting amino group. The 2',6'-Me2 
compound 2.5h used in this study was a generous give from Dr F. Yoneda b . Two 
different syntheses for this compound have been reported by Sako et al. [62] and Main, 
Kasperek and Bruice [47].
Some flavins used in this study were made by Dr W. B. Cowden and are 
acknowledged as such.
The experimental details of the above section can be found in section 7-2.
b Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606, Japan.
2-3 Physical properties 
2-3.1 General
All the flavins are yellow high melting crystalline solids which are highly 
fluorescent under long wave ultraviolet light (ca 365 nm).
2-3.2 Nuclear magnetic resonance spectra 
(i) 1H Nuclear magnetic resonance
The signal due to the 3-N methyl group of this series appears as a singlet located 
between 3.24-3.27 ppm (Table 2-1). This methyl peak appears typically downfield 
because of the electron withdrawing effects of the neighbouring nitrogen and the two 
adjacent ß carbonyl groups.
The hydrogen atoms on the benzenoid ring-3 of the flavin differ enough in their 
electronic environments to allow accurate assignment of peaks. The peak for H 6 appears 
downfield between 8.20-8.28 ppm as a doublet, the signal for H 7 is a triplet with a shift 
range of 7.62-7.68 ppm, the signal from H 8 also occurs as a triplet between 7.76-7.80 
ppm and the signal due to H 9 is a doublet occurring considerably upfield at 6.70-7.00 
ppm. The spectral data of these hydrogen atoms are presented in Table 2-1. The 
resonance from H 9 has the largest range of chemical shifts of these four hydrogen atoms 
as it is in closest proximity, and most subject to effects of the 10-phenyl ring and the 
various electron withdrawing and donating groups present there.
The simple splitting pattem (apparently first order) that occurs in this spin system 
results from the almost equal coupling constants Jöj = J7,8  = ^8,9 = 8 Hz, the small 16,8 
and J7 ,9 coupling constants of approximately 1 Hz and the relative spread of chemical 
shifts of the peaks. The simulated splitting pattem c based on the above information 
about peak positions and coupling constants for 10-(3',5'-dimethylphenyl)-3- 
methylflavin (2.5g) and assuming an ABCD spin system is shown in Fig 2-lb.
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c Kindly run by Ms P. T. Culnane, University Nuclear Magnetic Resonance Centre, The Australian 
National University, using a Gemini 300 spin simulator.
Table 2-1: *H nana*, spectral data (S)a for 3-methyl-10-(substituted 
phenyDflavins
w  5
:h3n^ Y NY^1 7
8
a Chemical shifts reported as parts per million (8) in CD3SOCD3. b Peaks appear as 
singlets with integration of 3H. c Peaks appear as doublets with integration of 1H, 
and J8,9 are 8.0 Hz.d Peaks appear as triplets with integration of 1H, 17$ is 8.0 Hz. 
e Peak obscured by hydrogen atom peaks of the 10-phenyl ring. f Compound provided 
by Dr W. B. Cowden. 8 Also synthesised in Chapter 3. h Compound provided by Dr F. 
Yoneda.
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Compound
no.
(X)n 3-N M eb H 6 c H 7 d H 8 d H 9 c
2.5a f .g H 3.25 8.24 e e 6.78
2 .5 b 2-Me 3.24 8.24 e e 6.70
2 . 5 c 3-Me 3.26 8.24 e e 6.82
2.5d f 4-M e 3.26 8.23 7.63 7.78 6.84
2 . 5 e 2,4-(Me)2 3.25 8.24 7.63 7.76 6.74
2 . 5 f 3,4-(Me)2 3.24 8.22 7.62 7.76 6.84
2 .5 g  f 3,5-(Me)2 3.26 8.23 7.64 7.78 6.84
2.5h h 2,6-(Me)2 3.27 8.28 7.67 7.80 6.70
2 .5  i 2-Et 3.25 8.24 e e 6.71
2.5j f 3-Et 3.27 8.22 7.64 7.78 6.80
2 .5 k 4-Et 3.25 8.23 7.63 7.77 6.81
2.51 f 4-/i-butyl 3.25 8.22 7.62 7.77 6.79
2 .5m  f 2-CI 3.25 8.28 e e 6.90
2.5n f 3-C1 3.25 8.25 e e 6.98
2 .Sof 4-C1 3.25 8.24 7.64 e 6.88
2.5p f 2,4-Cl2 3.25 8.28 e e 6.90
2.5q f 2,5-Cl2 3.25 8.28 e e 6.91
2.5r f 3,4-Cl2 3.26 8.25 7.66 7.79 6.99
2.5s  f 3,5-Cl2 3.26 8.26 e 7.81 7.00
2 .5 t 3-C l,4-M e 3.26 8.25 e e 6.91
2 .5 u 3-Cl,5-M e 3.25 8.24 7.65 7.79 6.89
2 .5v  f 4-C l,2-M e 3.25 8.25 e e 6.79
2 . 5 w 4-C l,3-M e 3.25 8.23 7.63 e 6.89
2 . 5 x 4-Cl,2-F 3.24 8.25 e e e
2 .5 y  f 4-Cl,3-CF3 3.26 8.26 e e 6.97
2 .5z  f 3-Br 3.25 8.24 e e 6.86
2.5aa f 4-Br 3.25 8.24 7.64 7.77 6.87
2.5bb f 3-F 3.25 8.24 e e 6.87
2 .5cc  f 4-F 3.25 8.23 7.63 7.77 6.85
2 .5 d d 3,4-F2 3.25 8.24 e e 6.96
2 . 5 e e f 3-OMe 3.25 8.23 e 7.78 6.86
2 .5 f f  f 4-OMe 3.25 8.21 7.62 7.77 6.87
2 - 5 g g 3,5-(OMe)2 3.26 8.22 7.64 7.79 6.94
2 .5 h h 4-OH 3.24 8.20 7.62 7.77 6.89
2 .5 i i 3-NO2 3.26 8.27 7.66 7.77 6.91
2.5jj 4-NMe2 3.25 8.21 7.62 7.77 e
2.5kk f 3-CF3 3.26 8.26 e e 6.81
2.511 4-CF3 3.25 8.21 e e 6.83
2 .5m m  f 3,5-(CF3)2 3.26 8.28 7.68 7.80 6.96
2 .5 n n 3-SM e 3.26 8.24 e 7.80 6.86
2 . 5 o o 4-SM e 3.25 8.23 7.63 7.77 6.88
2 .5 p p 4 -S 0 2Me 3.25 8.25 e e 6.82
2 .5 q q 4-CN 3.25 e e e 6.83
2.5rr 4-CO2H 3.25 e 7.64 7.76 6.82
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This simulated pattern verifies the assignment of the two doublets and two triplets in the 
observed spectrum (Fig 2-la). In the better resolved spectra the fine structure due to the 
long range hydrogen atom coupling can usually be seen and is similar to that in the 
simulated splitting pattern shown in Fig 2-lb.
The above assignments of peaks for the ring-3 hydrogens are in agreement with 
those made by Grande et al. [71] in their n.m.r. study of methyl substituted flavins. 
Furthermore, the *13 n.m.r. spectra of flavins substituted in the 7, 8 and 9 positions 
(discussed in section 4-3.1) are consistent with the assignments given. A decoupling 
experiment on 10-(2',6'-dimethylphenyl)-3-methylflavin (2.5h) in which the peak from 
H 6 was decoupled, resulted in the collapse of the H 7 triplet to a doublet while the 
decoupling of the peak from H 9 resulted in the collapse of the H 8 triplet to a doublet. 
This further confirms the assignment of the signals and splitting pattem of the spin 
system due to H 6, 7, 8 and 9.
The coupling and shifts of the variously substituted 10-phenyl rings are presented 
in Table 2-2. The chemical shifts, splitting patterns and integration of the 10-phenyl 
hydrogen atom peaks are consistent with the electronic nature of their substituents and 
substitution pattem. The peaks due to substituents ((X)n) containing hydrogen atoms are 
also in agreement with their assigned structure.
The multiplicity and integration of the most upfield peak in the 10-phenyl spin 
system of the following compounds indicate these upfield peaks are due to H 2’ (when 
present) and H 6':
(1) 2.5a (unsubstituted) in which it appears as a doublet that integrates for 
2H;
(2) 2.5g (3',5’-Me2), 2.5s (3\5’-Cl2), 2.5gg (3',5’-(OMe)2) and 
2.5mm (3',5’-(CF3)2) in which it appears as a singlet that integrates for 
2H; and
(3) 2.5b (2'-Me) and 2.5i (2'-Et) in which it appears as a doublet that 
integrates for 1H.
Table 2-2: 1H narur. spectral data (5)a for 3-methyl-10-(substituted
phenyDfiavins
a Chemical shifts reported as parts per million (8) in CD3SOCD3. b Data are presented in the following 
form; chemical shift, multiplicity, coupling constants (where appropriate) and integration. The following 
abbreviations were used: s (singlet); d (doublet); t (triplet); q (quartet); qu (quintet); sex (sextuplet); com 
(complex); and in cases where the coupling constants are the same in a spin system it is presented lastly. 
c For some compounds the hydrogen atom signals of the H 6,7 , 8 and/or 9 are inseparable from signals 
from the 10-phenyl hydrogen atoms. In these cases those signals which were not included in Table 2-1 
are incorporated in this column and are apparent by integration. d Also synthesised in Chapter 3. 
e Compound provided by Dr W. B. Cowden. f Compound provided by Dr F. Yoneda. S Two symmetrical 
doublets seem to be present within this complex splitting pattern.
4'
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Cm pd
no.
(X)n (X )„ b 10-Substituted phenyl b’c
2 .5 a  d ’e H 7.43 d 8.0 Hz 2H , 7.60-7.81 com  5H
2 .5 b 2-M e 1.95 s 3H 7.30 d 7.0 H z 1H, 7 .46-7.84 com  5H
2 .5 c 3-M e 2.44 s 3H 7.20-7.84 com  6H
2 .5 d  e 4-M e 2.47 s 3H 7.32 d 2H , 7.53 d 2H  8.2 Hz
2 .5 e 2,4-(M e)2 1.90 s 3H , 2 .42 s 3H 7.14-7.35 com  4H
2 . 5 f 3,4-(M c)2 2.31 s 3H, 2 .36 s 3 H 7.11-7.49 com  4H
2 .5 g  e 3,5-(M e)2 2.39 s 6H 7.04 s 2 H , 7.31 s 1H
2 .5 h  f 2 ,6 -(M e)2 1.88 s 6H 7.36-7.52 com  4H
2 .5  i 2-E t 0.98 t 3H, 2.28 q 2H  7.6 Hz 7.29 d 8.0 Hz 1H, 7.46-7.84 com  5H
2 .5 j  e 3-Et 1.25 t 3H , 2.75 q  2H  7.6 Hz 7.24-7.55 com  4H
2 .5 k 4-E t 1.23 t 3H , 2.77 q 2H  7.6 Hz 7.33 d 2 H , 7.55 d 2 H  8.2 Hz
2 .51  e 4-n-butyl 0.95 t 3H , 1.40 sex 2H .1.68 
qu 2H , 2.73 1 2H  7.6 H z
7.32 d 2H , 7.53 d 2H  8.2 Hz
2 .5 m  e 2-C1 - 7.56-7.92 com  6H
2 .5 n  e 3-C1 - 7.42-7.84 com  6H
2 .5 o  e 4-C1 - 7.48 d  2H , 7.81 d  3H  8.6 Hz
2 .5 p  e 2 ,4 -C l2 - 6.60-8.13 com  5H
2 .5 q  e 2 ,5 -C l2 - 7.64-7.97 com  5H
2 .5 r  e 3 ,4 -C l2 - 7.50 d  1H, 7.84 s 1H, 8.03 d 1H 8.5 Hz
2 .5 s  e 3 ,5 -C l2 - 7.65 s 3H , 8.02 s 1H
2 . 5 t 3-C l,4-M e 2.50 s 3H 7.33-7.83 com  5H
2 .5 u 3 -C U -M e 2.43 s 3H 7.25 s 1H, 7 .40 s 1H, 7.61 s 1H
2 .5 v  e 4 -C U -M e 1.96 s 3H 7.56-7.83 com  5H
2 .5 w 4-C l,3-M e 2.43 s 3H 7.31 d  7.8 H z 1H, 7.44 s 1H, 7.79 d 8.2 Hz 2H
2 .5 x 4 -C U -F - 6.24-7.98 com  6H
2 .5 y  e 4 -C l,3 -C F 3 - 7.62-7.86 com  3H
2 .5 z  e 3*Br - 7.47-7.92 com  6H
2 .5 a a  e 4-Br - 7.41 d 2 H , 7.94 d 2 H  8.8 H z
2 .5 b b  e 3-F - 7.30-7.86 com  6H
2 .5 c c  e 4 -F - 7.46-7.60 com  4H
2 .5 d d 3 ,4 -F 2 - 7.31-7.92 com  5H
2 .5 e e  e 3-OM e 3.80 s 3H 6.98-7.67 com  5H
2 .5 f f  e 4-OM e 3.88 s 3H 7.24 d 2H , 7.35 d  2H  9.4 Hz
2 .5 g g 3,5-(O M e)2 3.78 s 6H 6.21 s 2H , 6.79 s 1H
2 .5 h h 4-OH - 7.03 d 2 H , 7.20 d 2 H  8.8 Hz
2 . 5 i i 3 -N 0 2 - 7.61-8.11 com  6H
2 . 5 j j 4 -N M e2 3.02 s 6H 6.94 d  3H , 7.17 d 2H  9.0 Hz
2 .5 k k  e 3-C F 3 - 7.61-8.11 com  6H
2 .511 4-CF3 - 7 .65-8.16 com  6H  g
2 .5 m m  e 3 ,5-(C F 3)2 - 8.33 s 2H , 8.55 s 1H
2 .5 n n 3-SM e 2.51 s 3H 7.19-7.71 com  5H
2 . 5 o o 4-SM e 2.59 s 3H 7.35 d 2 H , 7.57 d 2 H  8.4 Hz
2 .5 p p 4 -S 0 2M e 2.92 s 3H 7.60-8.10 com  6H
2 .5 q q 4-C N - 7.60-8.27 com  7H  g
2 .5 r r 4 -C O 2H * 7.56 d 2H , 8.26 d  3H  8.6 Hz
Table 2-3: Comparison of the chemical shift (ppm) of the carbon
atoms in 3,10-dimethylflavin a and (3',5’-dimethyIphenyl)- 
3-methylflavin
JL
3,10-dimethylflavin
7
8
Carbon 3,10-dimethyflavin b 2.5g c
C 2 156.6 155.1
C 4 160.3 159.3
C 4a d 138.4
C 5a 136.2 134.8
C 6 133.5 131.3
Cl 127.2 126.0
C 8 136.4 134.8
C 9 115.8 116.9
C 9a 133.8 133.9
C 10a 149.7 150.1
c  r - 135.7
C 2',6’ - 124.9
C 3',5' - 139.8
C 4' - 131.2
NCH3 28.8 28.0
3,5-(CH3)2 - 20.8
10-CH3 32.3 -
a Spectral data for 3,10-dimethylflavin obtained from reference [74].b Spectrum obtained 
in the solvent mixture CDCI3/CD3OD on a Varian XL 100 spectrometer. c Spectrum 
obtained in CD3SOCD3 on a Varian VXR 300 spectrometer. d Not observed.
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Most of the 4'-substituted 10-phenyl hydrogen atom peaks have a splitting pattern of two 
symmetrical doublets characteristic of para disubstituted benzene (either an AA'BB' or 
AA’XX' system).
(ii) 13C Nuclear magnetic resonance
A carbon-13 spectrum was run on 10-(3,,5'-dimethylphenyl)-3-methylflavin 
(2.5g) as a representative of this series. The spectrum revealed three carbon peaks at 
low field (159.3, 155.1 and 150.1 ppm), eleven peaks between 116 and 140 ppm and, 
two high field peaks at 28.0 and 20.8 ppm (Fig 2-2a,b).
The peak at 28.0 ppm was assigned to the deshielded 3-N methyl carbon and the 
intense peak at 20.8 ppm was assigned to the two equivalent carbons of the 3',5'- 
dimethyl groups on the 10-phenyl ring.
The tertiary carbons were unambiguously assigned with the aid of a two 
dimensional heteronuclear one-bond correlations plot (HETCOR) d . Fig 2-3 shows the 
HETCOR spectrum of the aromatic region of the hydrogen and carbon spectra making it 
possible to relate the assigned hydrogen spectrum to the carbon spectrum. The 
assignments made using the HETCOR spectrum for carbons 6, 7, 8, 9, 2’, 6' and 4' are 
shown in Table 2-3.
A hydrogen-detected carbon-13 heteronuclear multiple bond correlation (HMBC) 
experiment was also run on this compound d. The HMBC was used to detect long range 
carbon hydrogen atom coupling connectivities while suppressing the one bond coupling 
[72]. The aromatic region of this spectrum shown in Fig 2-4 consisted of a number of 
cross peaks (the intensity of which reflects the size of the long-range coupling) which are 
mostly due to three bond carbon-hydrogen coupling. These cross-peaks confirmed the 
assignment of the above tertiary carbons and allowed the assignment of the quartemary
d Kindly run by Ms P. Simmonds, University Nuclear Magnetic Resonance Centre, The Australian 
National University, using a Varian VXR 300 spectrometer.
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Figure 2-4 Two dimensional HMBC spectrum of 10-(3',5'- 
dimethylphenyI)-3-methy!flavin (2.5g)
H 2', 6'
H 4'
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carbons 5a and 9a (Table 2-3). Carbon C-T was assigned on the basis of the weak cross 
peak between the resonance at 135.7 ppm and the hydrogen atom peak assigned to H 2\
6'. This cross-peak is due to two-bond coupling and agrees with the fact that two-bond 
coupling constants are usually smaller than three-bond coupling constants in aromatic 
systems [73].
The carbon peak at 139.8 ppm which integrated for 2 carbons was assigned to the 
equivalent quartemary carbons C-3' and C-5'.
Of the remaining four unassigned peaks carbons 2, 4 and 10a were assigned on 
the basis of the assignments made by Grande et al. [74] who used 13C enrichment 
techniques to study 3,10-dimethylflavin. By the process of elimination the resonance at 
138.4 ppm was assigned to C-4a. For comparison the assignments made by Grande et 
al. are given in Table 2-3. It can be seen that even though a different solvent system was 
used and the substituent at the 10-position is different there is good agreement between 
the two sets of peak positions.
2-3.3 Ultraviolet and visible spectra
The ultraviolet and visible (UV) spectral data for the 3-methyl-10-(substituted 
phenyl)flavins series are recorded in Table 2-4. The spectra consist of an intense broad 
peak at 263-270 nm (log e 4.27-4.69) and two well separated broad peaks at 326-340 nm 
(log e 3.60-4.00) and 436-442 nm (log e 3.65-4.05). These spectra are typical of the 
flavin chromophore and compare well with the ultraviolet and visible spectra of similar 
compounds reported by Yoneda et al. [60].
2-3.4 Mass spectra
The mass spectrum of 10-(4'-chlorophenyl)-3-methylflavin (2.5o) is discussed in
section 3-4.2.
Table 2-4: Ultraviolet and visible maxima of the 3-methyI-10-
(substituted phenyl)flavins a
a Experimental details are given in section 7-1. b Also synthesised in Chapter 3. 
c Compound provided by Dr W. B. Cowden. d Compound provided by Dr F. Yoneda. 
e Data taken from reference [42] and included for comparison and completeness.
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Compound no. (X)n X max nm (log e) (EtOH)
2.5a b>c 
2.5b  
2.5c  
2.5d c 
2.5e  
2 .5 f  
2.5g c 
2.5h d
2.5 i 
2.5j c 
2.5k  
2.51 c 
2.5m e 
2.5n e 
2.5p e 
2.5q e 
2.5r e 
2.5s e 
2.5t 
2.5u  
2.5v e
2.5 w 
2.5x  
2.5y c 
2.5z e 
2.5aa e 
2.5bb e 
2.5cc e 
2.5dd  
2 . 5 e e c 
2.5ff c 
2.5gg  
2.5hh
2.511 
2.5jj 
2.5kk c
2.511 
2.5mm c 
2.5nn  
2.5oo  
2.5pp  
2.5qq  
2.5rr
H
2- CH3
3- CH3
4- CH3
2.4- (CH3)2
3.4- (CH3)2
3.5- (CH3)2
2.6- (CH3)2
2- CH2CH3
3- CH2CH3
4- CH2CH3 
4-n-butyl
2- C1
3- C1
2.4- 0 2
2.5- Cl2
3.4- Cl2
3.5- Cl2 
3-Cl,4-CH3
3- Cl,5-CH3
4- Cl,2-CH3 
4-Cl,3-CH3 
4-C1.2-F 
4-Cl,3-CF3
3- Br
4- Br
3- F
4- F
3.4- F2
3- OCH3
4- OCH3
3.5- (OCH3)2 
4-OH
3- NO2
4- N(CH3)2
3- CF3
4- CF3
3.5- (CF3)2
3- SCH3
4- SCH3 
4-SO2CH3 
4-CN 
4-C02H
270 (4.27) 
269 (4.55) 
269 (4.48) 
269 (4.50)
269 (4.49)
270 (4.49) 
269 (4.52) 
269 (4.53)
269 (4.54)
270 (4.44) 
270 (4.50) 
270 (4.61) 
269 (4.48) 
269 (4.43)
268 (4.38)
269 (4.33)
268 (4.30) 
267 (4.36)
269 (4.51) 
269 (4.50) 
269 (4.39) 
269 (4.53) 
267 (4.52)
267 (4.25) 
269 (4.40)
268 (4.41)
268 (4.46)
269 (4.36) 
269 (4.47)
269 (4.55)
270 (4.54)
269 (4.54)
270 (4.50) 
265 (4.56) 
265 (4.69) 
269 (4.49) 
269 (4.50)
263 (4.43)
264 (4.59)
265 (4.52) 
267 (4.50) 
265 (4.48) 
269 (4.51)
332 (3.60)
334 (3.94) 
330 (3.85)
335 (3.96) 
334 (3.83) 
334 (3.84) 
334 (3.86) 
334 (3.94)
336 (3.97)
333 (3.85)
334 (3.87) 
334 (3.97) 
338 (3.90)
338 (3.85)
339 (3.86)
340 (3.78) 
340 (3.72) 
339 (3.78) 
336 (3.91) 
333 (3.90) 
339 (3.78)
333 (3.93)
336 (4.00)
332 (3.68)
338 (3.80)
337 (3.85) 
336(3.88)
339 (3.74)
334 (3.93)
333 (3.89)
335 (3.89)
334 (3.89) 
334 (3.86) 
334 (3.93) 
326 (3.86) 
333 (3.90) 
333 (3.88) 
333 (3.90)
333 (3.88)
334 (3.74)
335 (3.88) 
334 (3.90)
336 (3.87)
439 (3.65) 
439 (4.03) 
439 (3.89) 
441(3.96)
439 (3.94)
440 (3.93) 
440 (3.96)
437 (3.99) 
439 (4.03)
439 (3.81)
440 (3.94) 
440 (4.05)
438 (4.00) 
438 (3.93)
437 (3.96)
438 (3.89)
439 (3.85)
438 (3.90)
439 (3.99) 
438 (3.97)
438 (3.89)
439 (4.00) 
437 (4.05)
437 (3.73)
439 (3.90)
440 (3.93)
436 (3.94)
438 (3.86)
437 (3.97)
440 (3.97)
441 (3.98) 
440 (3.99)
442 (3.92)
438 (4.00) 
437 (3.95)
437 (3.98)
438 (3.95)
437 (3.98) 
440 (3.95) 
440 (3.98)
438 (3.99) 
437 (3.96) 
440 (3.97)
2-4 In vivo antimalarial testing 
2-4.1 Introduction
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The host specificity of the malaria parasite precludes the direct experimental study 
of human species of Plasmodium in vivo. The most commonly used in vivo models are 
the murine malarias as they are easily and relatively inexpensively maintained in the 
laboratory. The P. vinckei vinckei parasite was selected as an appropriate malaria model 
as it causes a virulent, fulminating and lethal infection, characteristics which make it 
suitable for chemotherapeutic studies. P. vinckei vinckei was first isolated from Shaba, 
Zaire and adapted to mice in 1952. Since then it has been used successfully in numerous 
malaria studies [10b]. This model provides a simple convenient method of monitoring 
blood schizontocial activity which has been shown to correlate well with antimalarial 
activity in primates [75].
2-4.2 Method
In this model the infection (after inoculation of CB A mice) was allowed to reach 
15 to 35% parasitemia when a single dose of the test compound was injected 
intraperitoneally. The groups of mice at each dose usually consisted of 4 to 6 animals. 
The three criteria used to judge the activity of compounds were the per cent of animals 
cured, the increase in mean survival time compared to controls and the percentage 
parasitemia on day two after treatment A control was provided by injecting vehicle 
alone, here there was a 100% mortality three days after treatment. The parasitemia on day 
two after treatment of the control animals was 79 ± 6% (n = 40). A test compound was 
considered toxic if it either reduced mean survival time or treated animals died even 
though parasite counts on day two were low enough to indicate that the mice should have 
been cured of the infection.
The experimental details of the murine model are given in section 7-3. l(i).
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Figure 2-5 Dose response curves for compounds 2.5gg (3',5'-(OMe)2) 
and 2.5o (4'-Cl)
Dose (mg/kg)
150
Each datum point represents the parasitemia of a single mouse on day two after treatment. 
The dose response curves shown here are for illustrative preposes only. See section 
7-3. l(i) for experimental details.
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2-4.3 Results
Tables 2-5 and 2-6 show the average per cent survival and the average mean 
extension in lifespan at doses ranging from 10 to 140 mg/kg for this flavin series (2.5a- 
2.5rr). Some of the flavins in these tables have been previously tested by Cowden et al. 
[42] and are indicated as such; these compounds in Table 2-5 were retested to allow direct 
comparison of biological activity between the new compounds and the previously 
reported compounds. Table 2-6 contains all those flavins with a 2'-substituent; the 
biological data of the compounds with substituents 2',4'-Cl2 (2.5p) and 2 '-CH3t 4'-Cl 
(2.5v) from the previous study are included for comparison.
Two examples of dose-response curves of the flavins 2.5gg and 2.5o are shown 
in Fig 2-5, in which the response is per cent parasitemia on day two after treatment
The ED40 value is the effective dose in mmoles/kg required to obtain a parasitemia 
of 40% on day two. The ED40 values were used as a measure of the relative 
schizontocidal activity of the active flavins. These values were estimated by interpolation 
from linear regression analysis of the logit biological response (log p/(100-p), where p is 
the parasitemia of individual mice on day 2) versus dose. The regression was restricted 
to the linear part of the plot corresponding to the change in activity. Alternate ED40 
values were also obtained using a similar technique except that logit biological response 
versus log dose were used. These values were similar to the other ED40 values, 
however, the fits were slightly poorer and, therefore, the logit biological response versus 
dose derived ED40 values were used in subsequent discussion and calculations. The 
ED40 values, as well as their upper and lower 95% confidence limits, are presented in 
Table 2-7 for all the compounds in Table 2-5 which were active excepting those 
compounds where ED40 determination was not possible because of toxicity or a lack of 
data due to activity only being detected in the upper part of the dose range tested.
Table 2-5: Antimalarial activity of 3-methyl-10-(substituted 
phenyl)flavins against P. vinckei vinckei in mice a
Cmpd no. (X)n
Per cent cured and increase in mean survival (days) at dose, mg/kg b
10 15 20 25 30
2.5a H 0(0) - - - 0(0)
2.5c 3-Me 0 (0.8) 0(0) 0 (0.5) 0(0) 0(0)
2.5d 4-Me 0(0)d - - - 0 (0.2)
2.5f 3,4-(Me)2 0 (0.3) - 0 (-0.2) - 0 (0.8)
2.5g 3,5-(Me)2 c 0(0) 60 (1.0) 100 100 100
2.5j 3-Et - 0(0) 0(0) 0(0) 0(0)
2.5k 4-Et 0 (0.2) - 0 (0.3) - 0(0)
2.51 4-n-butyl - - - - 0(0)
2.5n 3-C1 c - - - - -
2.5o 4-C1 c 20 (0.25) 80 (4.0) 100 100 100
2.5r 3,4-Cl2 c - - - - 0(0)
2.5s 3,5-Q 2 c 100 100 100 100 100
2.5t 3-Cl,4-Me - - - - 0 (0)d
2.5u 3-Cl,5-Me 0 (0.2) 60 (0.5) 80(1) 100 100
2.5w 4-Cl,3-Me - - - - -
2.5y 4-Cl,3-CF3 - - - - -
2.5z 3-Brc - 0(0) - - 0(0)
2.5aa 4-Brc 0 (1.3) 100 100 100 -
2.5bb 3-F c 0 (0.2) 0 (0.2) 0(0) 0(0) 0 (0.2)
2.5cc 4-F c 0(0) 0(0) 0 (13.4) 0(0) 80 (0)
2.5dd 3,4-F2 - - 0 (-0.5) - 0(0)
2.5ee 3-OMe 0(0) - 0(0) - 0(0)
2.5ff 4-OMe 0(1.0)d - - - 0 (0.4)
2-5gg 3,5-(OMe)2 - - - - -
2.5hh 4-OH 0 (0.5)d - - - 0 (0.2)
2.5ii 3-N02 - - - - 0(0)d
2.5jj 4-N(Me)2 0(0) - - - 0(0)
2.5kk 3-CF3 0(0) 100 100 100 100
2.511 4-CF3 0(0) - 0(0) - 80 (2.0)
2.5mm 3,5-(CF3)2 0(0) - 0(0) - 0(0)
2.5nn 3-SMe 0 (0.2) - 0(0) - 0(0)
2.5oo 4-SMe 0 (0.2) - 0 (0.5) - 0 (0.5)
2.5pp 4-S02Me 0(0)d - - - 0 (0.2)
2.5qq 4-CN 0 (0.5)d - - - 0(0) '
2.5rr 4-CO2H 0(1.0)d • 0 (0.2)
a See section 7-3.l(i) for experimental details. b Most groups consist of 4 to 6 animals. c Compounds 
which were retested, for previous testing see references [42,76]. d Denotes a group of two mice.e Toxic 
at 80 mg/kg.
oCmpd no. (X)n
Per cent cured and increase in mean survival (days) at dose, mg/kg b
40 50 60 70 140
2.5a H - 0 (0.3) 20 (0.5) 60(0) e
2.5c 3-Me - 0 (0.6) - 0(0) 0(-1.5)d
2.5d 4-Me - 0 (0.3) - 0(0) 0 (0.5)d
2.5f 3,4-(Me)2 - 20 (0.25) 60 (0.5) 100 -
2.5g 3,5-(Me)2 c 100 60 (5.5) 0 (0.4) - -
2.5j 3-Et - - - 0 (0.3) -
2.5k 4-Et - 0 (0.5)d - 0 (-0.4) -
2.51 4-n-butyl - 0(0) - 0 (0.5) 0 (0.5)d
2.5n 3-C1c - 0 (0.4) 50 (-0.5) 100 -
2.5o 4-C1 c 100 20 (-0.8) - 0 (-1.0) -
2.5r 3 ,4 -0 2  c - 0(0) - 0(0) 100d
2.5s 3,5-Cl2 c 100 - - 60 (16.5) -
2.5t 3-Cl,4-Me - - - 0(0)d 100
2.5u 3-Cl,5-Me 100 100 - 100 -
2.5w 4-Cl,3-Me 0 (0.25) 25 (-0.33) 100 80 (2.0) 50 (0)d
2.5y 4-Cl,3-CF3 - - - 0 (0.2) 0(0)d
2.5z 3-Brc 0(0) 80 (1.0) 80 (-1.0) 100 -
2.5aa 4-B rc - 40 (9.0) - 0 (7.4) -
2.5bb 3-F c 0 (0.8) 20(0) - 0 (-1.0) -
2.5cc 4-F c 80(0) 20 (-0.5) - 0 (-0.6) -
2.5dd 3,4-F2 - - - 0(-1.0) -
2.5ee 3-OMe - - - 0(0) 0 (0.5)
2.5ff 4-OMe 20 (1.0) 75 (2.0) 40 (0.7) 60 (-0.5) -
2.5gg 3,5-(OMe>2 - 0(0) 20 (3.0) 100 100 d
2.5hh 4-OH - - - 0(0)d 0(0)d
2.5ii 3-N02 - - 0 (1.0)d 0 (-0.5)d 0(-1.0)d
2.5jj 4-N(Me)2 - - - 0(0)
2.5kk 3-CF3 100 100 40 (10) 0 (7.5)d -
2.511 4 -CF3 - 100 100 100 -
2.5mm 3,5-(CF3)2 - - - 0(0) 0(0)d
2.5nn 3-SMe - - - 0(0) 0(0)d
2.5oo 4-SMe - - - 0(0) 0 (1.5)d
2.5pp 4-S02Me 0 (-0.5) 0 (-0.8) - 0 (-2.0) -
2.5qq 4-CN - - - 0(0) 0(0)d
2.5rr 4 -CO2H “ • * 0 (-0.2) 0 (-0.5)d
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Table 2-6: Antimalarial activity of 3-methyI-10-(2'-substituted
phenyl)flavins against P. vinckei vinckei in mice a
Per cent cured and increase in mean survival (days) at dose, mg/kg b
Cmpd
no. (X)n 10 15 20 25 30 40 50 70
2.5b 2-Me 0 (-0.2) 0 (-1.0) 0 (-2.0) . .
2.5e 2,4-(Me>2 0 (0.4) - - - 20 (1.3) 40 (-1.7) 0 (-2.0) 0 (-2.0)
2.5h 2,6-(Me)2 0(0) - 0 (-0.3)c 0 (-2.0) - - - 0(-2.0)d
2.5i 2-Et 0(0) - 0 (-2.0) - 0 (-2.0) - - -
2.5m 2-C1 e - - - - 0 (-0.3) - - 0 (-2.0)
2.5p 2 ,4 -02  f o (1.7) 0 (0.5) 0(0) 0 (-1.2) 0(-1.0) - - -
2.5q 2,5-Cl2 e - - - - 0 (0.3) - - 0 (-0.6)8
2.5v 4-Cl,2-Me f 0 (0.5) 0 (1.2) 0(1.2) 0 (-1.4) 0 (-2.0) - - -
2.5 x 4-Cl,2-F 0 (1.0)d - 0 (4.0)d’h - 0 (-2.0)d - - -
a See section 7-3.l(i) for experimental details. b Most groups consist of 4 to 6 animals. c Activity 
detected by day two blood smear, average parasitemia 50%. d Denotes a group of two mice. 
e Compounds which were retested, for previous testing see reference [42]. f This compound included for 
comparison; see reference [42]. 8 Activity detected by day two blood smear, average parasitemia 56 %. 
h Activity detected by day two blood smear, average parasitemia 27 %.
Table 2-7: E D 40 values o f some active 3-m ethyl-10-(substituted
phenyl)flavins a
ch3n^ Vv^ nN | x:::^
■(X) n
Cmpd no. (X)„ ED40
(mmoles/kg xlO'3)
95 % confidence limits 
lower upper
2.5aa 4-Br 38.4 35.4 40.9
2.5o 4-C1 38.8 35.5 41.6
2.5s 3,5-Cl2 40.2 36.0 44.1
2.5kk 3 -CF3 79.3 73.1 86.1
2.5u 3-Cl,5-Me 85.7 80.2 92.6
2.5cc 4-F 103 95.0 112
2.5g 3,5-(Me)2 105 94.2 118
2.511 4 -CF3 135 124 146
2.5hh 4-OMe 138 133 143
2.5z 3-Br 148 138 162
2.5w 4-Cl,3-Me 182 176 195
2 .5f 3,4-(Me)2 210 205 216
2-5gg 3,5-(OMe)2 219 210 229
2.5n 3-C1 229 221 242
2.5a H 248 235 290
2.5k 4-Et 281 271 292
2.5t 3-Cl,4-Me 456 363 582
a See section 2-4.3 for details.
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2-4.4 Discussion
(i) Structure activity relationships (SAR)
On enlarging the series of 3-methyl- 10-(substituted phenyl)flavins first 
investigated by Cowden ex al. [42,76], ten new active compounds were found though 
none were more active than the previously noted 4'-Br (2.5aa), 4’-Cl (2.5o) and 
3',5'-Cl2 (2.5s) substituted compounds. The two new compounds which showed the 
next best activity were the 3'-CF3 (2.5kk) and 3’-Cl, 5’-CH3 (2.5u) substituted flavins. 
The relative order of activity of the active compounds is shown in Table 2-7. The action 
of these compounds as blood schizontocides is clear by the suppression of parasitemia on 
day two after treatment
When activity was detected in a flavin with a single substituent it was noted that 
the 4'-substituted substance was more active than its 3'-substituted positional isomer, the 
only exception to this was the 3-methyl-10-(3'-trifluoromethylphenyl)flavin which was 
found to be more active than its 4'-substituted analogue. Of the disubstituted compounds 
those that were 3',5'-disubstituted and active, were always found to have higher potency 
than their 3',4'-disubstituted isomers. This is exemplified by the substituted flavins 
3',5'-Cl2 (2.5s), 3',5'-Me2 (2.5g) and 3'-Cl, 5-Me (2.5u) as seen in Table 2-5.
All the flavins in the subgroup comprising 2 -substituted compounds (activity 
shown in Table 2-6) showed toxicity in the dose range tested and were always more toxic 
than any other positional isomer tested. A number of these compounds had activity, the 
most obvious one being the 2',4'-Me2 compound (2.5e), which showed activity at 30 
and 40 mg/kg. Of the other 2'-substituted phenyl compounds activity could only be 
detected by examination of the day two parasite counts, since toxicity masked activity as 
gauged by percentage cured or extension in lifespan. The three other active 2'-substituted 
phenyl compounds included the 2',5'-Cl2 (2.5q), 2',6’-Me2 (2.5h) and 2'-F, 4'-Cl 
(2.5x) substituted derivatives.
It has been shown that large groups in the 2'-positions of similar 10-phenyl 
flavins restrict the rotation of the phenyl group around the C(l') - N(10) bond because of 
steric hindrance [77]. It was thought that steric hindrance by the groups in the 2' position
Figure 2-6 Schematic diagram of the principles of quantitative
structure-activity analysis
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and the resulting loss of free rotation of the 10-phenyl group may have been the common 
feature responsible for the high toxicity of this subgroup. To investigate this possibility 
the 2' position was substituted with the small fluoro group in the 2'-F, 4'-Cl compound 
2.5x. However, while this compound did show activity it still remained toxic indicating 
that the relatively high toxicity characteristic of this subgroup is apparently not dependent 
upon the steric bulk of the 2’-substituent. Because of the high toxicity and obvious low 
therapeutic index of these flavins work was terminated in this area after testing five new 
compounds.
(ii) Quantitative structure-activity analysis (QSAA)
A systematic method was required for selecting substituents to be introduced into 
the 10-phenyl ring that would lead to compounds with higher antimalarial activity. An 
approach dealing with this problem is quantitative structure-activity analysis (QSAA).
This technique assumes that congeners of a series are all acting in the biosystem by the 
same mechanism to produce biological activity and that the activity is related to the 
chemical structure of the compound. Fig 2-6 schematically illustrates the principles of 
this method [78]. The aim of this technique is to obtain a quantitative structure-activity 
relationship (QS AR) from the biological and molecular descriptive data obtained from a 
sample of compounds. The QS AR reveals the molecular parameters (descriptors) of 
importance to the biological response and how they are quantitatively related. This allows 
the prediction of activity of as yet unsynthesised compounds.
In the present case it is the substituents on the 10-phenyl ring that are varied and 
the biological activity is their in vivo antimalarial activity. Variation of the substituents on 
benzene rings is a common method used to change biological activity and has been 
utilized extensively, in combination with QSAA, in the study of compounds with 
antimalarial [79], antiallergic [80], antileishmanial [81] and antiviral activity [82] to cite 
but a few examples. The advantage, among others, of altering substituents on a benzene 
ring is that there exists a large literature data base of molecular descriptors available for 
such substituents [83-87]. This obviates the need for experimentally determining the
Table 2-8 Physicochemical parameters used in QSAA of the 3-methyI- 
lO -P '^ '^ '-substitu ted  phenyl)flavins
Physicochemical parameters a
Cmpd no. (X)n b
l 7 Cc I * d X r d l a I F I R S  MR
2.5a H 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2.5c 3-Me 0.56 0.52 0.50 -0.07 -0.05 -0.05 4.70
2.5d 4-Me 0.56 0.60 0.48 -0.17 -0.05 -0.14 4.70
2.5f 3,4-(Me)2 1.12 1.12 0.98 -0.24 -0.10 -0.19 9.40
2.5g 3,5-(Me)2 1.12 1.04 1.00 -0.14 -0.10 -0.10 9.40
2.5j 3-Et 1.02 0.99 0.94 -0.07 -0.06 -0.04 9.40
2.5k 4-Et 1.02 1.10 0.98 -0.15 -0.07 -0.11 9.40
2.51 4-n-butyl 2.13 2.10 1.98 -0.16 -0.06 -0.13 18.7
2.5n 3-C1 0.71 0.77 1.04 0.37 0.68 -0.06 4.8
2.5o 4-C1 0.71 0.73 0.93 0.23 0.69 -0.16 4.8
2.5r 3,4-Cl2 1.42 1.50 1.97 0.60 1.37 -0.22 9.6
2.5s 3,5-Cl2 1.42 1.44 2.08 0.74 1.36 -0.12 9.6
2.5t 3-Cl,4-Me 1.27 1.37 1.52 0.06 0.63 -0.20 9.5
2.5u 3-Cl,5-Me 1.27 1.29 1.54 0.30 0.63 -0.11 9.5
2.5w 4-Cl,3-Me 1.27 1.25 1.43 0.16 0.64 -0.21 9.5
2.5y 4-Cl,3-CF3 1.59 1.83 2.42 0.66 1.31 -0.09 8.8
2.5z 3-Br 0.86 0.96 1.17 0.39 0.71 -0.06 7.6
2.5aa 4-Br 0.86 1.19 1.13 0.23 0.73 -0.18 7.6
2.5bb 3-F 0.14 0.22 0.47 0.34 0.69 -0.12 -0.04
2.5cc 4-F 0.14 0.15 0.31 0.06 0.71 -0.34 -0.04
2.5dd 3,4-F2 0.28 0.37 0.78 0.40 1.40 -0.46 -0.08
2.5ee 3-OMe -0.02 0.12 0.12 0.12 0.41 -0.17 6.5
2.5ff 4-OMe -0.02 -0.03 -0.12 -0.27 0.41 -0.50 6.5
2.5gg 3,5-(OMe>2 -0.04 0.24 0.24 0.24 0.82 -0.34 13.0
2.5hh 4-OH -0.67 -0.61 -0.87 -0.37 0.49 -0.64 1.5
2.5ii 3-N02 -0.28 0.11 0.54 0.71 1.09 0.05 6.0
2.5jj 4-N(Me>2 0.18 -0.08 -0.69 -0.83 0.03 -0.85 14.4
2.5kk 3-CF3 0.88 1.10 1.49 0.43 0.62 0.07 4.0
2.511 4 -CF3 0.88 1.04 1.05 0.54 0.63 0.19 4.0
2.5mm 3,5-(CF3)2 1.76 2.20 2.98 0.86 1.24 0.14 8.0
2.5nn 3-SMe 0.61 0.64 0.55 0.15 0.33 -0.07 13.0
2.5oo 4-SMe 0.61 0.87 0.32 0.00 0.33 -0.19 13.0
2.5pp 4-S02Me -1.63 -1.20 -1.02 0.72 0.90 0.22 12.5
2-5qq 4-CN -0.56 -0.33 0.14 0.66 0.85 0.18 5.2
2.5rr 4-C02H -4.36 e e 0.00 e e e
a Physicochemical parameters defined in section 2-4.4(ii).b Indicates substitution of the 10-phenyl of the 
flavins. c Obtained from reference [88].d Obtained from reference [86].e Not avialable.
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molecular parameters. It is therefore possible to attempt to relate changes in biological 
activity to changes in the molecular descriptors of the different substituents used.
The molecular descriptors are defined in terms of physicochemical properties 
which usually consist of the three major subgroups of lipophilic, electronic and steric 
parameters. In this study no mode of action was previously known and thus there was 
no guide suggesting which of these physicochemical properties might have been most 
important to antimalarial activity, so parameters related to all three properties were used in 
the following analysis. The 3-methyl-10-(substituted phenyl)flavins and their 
physicochemical parameters considered are shown in Table 2-8.
To define the relative lipophilicity of the substituents, k values were used (n 
values from model systems are defined by the equation 
7tx = log Px - log PH
where Px is the partition coefficient of a X-substituted derivative and Ph that of the parent 
compound). A positive k value indicates that relative to hydrogen the substituent is 
lipophilic, while a negative value indicates it hydrophilic vis-a-vis hydrogen. In Table 
2-8 the X tc values are the sum of the k values of substituents in the 3', 4' and 5’ 
positions. The three different X n values presented are based on: (1) % values obtained 
from Martin [88]; (2) n values obtained from Norrington et al. [86] in which k is 
positionally dependent; and (3) tC values also obtained from Norrington et al. which are 
based on a model system containing an electron donating side chain on the benzene ring. 
These three represent alternative measurements of the same property. The importance of 
the K parameter lies in its established correlation in binding to biological macromolecules 
and transport through biological systems.
The electronic properties of a compound were represented by the sum of the 
Hammett constants (a) of the 3', 4' and 5’ substituents on the 10-phenyl ring. The a  
constant is comprised of both inductive and mesomeric effects and therefore can also be 
represented by F and R values which are positionally weighted parameters indicating the 
inductive and mesomeric effects respectively, [86]. The X a, and X F and X R values 
represent two alternate measures of the electronic properties of the substituted flavins.
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The values used to obtain E a  were obtained from Martin [88] and those for E F and E R 
were obtained from Norrington et al. [86].
The steric properties of the substituents were represented by the sum of their 
molar reffactivity values (E MR). MR values are usually obtained experimentally by the 
Lorentz-Lorenz equation;
where V is molar volume and n is the refractive index. The MR values of common atoms 
and groups of atoms have been calculated using model systems. Since for liquid organic 
compounds n does not vary much, MR is really a "corrected" form of molar volume and 
as such represents a measure of the bulk of a substituent [83,85]. As MR increases so 
does the bulk of the substituents, the MR values used to obtain E MR were taken from 
Norrington et al. [86].
The importance of the electronic and steric properties of a drug relate to their 
intrinsic importance in the interactions, both physically and chemically, in the biosystem.
It was decided to use the methodology of QS AA as no obvious trend was 
observed between activity and any single one of the above parameters. It was thought 
that QS AA might indicate a relationship between activity and a combination of these 
parameters.
The first step in QSAA is choosing substituents to be used for synthesising a 
sample group of compounds. This group is referred to as the "training set", upon whose 
physicochemical and biological data the QS AR is to be based. The aim of this selection is 
to obtain a preliminary series in which all the physicochemical and structural properties 
that may be governing biological activity are varied systematically and independently from 
each other over a sufficiently large range. Different techniques for designing training 
series have been discussed by Craig [89], Wooldridge [90], Wootton et al. [91], Hansch 
et al. [92], and Dove et al. [93].
In the present study the training series was based on the expansion of an already
existing group of compounds made by Cowden et al. [42]. The selection of new 
congeners was made on the basis of the following:
1. With the aid of the TMIC (two-dimensional mapping of intraclass correlation matrices) 
method of Dove et al. [93], which allows the selection of single substituents that have 
high data variance and low collinearities of the major physicochemical parameters, by 
simple inspection of a two dimensional map of 35 possible single substituents;
2. For the majority of the disubstituted compounds, selection of substituents and position 
was made to determine the effect of various substitution patterns or, in an effort to 
increase activity, by combining single substituents which had shown activity; and
3. The selection processes above in 1. and 2. were subject to the synthetic feasibility of 
preparing potential congeners (see section 2-2).
The toxicity of and the difficulty in obtaining reliable physicochemical parameters 
for the 2'-substituted phenyl flavins meant that they were excluded from the following 
attempts at QS AA.
Initially an attempt was made to obtain a QSAR using the popular "Hansch" 
methodology. The Hansch method uses least squares multiple linear regression to 
correlate biological activity data to molecular parameters [94]. A requirement of the 
Hansch approach is that the biological data be in the form of a continuous quantity, 
usually the log molar dose of a drug required to produce a standard biological response. 
Of the training series made and tested shown in Table 2-5 such values were only 
obtainable for the subgroup of compounds in Table 2-7 in the form of ED40 values. For 
16 of the flavins in the training series ED40 determination was not possible usually 
because they were inactive in the dose range tested.
The physicochemical data used in the multiple regression analysis is shown in 
Table 2-8. As well as these parameters four indicator variables, indicating whether the 
flavins were 3'-, 4'-, 3',4'- or 3',5’- substituted, were included as the substitution 
pattem appeared to be a factor of importance from the S AR analysis.
In the hands of a statistical analyste a linear regression model was fitted;
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e The author is grateful to Mr R. Cunningham, statistical consultant, Statistics Department, The 
Australian National University, for the statistical analysis.
Table 2-9: Biological data used in QSAA and predicted ED40 values
Compound
no.
(X)n a Activity b e d 40c
(mmoles/kg x
Predicted ED40 d 
10'3) (mmoles/kg x 10'3)
2.5a H 1 248 204
2.5c 3-Me 0 - 201
2.5d 4-Me 0 - 201
2.5f 3,4-(Me>2 1 210 221
2.5g 3,5-(Me)2 1 105 221
2.5j 3-Et 0 - 214
2.5k 4-Et 1 281 216
2.51 4-n-butyl 0 - 214
2.5n 3-C1 1 229 113
2.5o 4-C1 1 38.8 112
2.5r 3,4-Cl2 1 - 62.7
2.5s 3,5-Cl2 1 40.2 62.7
2.5t 3-Cl,4-Me 1 456 118
2.5u 3-Cl,5-Me 1 85.7 118
2.5w 4-Cl,3-Me 1 182 118
2.5y 4-Cl,3-CF3 0 - 65.9
2.5z 3-Br 1 148 110
2.5aa 4-Br 1 38.4 109
2.5bb 3-F 1 - 112
2.5cc 4-F 1 103 110
2.5dd 3,4-F2 0 - 60.8
2.5ee 3-OMe 0 - 142
2.5ff 4-OMe 1 138 142
2.5gg 3,5-(OMe)2 1 219 100
2.5hh 4-OH 0 - 133
2.5ii 3-N02 0 - 79.6
2.5jj 4-N(Me)2 0 - 198
2.5kk 3-CF3 1 79.3 119
2.511 4-CF3 1 135 118
2.5mm 3,5-(CF3)2 0 - 69.9
2.5nn 3-SMe 0 - 153
2.5oo 4-SMe 0 - 153
2.5pp 4-SC^Me 0 - 93.5
2.5qq 4-CN 0 - 97.3
2.5rr 4-CC^H 0 * *
a Indicates substitution of the 10-phenyl of the flavins. b Activity is indicated by 1, inactivity by 0; based 
on the data in Table 2-5 .c ED40 values taken from Table 2-7. d ED40 values predicted using equation 2-1 
and parameters from Table 2-8.
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computations were executed using the statistical package Genstat 5. The analysis 
involved first using all the independent variables (i.e. the physicochemical parameters and 
the four indicator variables) in a full model followed by removing the variables 
individually. Using the F  distribution statistic (variance ratio) compared to the 
appropriate F  value (according to degrees of freedom) it was possible to determine the 
significance of each independent variable as it was removed The best model which could 
be found using this method is shown in equation 2-1.
ln (ED40) = -1.592 - 0.863 I F  Equation 2-1
(0.277) (0.426) estimated std errors
n = 17 R2adj = 16.2 s = 0.725
This equation indicates that the greater the inductive electron withdrawing effect (large 
positive I  F  values) of the substituents in the 3', 4' and 5' positions the higher the 
activity. However, the t statistic (2.02) is barely significant (considered significant if 
greater than 2.1), thus this was a poor model for predicting activity. This is highlighted 
by the inactivity of the 3'-NC>2, 3',5'-(CF3)2, 4’-S02CH3 and 4'-CN substituted flavins, 
which were not included in this analysis, but by equation 2-1 were predicted to have good 
activity (shown in Table 2-9).
This method, because of the type of statistical analysis used was limited to the 
biological data that was presented as ED40 values. This left out a large proportion of the 
training set, therefore limiting the physicochemical "space" covered in the model as well 
as reducing the number of compounds that could be included in the regression. The 
failure to use the entire training set could be responsible for the poor model produced.
To overcome this data gap an alternative statistical method was used that allowed 
inclusion of the entire series. This method, of logistic regression [95], allowed the 
biological response to be entered as binary data, in this case either as active or inactive. 
This method is similar to previously used methods of discriminant analysis [96,97] in that 
it allows the use of qualitative biological responses.
In this study logistic regression analysis was used to determine if the independent 
variables considered in the Hansch approach effect the probability of a compound being 
active or not Activity is defined by detection of antimalarial activity (Table 2-5) and is
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indicated by 1 in the activity column of Table 2-9; 0 indicates the compound to be 
inactive.
In a stepwise analysis of a full model similar to that done in the linear regression 
analysis, it was found that none of the terms were significant using the Chi-square test as 
a measure of significance and no equation could be found that was superior to the null 
hypothesis (the random probability of a compound being active).
Aliens [98] has listed and discussed eight factors that could be involved in the 
apparent lack of a structure-action relationship. These include:
1. A lack of a relationship between the physicochemical parameters used and 
those of importance in the bioreaction that produces activity.
2. It is a metabolite which is responsible for activity and not the administered 
drug itself.
3. The action of a drug can be the result of a sequence of complicated events often 
involving pharmacokinetic processes. Each event may be related differently to 
the physicochemical properties of the drugs. If the physicochemical property 
requirements between events relate to each other in a contradictory or incompatible 
fashion then drug action as a whole may not be easily related to physicochemical 
properties. This is because, in essence, they are not of an additive nature amongst 
the different processes.
4. The possibility of a mixture of isomeric compounds which have different 
effects biologically being administered as a single test compound. Obviously such 
occurrences would severely compromise the nature of the biological data.
5. It is assumed that all members of a series are working by the same mechanism 
of action and in in vivo models that they have similar pharmacokinetic 
mechanisms. If this is not the case a clear cut QS AR could not be expected.
6. The route of administration and the pharmaceutical preparation of compounds 
can often have large influences on the potency of drugs, for example, the particle 
size and crystal structure of a drug may influence its potency. The disparity that 
may be occasioned by these differences may obscure a structure-activity 
relationship.
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7. Drugs often have more than one biological action which may coincide or 
overlap to a considerable degree. Toxic side effects can be especially important in 
the in vivo model. Thus drugs which are multipotent have the ability to 
complicate the determination of a QSAR.
8. The diversity in drug action between species is well known, due in a large 
number of cases to pharmacokinetic differences amongst species. Such 
differences must be taken into account in formulating a QSAR.
With this in mind, it seems that the most likely reason for not obtaining a satisfactory 
QSAR for the flavins was the in vivo nature of the biological response. Thus, as noted in 
vivo results give valuable information about toxicity and compounds with favourable 
pharmacokinetics but in the determination of a QSAR this extra information may obscure 
the relationship. The possible factors that may be responsible in the present case include 
points 2, 3, 5, 6 and 7 from above. The importance of the complicated pharmacokinetic 
processes in this series is shown by the differences observed in the SAR of the in vitro 
and in vivo testing of these compounds (discussed in section 2-5.4) and the differences in 
the dose-response curves amongst the active flavins demonstrated in Fig 2-5.
The other major possibility of why no QSAR could to be obtained was that the 
descriptor parameters used were not those of importance to biological activity (point 1 
above). This is always a possibility in QSAA in systems where there is no mechanistic 
model available on which to base the choice of molecular descriptors. In this flavin 
QSAA the selection of parameters was based on those that have most frequently been 
shown to be important in determining biological activity. The additional inclusion of the 
many other possible molecular parameters available [83,99] was not considered as these 
other parameters are usually less well defined and often have a high degree of collinearity 
with those parameters already tested. Besides this, it has been shown there is a limit to 
the number of explanatory variables, relative to sample size, which may be used in QSAA 
before the occurrence of chance correlations [100]. It is necessary to increase the sample 
size before increasing the number of variables screened in order to avoid obtaining 
correlations of doubtful significance.
In conclusion, a large number of compounds with different substituents, in which
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the physicochemical properties were altered over a wide range, were made and tested. 
Since none were found to be more active than those in the original set prepared by 
Cowden et al. [42] and no useful predictive equation could be obtained using the methods 
outlined above, it was felt that further work on phenyl substitution to enhance potency 
was not warranted.
The information about the in vivo effects of substituents on the 10-phenyl ring 
was utilized to optimize activity when other structural changes were subsequently made in 
the following chapters.
2-5 In vitro antimalarial testing 
2-5.1 Introduction
With the advent of a continuous culture method for P. falciparum in human 
erythrocytes, made possible by the work of Träger and Jensen [101] in 1976, it became 
possible to routinely test compounds against the principal human malarial parasite in a 
model free of the majority of the undesirable pharmacokinetic effects characteristic of in 
vivo models. Desjardins et al. [102] utilized the methods of continuous culture to 
develop a rapid, semiautomated, microdilution technique to measure the antimalarial 
activity of compounds against the asexual intraerythrocytic forms of P . falciparum. Their 
technique involved the growing of cultures in 9 6-well microtiter plates and the addition of 
a radiolabelled substrate which would be incorporated into the nucleic acid of the 
parasites. The 96-well plate allowed for large scale testing of compounds as each 
microwell is capable of being treated with different drugs and concentrations. In this 
particular method parasite development, after an incubation period, is quickly and 
accurately measured by determining the level of 3H-hypoxanthine incorporation into the 
parasite using liquid scintillation counting.
The basic method of Desjardins et al. has been used successfully by numerous 
workers to, amongst other things, detect activity of potential antimalarials, identify the 
stage specificity of existing drugs and to investigate synergy of new and old antimalarials 
[102-105]. A brief review by Träger [106] relates the many applications of cultured
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P. falciparum in both basic and applied malaria research.
In this investigation the Desjardins technique, with slight modifications, was used 
to confirm the activity of the flavins against the human parasite, look for cross resistance 
between the flavins and the established antimalarials chloroquine and pyrimethamine, and 
to carry out limited structure activity relationship studies in a situation free of many of the 
problems related to pharmacokinetics.
2-5.2 Materials and methods
In this work two variations of the Desjardins in vitro radioisotopic technique were 
used to determine the activity of ten flavins and three established antimalarials against 
P. falciparum. The first method (method 1) was conducted in collaboration with Dr G. 
A. Butcherf in which activity was determined against the chloroquine-sensitive FC-27 
strain. The second method (method 2) involved testing against both the chloroquine- 
sensitive FC-27 and chloroquine-resistant K-l strains. (The K-l strain is also resistant to 
other established antimalarial drugs, see Table 2-10.) This was kindly carried out by 
Dr K. A. Rockett 8 . In both methods incubation times were 48 hours to allow one 
complete cycle of blood schizogony.
The experimental details of both methods are contained in section 7-3. l(ii).
f Department of Pure and Applied Biology, Imperial College, Prince Consort Rd, London, SW7 2BB. 
8 Division of Cell Biology, John Curtin School of Medical Research, The Australian National 
University, Canberra, ACT, 2601, Australia.
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2-5.3 Results 
Method 1
The results of the P. falciparum (FC-27) assay are presented in Fig 2-7, in which 
the percentage inhibition of parasite growth is measured by the inhibition of the uptake of 
tritiated hypoxanthine in drug-treated parasite cultures compared to drug-free control 
cultures.
Figure 2-7 Inhibition of cultured P. falciparum (FC-27 chloroquine- 
sensitive) by 3-methyl-10-(substituted phenyl)flavins
£ouex
*35auce
Q.
co
c
hH
2.5o (4'-Cl) 
2.5nn (3'-SMe) 
2.5a (H)
2.5r (3\4'-diCl) 
2.5ff(4’-OMe)
[ Flavin ] (jiM)
Each datum point is the mean for the sample tested in triplicate in a single experiment. 
Substituents on the 10-phenyl ring are shown in brackets. The point used to compare 
activity is the concentration that inhibits the uptake of 3H-hypoxanthine by 50%.
Table 2-10: In vitro antimalarial activity of chloroquine,
pyrimethamine, quinine and flavins against 2 isolates of 
P. falciparum  (FC-27 and K-l)
Compound a IC50b-c (HM) 
FC-27 K-l
Factor of resistance in K -ld
Chloroquine 0.04 2.5 63
Pyrimethamine 0.34 >100 >294
Quinine 7.4 x 10-2 0.56 8
2.5kk (3'-CF3) 3.0 3.6 1.2
2.5s (3\5’-Cl2) 2.3 4.8 2.1
2.5g (3',5’-Me2) 5.6 13.6 2.4
2.5qq (4’-CN) 4.2 e -
2.5rr (4'-C02H) 24.7 e -
a Substitution of the 3-methyl-10-(substituted phenyl)flavins is indicated inside brackets. 
b IC50 is the concentration required to inhibit the uptake of 3H-hypoxanthine by the 
culture by 50%. c These results were obtained from a single experiment done in triplicate. 
d This value was obtained by dividing the K-l IC50 by the FC-27 IC50. e Not done.
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Method 2
Results of a typical assay for 3-methyl-10-(3'-trifluoromethylphenyl)flavin against 
both the VC-21 strain and K-l multidrug-resistant strain are shown in Fig 2-8. The IC50 
values (concentration of the compound causing 50% inhibition of 3H-hypoxanthine 
incorporation) of the flavins and other antimalarials are given in Table 2-10.
Figure 2-8 Inhibition of cultured P. falciparum strains FC-27
(chloroquine-sensitive) and K-l (chloroquine-resistant) by 
3-methyl-10-(3'-trifIuoromethylphenyl)flavin
FC-27 strain
K-l strain
[Flavin] (jiM)
Each datum point is the mean ± 1 Std Dev for the sample tested in triplicate in a single 
experiment. The point used to compare activity is the dose that inhibits the uptake of 
3H-hypoxanthine by 50%. The concentration is plotted on a log scale.
Table 2-11: 3-M ethyI-10-(substituted phenyl)flavins selected on the
basis of in vivo activity and physicochemical param eters
CH
O
X /  N 
[1ST
X
( X ) „
Compound (X)n 
no.
In vivo 
activity a
Z o b I i t b Z MR b
2.5o 4-C1 38.8 0.23 0.71 4.8
2.5nn 3-SMe not active 0.15 0.61 13.0
2.5a H 248 0.00 0.00 0.0
2.5ff 4-OMe 138 -0.27 -0.02 6.5
2.5r 3,4-Cl active c 0.60 1.42 9.6
a Activity is reported as ED40 values (mmoles/kg x 10‘3) from Table 2-7 or as active or 
not active according to results from Table 2-5. b Physicochemical parameters are the same 
as those in Table 2-8. c Activity was detected at a dose of 140 mg/kg.
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2-5.4 Discussion of results
Using method 1 a subgroup of five of the forty compounds in this series was 
selected for in vitro testing against P. falciparum (FC-27). The five compounds selected 
comprised a group that varied in in vivo activity and in their physicochemical properties 
(based on their 10-phenyl ring substituents). Table 2-11 shows the compounds selected, 
their in vivo activity and the physicochemical properties of the substituents. Figure 2-7 
shows that all these compounds were active in vitro confirming similar findings of 
Cowden et al. [41] and Becker et al. [107] who also noted good in vitro activity for 
members of this series. By interpolation from this graph, the five flavins have IC50 
values ranging from approximately 5 to 13 |i M.
This narrow range of potency from a series of compounds which vary widely in 
the nature of their substituents, makes it seem likely that variation of substituents on the 
10-phenyl ring of the flavin has little effect in terms of direct anti-parasitic action. The 
significance of this observation becomes apparent when compared to the in vivo results. 
The fact that the order of the in vivo activities of these compounds was not reflected in the 
in vitro activities strongly suggests that alteration of the substituents on the 10-phenyl ring 
is primarily important in terms of in vivo events such as drug transport, distribution and 
excretion after injection. This difference in activity between culture and in vivo testing is 
especially highlighted in the case of 3-methyl-10-(3'-methylthiophenyl)flavin (2.5nn) 
which was inactive in vivo but showed nearly equivalent in vitro activity to the highly (in 
vivo) active 10-(4'-chlorophenyl)-3-methylflavin (2.5o). This indicates the in vivo 
results are not direct indicators of mechanistic activity.
Using method 2 a different group of five 3-methyl-10-(substituted phenyl)flavins 
were tested against P. falciparum. All of these flavins were tested against the FC-27 strain 
and three of the five were tested against the drug resistant K-l strain.
The 10-(4'-carboxyphenyl)-3-methylflavin (2.5rr) is unique among the series of 
3-methyl- 10-(substituted phenyl)flavins in that at physiological pH it is likely to form a 
carboxylic acid anion. This compound was originally synthesised in order to take 
advantage of the reported increase in permeability to anions of malaria-infected
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erythrocyte cell membranes [108], however, it failed to show any activity in the in vivo 
testing. This compound was selected for in vitro testing to determine if its anion forming 
properties had any detectable benefit in this more direct testing system. The IC50 of this 
compound showed it to be the least efficacious of the flavins examined, thus indicating 
that anion formation in this case had no beneficial effect.
The IC50 values of the other four flavins examined against the FC-27 strain 
ranged from 2.3 to 5.6 |1 M. These values are not directly comparable to the results 
obtained using method 1 because of differences in experimental procedure. Nonetheless, 
the potency and narrow range of activity are similar to those observed in method 1 and 
confirm the conclusions that: (i) variation of the 10-phenyl substituents usually has only 
small effects on in vitro activity; and (ii) in vitro activity does not directly correlate with 
in vivo activity.
In a comparison of the drug sensitivity of the two P. falciparum strains PC-21 and 
K-l, the K-l strain was found to be resistant to the currently used antimalarial drugs 
pyrimethamine and quinine by factors of >294 and 8, respectively, as well as to 
chloroquine by a factor of 63. These findings are consistent with previous reports 
[105,109] and established that the K-l strain used in this study was indeed multidrug- 
resistant.
The results of testing the three flavins (2.5kk, 2.5s, 2.5g) against both the 
drug-sensitive and drug-resistant strains in Table 2-10 show that the flavins are 
consistently slightly less active against K-l than FC-27 by a factor of 1.2 to 2.4. These 
small differences in activity between strains, when compared to the large differences in 
the chloroquine and pyrimethamine sensitivities indicate there is no substantial cross 
resistance between these agents. This finding is important since it shows that these 
flavins, which have good in vivo activity, are of potential use in cases of chloroquine- 
and pyrimethamine-resistant malaria. This finding also indicates that the flavins' mode of 
action is most likely dissimilar to that of chloroquine and pyrimethamine.
In addition to the above findings the in vitro assay also provides an estimate of the 
plasma drug levels that need to be achieved for in vivo inhibition of the parasite. Studies 
on plasma levels of active and inactive flavins could be used to confirm that variation in
Figure 2-9 The ineffectiveness of flavins 2.5s (3',5'-Cl2) and 2.5o 
(4‘-Cl) against B. microti infection in mice
Control
Group 1 
Group 2 
Group 3
CU 30 -
Days
For all groups treatment began on day 1. Group 1 with a daily dose of 15 mg/kg of 
compound 2.5s for 5 days. Group 2 with a daily dose of 5 mg/kg of compound 2.5s 
for 5 days. Group 3 with a daily dose of 10 mg/kg of compound 2.5o for 4 days. The 
control received a daily injection of vehicle only for 5 days. Each datum point is the mean 
of the daily parasitemia of a group of 4-6 mice. For clarity only the control group has 
error bars representing ± 1 Std Dev.
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in vivo activity of the 3-methyl-10-(substituted phenyl)flavins is primarily a function of 
pharmacokinetics. Such a study could also yield information concerning the possibility 
that antimalarial activity might be due to an active metabolite. Though there is no 
evidence for this supposition, the apparent lack of correlation between in vivo and in vitro 
antimalarial activity and the failure to obtain a QS AR could be explained in these terms 
[110]. It should be noted, however, that the observed activity of these compounds both 
in vitro and in vivo would tend to indicate that this is not the case.
In this study only blood schizontocidal activity was studied. The development of 
new culturing techniques for the exoerythrocytic and gametocyte stages of the human 
malaria parasite in the 1980s [111-114] means that drug testing assays against these 
stages could soon become commonly available. If this happens it would be interesting to 
determine the activity of the flavins against these other parasite stages.
2-6 Other test systems
2-6.1 In vivo antibabesial testing
Babesiosis is a tick-borne disease of wild and domestic animals, its major 
economic importance is in the cattle industry. It is caused by an intraerythrocytic 
protozoan parasite of the genus Babesia. Occasionally human infection occurs, of these 
the majority of cases have been caused by Babesia microti, a parasite of rodents [115].
The morphological similarities between B. microti and malaria parasites and the 
overlap of effective drugs for both diseases [115] lead to the decision to screen two of the 
more effective antimalarial flavins for antibabesial activity.
This screening, using B. microti in mice [116] involved the daily intraperitoneal 
injection of 10-(3',5'-dichlorophenyl)-3-methylflavin (2.5s) at 5 and 15 mg/kg and 
10-(4’-chlorophenyl)-3-methylflavin (2.5o) at 10 mg/kg for 4-5 days after the disease 
first became patent. The result of this screen is seen in Fig 2-9 where the average daily 
percentage parasitemia of the treated groups are compared to a control group throughout 
the course of the disease. No significant suppression of parasitemia (the slight 
depression of the maximum parasitemia on day 6 in the treated groups was found not to
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be significant by Student's t test) and the resemblance of the curves of the treated groups 
to that of the control group indicated that these compounds had no activity against 
B. microti in mice over the dose range tested. The experimental details of this procedure 
are presented in section 7-3.2.
2-6.2 Giardia intestinalis
The protozoan parasite Giardia intestinalis is found world-wide and is an 
important cause of chronic and sometimes serious gastrointestinal disease especially in 
children. It has been shown that G. intestinalis is susceptible to l,3-bis(2-chloroethyl)-
1- nitrosourea (BCNU) and l-(2-chloroethyl)-3-(2-hydroxyethyl)-l-nitrosourea 
(HECNU) [117]. Both of these compounds are inhibitors of glutathione reductase (GR) 
and have been shown to have antimalarial activity [118-120]. Since the flavins are 
likewise antimalarials and inhibitors of GR (see Chapter 6) the two compounds 2.5o and 
2.5g have been submitted for screening against G. intestinalis h . The screening method 
to be used is that of Boreham, Phillips and Shepherd [121]. Results of this screen are 
pending.
2- 6.3 In vitro anti-HIV and anticancer testing
The National Cancer Institute* 1 has recently begun a world-wide screening 
program to discover new antiviral agents effective against the human immunodeficiency 
virus (HIV). The screening method used is described by Weislow et al. [122]. The 
following compounds were evaluated for in vitro anti-HTV activity and classified as 
inactive; 2.5b (2'-Me), 2.5d (4’-Me), 2.5e (2\4'-Me2), 2.5g (3\5’-Me2), 2.5i (2'- 
Et), 2.51 (4'-rt-butyl), 2.5n (3’-Cl), 2.5q (2',5'-Cl2), 2.5y (4'-Cl, 3'-CF3), 2.5z (3'- 
Br), 2.5aa (4'-Br), 2.5bb (3'-F), 2.5cc (4’-F), 2.5dd (3,,4,-F2), 2.5ee (3’-OMe),
h Testing is to be kindly carried out by Dr P. F. L. Boreham, Queensland Instituted of Medical Research, 
Bramston Terrace, Herston, Brisbane, Queensland, 4006.
i Dr V. L. Narayanan, Drug Synthesis and Chemistry Branch, Executive Plaza North, Suite 811, 
Bethesda, Maryland, 20892, USA.
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2.5hh (4'-0H), 2.5mm (3’,5’-(CF3)2) and 2.5nn (3'-SMe). These compounds were 
also submitted to the National Cancer Institute for an in vitro pre-screen consisting of 
human cell lines representing major tumour types such as lung, colon and melanoma. 
The results of this anticancer screen are pending.
CHAPTER 3
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CHAPTER 3 Syntheses and antimalarial activity of some 3-substituted 
10-(substituted phenyl)flavins
3-1 Introduction
In this chapter changes made at the 3-N position and to substituents on the 10- 
phenyl group of the flavin are outlined. The variation at the 3 position was undertaken 
primarily to effect changes in the overall lipophilicity of the flavins. Three subgroups 
were produced including a series of 3-ethyl-10-(substituted phenyl)flavins (3.4a-l), 
3-substituted 10-phenylflavins (3.7a, 2.5a, 3.4p-r) and 3-substituted 10-(4'- 
chlorophenyl)flavins (3.7b, 2.5o, 3.4m-o). These compounds were tested for in 
vivo antimalarial activity where gains in both activity and lower toxicity, compared to 
their 3-methyl analogues (Chapter 2), were noted in a number of compounds. The 
3-substituted 10-(4'-chlorophenyl)flavin series were tested in vitro against P. falciparum 
and found to have little variation in potency throughout the series.
The synthesis, chemistry (electrophilic substitution), mass spectra and *H n.m.r. 
spectral data, along with results of antimalarial, anti-HIV and anticoccidial testing of these 
flavins are discussed in the following sections.
Scheme 3-1
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3-2 Syntheses
The two main routes used to produce the 3-substituted 10-(substituted 
phenyl)flavins were, firstly a modification of the main reaction pathway used to produce 
the flavins in Chapter 2 (shown in Scheme 3-1) and secondly, N-alkylation of the 
10-phenyl flavins formed from the reaction of N-phenyl-l,2-benzenediamines (3.6) with 
alloxan (Scheme 3-2).
The advantage of the latter method is that it allows the introduction of the 3-N 
substituent at the last step in the reaction sequence. This method does, however, have 
limitations in that the 3-phenyl derivative cannot be produced in this way (because of the 
inactivity of phenyl halides towards nucleophilic displacement) and the frequent difficulty 
encountered in producing the N-phenyl-l,2-benzenediamine starting materials.
Therefore, the former method is still advantageous when the aim of the synthesis is a 
concurrent alteration of substituents in both the 3-N position and the 10-phenyl ring or 
when a phenyl group is required at the 3 position.
A common method for the production of N-substituted barbituric acids, the 
starting material for Scheme 3-1, could not be found. The condensation of the 
monosubstituted ureas with malonic acid using acetic anhydride as a condensing agent 
was used to produce the N-ethyl and N-propyl barbituric acids [123].
Pure N-phenylbarbituric acid was produced in 40% yield by the literature method 
of MacBeth et al. [124] using N-phenylurea, malonic acid and the condensing agent 
phosphorus oxychloride. Brückmann and Isaacs [123] reported a 58% crude yield of 
N-phenylbarbituric acid using sodium methoxide as the condensing reagent which they 
reported to be a superior method to that of using acetic anhydride.
Only low yields of N-benzylbarbituric acid were obtained using acetic anhydride, 
as the condensing agent, due to the formation of large amounts of a by-product, probably 
5-acetyl-3-benzylbarbituric acid [63]. It was possible to convert this by-product to the 
desired N-benzylbarbituric acid by acid hydrolysis though only in low yields. An attempt 
to produce N-benzylbarbituric acid using phosphorous oxychloride as a condensing agent 
failed and starting material was recovered. A further attempt using the more reactive
Scheme 3-2
°2NV V H2Nv^ .
SnCl2/HCl
3 .5 3 .6
X
3.4 or 2.5
3 .5 ,3 .6 ,3 .7  I x R X
a H 2 .5a Me H
b 4-Cl 2 .5 jj Me N(Me)2
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malonyl dichloride (instead of malonic acid) and N-benzylurea under similar conditions 
as those used by Whiteley [125] to make 1,3-diphenylbarbituric acid produced an 
intractable mixture. N-Benzylbarbituric acid was finally produced most satisfactorily in a 
high yielding clean reaction of N-benzylurea, diethyl malonate and sodium ethoxide.
Of the N-substituted ureas used to make the N-substituted barbituric acids (3.1) 
the ethyl and phenyl ureas are commercially available. The propyl and benzyl ureas were 
made by a modification of Wohler's famous synthesis of urea. An aqueous solution of 
sodium cyanate (isocyanic acid) was heated with the appropriate amine hydrochloride.
Monochlorination (position 6) of the barbituric acids (3.1a-d) was achieved in all 
cases with phosphorous oxychloride and water in yields of 22 to 55% after the method of 
Gauri [66]. The nucleophilic substitution of the 3-substituted 6-chlorouracils (3.2a-d) 
by the appropriate aniline produced 3-substituted 6-(substituted anilino)uracils (3.3a-p) 
which were reacted with nitrosobenzene to give the 3-substituted- 10-(substituted 
phenyl)flavins (3.4a-p). These preceding three steps were carried out essentially in the 
same fashion as discussed in section 2-2.4.
Cowden et al. [42] produced 6-(4'-chloroanilino)uracil by the transamination of 
6-aminouracil with excess 4-chloroaniline under harsh reaction conditions. A similar 
reaction, based on the method of Goldner et al. [68], using 3-trifluoromethylaniline 
hydrochloride and 6-aminouracil gave 6-(3'-trifluoromethylanilino)uracil (3.3s) in good 
yield; furthermore the reaction conditions required were less harsh. When this product 
was treated with nitrosobenzene in the usual way it formed 10-(3'-trifluoromethyl- 
phenyl)flavin (3.4s).
The production of the 2-nitro-N-phenylbenzenamines (3.5b,c) used as starting 
materials (Scheme 3-2) resulted from the action of two equivalents of 2-chloro-l- 
nitrobenzene on 1 equivalent of the appropriate aniline. Harsh reaction conditions were 
required as the 2-chloro is only activated towards nucleophilic substitution by the single 
nitro group. The reaction conditions required the reactants to be heated at 160-180° for 7 
to 10 hours with 4 equivalents of sodium acetate [126]. The two 2-nitro-N-(4'- 
substituted phenyl)benzenamines (3.5b,c) produced under these conditions were 
obtained in low yields. In the case of N,N-dimethyl-N'-(2'-nitrophenyl)-l,4-
Scheme 3-3
O
3.9a or 3.9b 2.5z (X=Br) 
2.5ii (X=N02)
68
benzenediamine, the reaction was done under nitrogen to retard the degradation of the 
reactive benzenediamine compounds. Fortunately, the necessity to synthesise 2-nitro-N- 
phenylbenzenamine was obviated by its recent commercial availability a. The
2- nitrobenzenamines (3.5a-c) were easily reduced to the corresponding
1.2- benzenediamines (3.6a-c) with acidic stannous chloride. The condensation of these
1.2- benzenediamines (3.6a-c) with alloxan in the presence of boric acid offered a facile 
method of producing 3-unsubstituted flavins (3.7). Some of these flavins were then 
easily alkylated by methyl iodide, propyl iodide and/or benzyl bromide. Alkylations were 
carried out using a modification of the methylation procedure reported by Shinkai et al. 
[77]. Thus the flavin, potassium carbonate and alkylating agent were heated at 60° for 30 
minutes. All alkylations of flavins worked well giving moderate to good yields of 
products.
3- 3 Electrophilic reactions
The easy synthetic access to 10-phenylflavin (3.7a) (because of the commercial 
availability of 2-nitro-N-phenylbenzenamine (3.5a)) allowed a study of the electrophilic 
substitution of the parent structure to be undertaken.
Nitration of the 10-methyl and 3,10-dimethylflavin by stirring at room temperature 
for three days in a mixture of fuming nitric acid (d-1.5) and concentrated sulfuric acid 
(1:2 v/v) was reported by Knappe [127] to yield the 7-nitro derivatives. Under the same 
conditions (Scheme 3-3a) 10-phenylflavin gave 7-nitro-10-(3'-nitrophenyl)flavin (3.8), 
although, only a low yield was obtained as repeated recrystallizations were required to 
separate it from a small amount of contaminating 10-(3'-nitrophenyl)flavin.
Mononitration (Scheme 3-3a) was achieved by heating 10-phenylflavin and 1.1 
equivalents of fuming nitric acid (d-1.5) in concentrated sulfuric acid at 130° for 1.5 
hours to obtain 10-(3'-nitrophenyl)flavin (3.9a) in 34% yield.
McCormick [128] achieved the bromination and chlorination of 7,8,10- 
trimethylflavin (lumiflavin) in the 9-position by treatment with N-halogenosuccinimide in
a From the Aldrich Chemical Company, 1988-89 Catalog.
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trichloroacetic acid in the presence of catalytic amounts of benzoyl peroxide.
The 10-(S'-bromophenyl)flavin (3.9b) was produced by using an acidic solution 
of bromine and silver sulfate which favours the formation of the highly reactive bromine 
cation electrophile [129]. In the bromination one equivalent each of 10-phenylflavin, 
bromine and silver sulfate in 90% sulfuric acid were shaken for 16 hours to yield 25% of 
the product 3.9b. An attempt to dibrominate under the same reaction conditions using 
two equivalents of bromine failed and only resulted in the formation of compound 3.9b. 
A further attempt to form the dibrominated compound by brominating 10-(3'- 
bromophenyl)flavin and extending the reaction time to five days resulted in 
decomposition of the flavin.
The identity of the nitro 3.9a and dinitro 3.8 products above was confirmed by 
*H n.m.r. spectroscopy and decoupling experiments discussed in section 3-4.1. The 
identity of 10-(3'-bromophenyl)flavin was confirmed by forming the 3-N-methyl 
derivative (Scheme 3-3b) which was found to be identical by melting point, mass spectra 
and *13 n.m.r. spectra to an authentic sample of 10-(3'-bromophenyl)-3-methylflavin 
(sample provided by Dr W. B. Cowden).
The results of the above electrophilic reactions indicate that the 3' position of the 
10-phenyl ring is more reactive towards electrophilic substitution than the 7 position of 
the flavin. The meta orientation of this substitution indicates that the flavin ring system is 
electron withdrawing towards the 10-phenyl ring. This is not unexpected because under 
the highly acidic conditions of the above reactions the protonation of the flavin at the 1-N 
position and localization of a positive charge in the flavin ring system would occur [130].
A general review of the reactivities of the flavins is given by Berezovskii et al.
[ 131].
Table 3-1: n.m.r. spectral data (5)a for 3-subs ti tu ted 10- (4'-
chlorophenyl and phenyl)flavins
O
3
RN' 4
JLO i
x
7
8
Cmpd no. R X H 6 b H7 c H 9 b
3.7a H H 8.19 e 6.74
2.5a Me H 8.24 e 6.78
3.4a Et H 8.22 e 6.78
3.4q d Pr H 8.23 e 6.78
3.4p f Ph H 8.36 e 6.92
3.4r d.f PhCH2 H 8.29 e 6.86
3.7b d H Cl 8.19 e 6.84
2.5o Me a 8.24 7.64 6.78
3.4b Et a 8.23 7.63 6.84
3.4m f.g Pr a 8.34 e 6.92
3.4n f Ph Cl 8.38 e 6.96
3.4o d PhCH2 Cl 8.25 e 6.88
a Chemical shifts reported as parts per million in CD3SOCD3 obtained using a Varian XL 
200 spectrometer unless stated otherwise. b Peaks appear as doublets with integration of 
1H, Jö,7 and Js,9 ~ 8.0 Hz. c Peaks appear as triplets with integration of 1H, 17^ is 8.0 
Hz. d Obtained using a Joel FX 90 spectrometer. e Peak obscured by hydrogen atom 
peaks of the 10-phenyl ring and/or the 3-N substituent. f Recorded in CDCI3. 8 Obtained 
using a Varian VXR 300 spectrometer.
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3-4 Physical properties
3-4.1 *H Nuclear magnetic resonance spectra
The *H n.m.r. spectral data of the two series of 3-substituted 10-(4'-chlorophenyl 
and phenyl)flavins are presented in Tables 3-1 and 3-2.
The 3-N substituents give the expected shifts and splitting patterns with the 
downfield influence of the N-3 nitrogen reflected in the chemical shifts of the signals of 
the adjacent methylene hydrogen atoms (Table 3-2). The remaining spectral features for 
the compounds are entirely consistent with the assignments made in section 2-3.2(i). In 
both the 4'-Cl substituted and unsubstituted 10-phenyl compounds the peaks due to H 6, 
H 7, H 8, H 9 and the 10-phenyl hydrogen atoms match (allowing for different solvent 
systems) that of the 3-N methyl analogues already discussed in Chapter 2.
The *H n.m.r. spectrum of 10-(3'-nitrophenyl)flavin (obtained in CD3SOCD3 
using a Varian XL 200 spectrometer) consisted of a doublet (8.0 Hz, 1H) at 6.86 ppm, a 
multiplet (2H) at 7.60-7.78 ppm, a multiplet (2H) at 7.92-8.08 ppm, a doublet (8.0 Hz, 
1H) at 8.21 ppm, a singlet (1H) at 8.42 ppm and a doublet (8.0 Hz, 1H) at 8.53 ppm. 
These peaks are assigned to H 9, H 7 and 8, H 5' and 6', H 6, H 2', and H 4', 
respectively.
The *H n.m.r. spectrum of the 7-nitro-10-(3’-nitrophenyl)flavin (obtained in 
CD3SOCD3 using a Varian XL 200 spectrometer) consisted of a doublet (9.4 Hz, 1H) at 
7.08 ppm, a multiplet (2H) at 7.92-8.13 ppm, a multiplet (2H) at 8.40-8.45 ppm, a 
doublet (8.0 Hz, 1H) at 8.56 ppm and a singlet (1H) at 8.96 ppm. These peaks were 
assigned to H 9, H 5' and 6', H 8 and 2', H 4', and H 6, respectively. This assignment 
is consistent with the above 10-(3'-nitrophenyl)flavin spectrum and the expected changes 
in the chemical shifts and coupling pattern that would occur with a 7-nitro substituent 
[132].
For both the mononitro 3.9a and the dinitro 3.8 compounds, decoupling 
experiments in which the doublets and multiplets of the spectra were decoupled confirmed 
the above assignments.
Table 3-2: 1H n.m.r. spectral data (5)a for 3-substituted 10-(4f- 
chlorophenyl and phenyDflavins
O
3
RN' 4 nY ^ iJL
X
7
8
a Chemical shifts reported as parts per million in CD3SOCD3 obtained using a Varian XL 
200 spectrometer unless stated otherwise. b Data are presented in the following form; 
chemical shift, multiplicity, coupling constants (where appropriate) and integration. The 
following abbreviations were used: s (singlet); d (doublet); t (triplet); q (quartet); sex 
(sextuplet); com (complex); and in cases where the coupling constants are the same in a 
spin system it is presented lastly. c For some compounds the hydrogen atom signals of 
the 3-N substituent or H 7 and H 8 are inseparable from signals from the 10-phenyl 
hydrogens. In these cases those signals which were not included in Table 3-1 or the 
adjacent column, are incorporated in this column and are apparent by integration. 
d Obtained using a Joel FX 90 spectrometer. e Recorded in CDCI3. f Peaks expected in 
the aromatic region are obscured by the hydrogen atom peaks of 10-phenyl ring, H 7 or 
H 8. S Two symmetrical doublets seem to be present within this complex splitting pattem. 
h Obtained using a Varian VXR 300 spectrometer.
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Cmpd no. R X R b 10-Substituted phenyl b*c
3 .7 a H H - 7.41 d 8.0 Hz 2H, 
7.55-7.78 com 5H
2 .5 a Me H 3.25 s 3H 7.43 d 8.0 Hz 2H, 
7.60-7.81 com 5H
3 .4 a Et H 1.13 t3 H , 3.89 q 2 H  6.8 Hz 7.44 d 8.0 Hz 2H, 
7.60-7.82 com 5H
3.4q d Pr H 0.88 t3 H , 1.57 sex 2H, 3.82 
12H 7.4 Hz
7.39-7.68 com 7H
3.4p  e Ph H f 7.26-8.20 com 12H
3 .4 r d.e PhCH2 H 5.25 s 2H f 7.21-7.66 com 12H
3.7b d H Cl - 7.42-7.85 com 6H
2 .5 o Me a 3.25 s 3H 7.48 d 2 H , 7.81 d 3H 
8.6 Hz
3 .4 b Et Cl 1.13 t3 H , 3.90 q 2 H  6.8 Hz 7.28 d 8.6 Hz 2H, 
7.73-7.85 com 3H g
3.4m  e«h Pr a 0.98 t3 H , 1.71 sex 2H, 4.03 
t 2H 6.0 Hz
7.28 d 8.6 Hz 2H, 
7.62-7.68 com 4H g
3 .4n  e Ph Cl f 7.27-7.68 com 11H
3.4o d PhCH2 Cl 5.08 s 2 H f 7.32-7.86 com l l H g
Table 3-3: Mass spectral data for 3-substituted 10-(4'-
cblorophenyl) flavins
Nominal mass m/z and intensities (relative % of base peak)
Cmpd
no.
R M+2 M M-l 281 253 246 239 218
3 . 7 b H 326 (12) 324 (24) 323 (96) ( I D (35) (10) (5) (17)
2 . 5 o Me 340 (13) 338 (31) 337 (100) (21) (31) (13) (8) (9)
3 . 4 b Et 354 (34) 352 (100) 351 (61) (39) (39) (16) (12) ( I D
3 . 4 m Pr 368 (38) 366 (100) 365 (9) (33) (30) (13) (10) ( i d
3 . 4 n Ph 402 (22) 400 (42) 399 (20) (100) (31) (18) (11) (8)
3 . 4 o PhCH2 416 (37) 414 (85) 413 (2) (100) (22) ( I D (10) (8)
72
3-4.2 Mass spectra
The electron impact induced fragmentation of the 3-substituted 10-(4'- 
chlorophenyl)flavin series has been studied. From Table 3-3 it is seen that peaks at M+2, 
M, M -l, m/z 281, 253, 246, 239 and 218 appear throughout the series.
The M+2 peak is characteristic of chlorine containing molecules and results from a 
33 % natural abundance of the 37C1 isotope. The M-l peaks are seen to varying degrees 
throughout the series but are most pronounced in the 3-unsubstituted, 3-methyl and 
3-ethyl compounds.
A proposed fragmentation pattern for this series based on the fragmentation 
pattem of 3,7,8,10-tetramethylflavin described by Holzmann and coworkers [133] is 
shown in Fig 3-1. After the C-4a/C-4 bond cleavage of the molecular ion, the major 
fragmentation involves initial loss of RNCO depicted by a peak at 281. Subsequent 
losses of CO or Cl or NCO appear as peaks at 253, 246 and 239 respectively. The peak 
at 218 is probably formed by the further loss of CO from the 246 fragment. Exact mass 
measurements of the peaks at 281, 253, 246, 239 and 218 for 10-(4'-chlorophenyl)-3- 
methylflavin support the above proposition.
The direct cleavage of the R groups or fragments thereof from the molecular ion is 
seen in 10-(4'-chlorophenyl)-3-ethylflavin with peaks at m/z 337 (M-CH3) and 323 (M- 
C2H5) and for 10-(4'-chlorophenyl)-3-propylflavin with peaks at m/z 351 (M-CH3), 337 
(M-C2H5) and 323 (M-C3H7).
Details of experimental methods are given in section 7-1.
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Figure 3-1 Generalized fragm entation pathway of 3-substituted 10-(4'- 
ch lorop h en yl)flav in s
M-R
(or fragments of R)
281
- NCO
253 246 239
I - C O
218
Table 3-4: Antim alarial activity of 3-ethyI-10-(substituted 
phenyl)flavins against P. vinckei vinckei in mice a
Cmpd
no. (X)n
Per cent cured and increase in mean survival (days) at 
dose, mg/kg b
10 15 20 25 30
3 .4a H 0 (0.7) 0 (1.3) _ 100
3 .4b 4-Cl 100 - 100 100 100
3 .4c 4-Br 60 (2.0) c 80 (39) 100 80(7) 75 (8.0)
3 .4d 3-F 0 (0.4) - 20 (4.3) - 40 (2.3)
3 .4e 4-F 0 (0.6) - 50 (1.0) - 100
3 .4 f 3,5-Cl2 80 (9.0) d 20 (9.3) 0(10) 0 (12.2) 0 (12.2)
3 .4 g 3,5-Me2 0 (0.6) 0 (0.4) 0 (0.6) 0 (1.0) 0 (1.6) e
3 .4h 3-CFs 100 100 100 0 (-1.0) -
3 .4  i 3-CN 0(0) - 0(0) - 0 (-0.25)
3 - 4 j 4-CN 0 (0.4) o (1.2) 0 (0.6) 0 (0.8) 0(0)
3 .4k 3-SMe 0(0) - 0 (0.5) - 0 (1.2)
3.41 4-SMe 0(0) 0(0) 0(0)
a See section 7-3. l(i) for experimental details. b All groups consist of 4 to 6 animals. 
c Average per cent day 2 parasitemia of 29 %. d Average per cent day 2 parasitemia of 
12 %. e 100 Per cent cured at 70 mg/kg.
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3-5 Antimalarial activity 
3-5.1 Methods and results
The compounds prepared in this study were tested against P. vinckei vinckei in 
vivo as described in sections 2-4 and 7-3. l(i). For the 3-ethyl- 10-(substi tu ted 
phenyl)flavin series the dose range examined was 10 to 30 mg/kg. For the other 
members of the 3-substituted 10-(4'-chlorophenyl and 10-phenyl)flavin series the dose 
range examined was 10 to 70 mg/kg. The results of the in vivo testing are given in 
Tables 3-4 and 3-5. The 10-(3'-trifluoromethylphenyl)flavin (3.4s) tested was found to 
be inactive at 10, 20 and 30 mg/kg.
The 3-substituted 10-(4'-chlorophenyl)flavin series was tested in vitro for 
antimalarial activity against P.falciparum (FC-27). The method used was the same as in 
sections 2-5 and 7-3. l(ii) (method 1). The results of this screen are shown in Fig 3-2. 
Results for compound 3.4o, at all concentrations, and compound 3.4m at 20 faM could 
not be obtained due to their insolubility in the culture medium.
3-5.2 Discussion
The compounds described in this section are discussed in terms of three main 
subgroups. These are the 3-ethyl-10-(substituted phenyl)flavins (3.4a-I), the 
3-substituted 10-phenylflavins (3.7a, 2.5a and 3.4p-r) and the 3-substituted 10-(4'- 
chlorophenyl)flavins (3.7b, 2.5o and 3.4m-o).
Table 3-4 shows the in vivo antimalarial activity of the 3-ethyl-10-(substituted 
phenyl)flavins in the dose range tested. In terms of activity this series reflects the 
findings of the 3-methyl-10-(substituted phenyl)flavin series discussed in Chapter 2 
(except for compound 3.4i (3'-CN) for which no 3-methyl analogue was made).
All the active compounds of this series, except compound 3.4g (3',5'-Me2), had 
higher schizontocidal activity than their corresponding 3-methyl analogues as gauged by 
parasite counts on day 2 after treatment. When the active flavins in this series were 
compared to their 3-methyl analogues it was found that:
Table 3-5: Antim alarial activity of 3-substituted 10-(4'-chIorophenyl 
and phenyl)flavins against P. vinckei vinckei in mice a
Per cent cured and increase in mean survival (days) at 
__________________ dose, mg/kg b________________
Cmpd
no. R X 10 20 30 50 70
3 .7a H H 0 (0.4) 0(0)
2.5a c Me H 0(0) - 0(0) 0 (0.3) 60 (0)
3 .4a Et H 0 (0.7) 0 (1.3) 100 0 (-2.0) 0 (-2.0)
3 .4q Pr H 20 (0) 20 (1.0) 75 (3.0) 100 100
3 .4p Ph H - - - 0 (-0.2) 0 (-0.6)
3 .4 r PhCH2 H - - - 0 (0.4) 0 (2.8) e
3 .7b H a 0 (0 )d - 0(0) - 0(0)
2.5o c Me a 20 (0.25) 100 100 20 (-0.8) 0 (-1.0)
3 .4b Et a 100 100 100 - 100d
3.4 m Pr a 0 (0.5) d 0(0) 0(0) 80 (1.0) 100
3 .4n Ph a 0(0) 0(0) 0(0) - 0(0)
3 .4 o PhCH2 a 0(0) 0(0) 0(0) - 0(0)
a See section 7-3. l(i) for experimental details.b Most groups consist of 4 to 6 animals. 
c Data taken from Table 2-5. d Denotes a group of two mice. e A group of 2 mice failed to 
cure at 140 mg/kg.
75
1. Compounds 3.4a (unsubstituted), 3.4b (4'-Cl), 3.4d (3'-F) and 3.4e (4'-F) had 
higher potency (while not showing any toxicity in the dose range tested).
2. Compound 3.4h (3'-CF3) was more active but also more toxic.
3. For compound 3.4f (3',5'-Cl2) and to a lesser degree compound 3.4c (4'-Br), it 
was noted that a number of mice and/or groups of mice with day two parasite counts 
low enough to indicate that a cure should be expected died after a mean extension of 
lifespan of 7 to 39 days. This curious discrepancy was probably due to the failure of 
these flavins to effect radical cures resulting in recrudescence and ultimately death from 
malaria.
To investigate the effect of modifying substituents at the 3-N position two series 
of compounds were produced by maintaining the 10-substituent as either phenyl or 
4'-chlorophenyl while the 3-N position was varied. The groups used as substituents as 
well as their associated n, a  and molar reff activity values are shown in Table 3-6.
Table 3-6: Some physicochemical parameters of the various 3- and
10-phenyl substituents of the flavins
3-N
substitutent
10-phenyl
substitutent
Physicochemical parameters a
7t (lipophilic) b a (electronic)b MR (steric)c
H _ 0.00 0.49 1.68
Me - 0.50 0.00 6.34
Et - 1.00 -0.10 11.0
Pr - 1.50 d 15.66
Ph - 2.13 0.60 25.66
CH2Ph - 2.69 0.22 31.32
- H e 0.00 0.00 1.68
- C le 0.71 0.23 6.64
a For definition of parameters see section 2-4.4(ii). b Parameter values obtained from 
reference [134]. c Parameter values obtained from reference [89]. d Not available. 
e Aromatic substituent parameters.
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Fig 3-2 Growth inhibition of P. falciparum in vitro after 48 hr 
incubation with 3-substituted 10-(4'-chlorophenyl)fIavins
O
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X nA nAA
Cl
3.7b (R=H) _
2.5o (R=Me) ■ 
3.4b (R=Et) " 
3.4m (R=Pr) - 
3.4n (R=Ph) J
[ Antimalarial ] ( jiM )
Details of this assay are given in sections 2-5 and 7-3.1(ii) (method 1).
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In both series the 3-unsubstituted (as well as 10-(3'-trifluoromethylphenyl)flavin 
(3.4s)), 3-phenyl and 3-benzyl compounds failed to show any significant activity.
In the 10-(4'-chlorophenyl) series activity increased when the 3-substituent was 
changed from methyl to ethyl but decreased when changed to propyl. In the 
10-phenylflavin series the activity increased when the 3-substituents were changed from 
methyl to ethyl and again from ethyl to propyl (Table 3-5). These results indicate that 
overall lipophilicity may be related to activity. Two reasons for this assertion are:
1. The P. falciparum inhibition data (Fig 3-2) on the 3-substituted 10-(4'- 
chlorophenyl)flavin series indicates that alteration at the 3-N position has little effect 
on the activity in vitro. From this it is reasonable to assume that the differences in in 
vivo activity among this series are due to the pharmacokinetic processes of distribution 
and elimination occurring in vivo. A parameter of major importance in these processes 
is lipophilicity; and
2. Using the combined k values of the 3- and 10-phenyl substituents as an estimate of 
overall lipophilicity, it is apparent that the most active compound from each series, that 
is 10-(4'-chlorophenyl)-3-ethylflavin (Etc = 1.71) and 10-phenyl-3-propylflavin (Etc 
= 1.50) have similar overall calculated lipophilic values.
10-(4'-Chlorophenyl)-3-ethylflavin was not only the most active member of both 
series (Table 3-5) but is also better tolerated at higher doses than its 3-methyl analogue.
In conclusion, some activity and toxicological advantages have been gained by 
alteration of substituents at the 3-N position in the above two series of compounds.
These gains seem to be associated with increased lipophilicity, although, the benefit 
appears to be limited by either a natural lipophilic optimum or possibly the associated 
increase in bulk or changes in the electronic nature (albeit minor) occurring as the 
substituents at the 3 position increase in lipophilicity in these two series.
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3-6 Other biological screens
Compounds 3.4a and 3.41 were evaluated for in vitro anti-HIV activity by the 
National Cancer Institute as described in section 2-6.3 and classified as inactive.
It has been reported by Graham et al. [135], and Ryley and Wilson [136] that 
some riboflavin antagonists have activity against poultry coccidiosis. With this in mind, 
3-ethyl-10-(3'-trifluoromethylphenyl)flavin was tested b and found to have activity 
against the Coccidia Eimeria vermiformis in C57/BL6 mice. A reduction by 90% 
compared to controls of the number of oocysts expelled during the course of the disease 
was achieved by a daily oral dose of 25 mg/kg given for twelve days after infection. The 
experimental details of this coccidiosis screen are given in section 7-3.3.
b Testing was done by Mr C. Reiger and Dr K. Ovington of the Department of Zoology, The Australian 
National University, Canberra, ACT, 2601.
CHAPTER 4
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CHAPTER 4 Syntheses and in vivo antimalarial activity of some 7,8,9- 
substituted 3-methyl-10-(substituted phenyl)flavins and a 
6,8-diazafIavin
4-1 Introduction
An investigation into substituent effects in the ring-3 of 10-phenylflavins are 
described in this chapter. A series of compounds with dimethyl or chloro substituents in 
the 7, 8 or 9 positions of the 10-phenylflavins and a 10-phenyl-6,8-diazaflavin were 
prepared (shown in Schemes 4-1, 4-2 and 4-4). These compounds were tested for 
antimalarial activity in vivo and found to be mostly inactive.
The syntheses, some of the physical properties, the results of biological testing 
and the rationale for preparing these compounds are presented and discussed in the 
following sections.
4-2 Syntheses
4-2.1 7,8,9-Substituted-10-(4’-chlorophenyl and phenyl)-3-methylflavins
The two routes considered for obtaining substituents on the ring-3 of the flavin are 
shown in Schemes 4-1 and 4-2 and were discussed generally in section 2-2. It is clear 
from these schemes that in both cases the formation of positional isomers is possible.
The starting materials for the first preparative programme were substituted 
nitrosobenzenes and 6-(4'-chloroanilino)-3-methyluracil (2.4o) (general synthesis 
discussed in section 2-2.4). The nitrosobenzenes for this reaction were prepared by 
oxidation of the appropriate anilines with Caro's acid (H2SO5) [137,138]. The formation 
of the 7,8,9-substituted-10-phenylflavins 4.2a-c and 4.3a,b involved the condensation 
of 6-(4'-chloroanilino)-3-methyluracil (2.4o) with 3 equivalents of the appropriately 
substituted nitrosobenzene in the presence of acetic anhydride, essentially according to the 
method of Yoneda et al. [60,61]. *H N.m.r. spectroscopy was used to detect the 
presence and proportion of the possible isomers.
Scheme 4-1
§0
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The condensation with 3-chloronitrosobenzene (4.1b) gave a mixture of 
approximately 1 to 2 of the 7- and 9-chloro isomers 4.2b and 4.3b, respectively. The 
9-chloro isomer 4.3b was isolated by fractional recrystallization from 
dimethylformamide. A 7-chloro isomer enriched mixture was recovered from the filtrate 
and recrystallized from glacial acetic acid to obtain the pure 7-chloro compound 4.2b.
By using the same reaction as described by Yoneda et al. [61], the condensation with the 
symmetrical 4-chloronitrosobenzene (4.1c) gave 8-chloro-10-(4'-chlorophenyl)-3- 
methylflavin (4.2c) in 37% yield.
The condensation of 3,4-dimethylnitrosobenzene (4.1a) gave a mixture of 
approximately one third of the 7,8-dimethyl isomer 4.2a and two thirds of the 
8,9-dimethyl isomer 4.3a. Only the 8,9-dimethylflavin 4.3a could be recovered from 
the isomer mixture by repeated recrystallizations with glacial acetic acid and 
dimethylformamide.
The above reaction scheme was successful in yielding the 7- (4.2b),8- (4.2c) 
and 9- (4.3b) monochlorinated and 8,9-dimethyl 4.3a compounds but failed to make 
available a pure sample of the 7,8-dimethyl flavin 4.2a. In the second synthetic scheme 
(Scheme 4-2) it was reported by Sako et al. [62] that ring closure of 6-anilino-5-(3',4'- 
dimethylanilino)-3-methyluracil (4.5a) gave only the 7,8-dimethyl isomer 4.2d. 
Therefore, this reaction sequence was undertaken in an effort to take advantage of this 
reported propensity to form a single isomer and apply it to produce 10-(4'-chlorophenyl)- 
3,7,8-trimethylflavin (4.2a).
The 5-bromouracil (4.4) starting materials for the reaction were prepared by 
bromination of the 6-anilino-3-methyluracils 2.4a and 2.4o. Two possible sites for 
bromination are found on 6-anilinouracils, they are the 4' position of the anilino group 
and the 5 position in the uracil ring. (Bromination of the 2' and 6’ positions of the anilino 
substituent is less likely on steric grounds.) In the bomination of 6-(4'-chloroanilino)-3- 
methyluracil only the 5-position is available but in the case of 6-anilino-3-methyluracil 
care had to be taken to keep the reaction mixture at -7° (in a salt-ethanol ice bath) during 
the addition of one equivalent of bromine to ensure monobromination of the slightly more 
active 5-position. Dibromination readily occurred at temperatures above this to give
Z
 I
Scheme 4-2
2.4a (X=H) 4.4a (X=H) 4.5a (X=H)
2.4o (X=C1) 4.4b (X=C1) 4.5b (X=C1)
o o
4.2a (X=C1) 
4.2d (X=H)
4.3a (X=C1)
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5- bromo-6-(4'-bromoanilino)-3-methyluracil (4.4c, X=Br). The 5-bromo compounds 
(4.4a,b) were treated with excess 3,4-dime thy laniline at room temperature for 17 hours. 
Nucleophilic substitution occurred smoothly under these conditions. The resulting
6- (substituted anilino)-5-(3',4'-dimethylanilino)-3-methyluracils (4.5a,b) were heated in 
an oxygen atmosphere at 120° for 2 hours in dime thy lformamide to achieve cyclization. 
The mechanism proposed for this reaction by Sako et al. [62] is shown in Scheme 4-3.
Sch em e 4-3
In this last synthetic step it was found that the 6-anilino-5-(3',4’-dimethylanilino)- 
3-methyluracil (4.5a) gave only the 7,8-dimethyl substituted flavin 4.2d as reported 
[62]. However, under the same reaction conditions the 6-(4'-chloroanilino)-5-(3",4"- 
dimethylanilino)-3-methyluracil (4.5b) gave a majority of 7,8-dimethyl isomer 4.2a but 
approximately 14% of the crude product consisted of the 8,9-dimethyl isomer 4.3a (as 
assessed by n.m.r. spectroscopy). This indicated that Scheme 4-2 cannot always be 
relied upon to give exclusively 7,8-dimethyl substituted flavins as obviously the 
substituent effect of the 4-chloro group promotes the formation of both possible isomers.
Scheme 4-4a,b
4.8 4.9
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The 7,8-dimethyl isomer (4.2a) was eventually obtained in its pure form by 
recrystallization of the above mixture from acetic acid and dimethylformamide.
4-2.2 10-(4'-Chlorophenyl)-3-methyl-6,8-diazaflavin
The synthetic pathway to the title compound is shown in Scheme 4-4. The last 
step (Scheme 4-4b) is a modification of the alloxan, N-substituted 1,2-benzenediamine 
flavin synthesis discussed in section 2-2.2(i). 3,10-Dimethyl-6,8-diazaflavin has been 
produced by Yano et al. [139,140] through condensation of N-methylalloxan and 
4-amino-5-methylaminopyrimidine. Therefore, 4-amino-5-(4'-chloroanilino)pyrimidine 
(4.8) was needed in order to obtain the desired 4'-chlorophenyl substituent in the 
10-position of the 6,8-diazaflavin 4.9. The synthesis of this key intermediate used an 
analogous method to that used by Bredereck et al. [141] in their synthesis of 4-amino-5- 
anilinopyrimidine.
Synthesis of the starting material 4'-chloroanilinoacetonitrile (4.6) was first 
attempted using the Strecker condensation with 4-chloroaniline, formaldehyde and 
sodium cyanide as described by Marxer [142]. It was latter found that the so-called 
"Knoevenagel-Bucherer" modification [143], which involves the initial formation of 
4-CIC6H4NHCH2S C>3'Na+ before addition of cyanide gave a better yield and was a 
simpler method for the production of 4'-chloroanilinoacetonitrile (4.6; Scheme 4-4a). 
The purine 4.7 was formed in a "one pot" reaction by refluxing 4'-chloroanilino- 
acetonitrile and 7.5 equivalents of formamidine acetate in 1-butanol. The volatile 7-aryl 
purine 4.7 was purified from reaction by-products by sublimation. The purine 4.7 was 
then readily hydrolysed with 0.5 M sodium hydroxide to give 4-amino-5-(4'- 
chloroanilino)pyrimidine (4.8) in excellent yield.
The N-methylalloxan required in the next step was formed by treatment of 
N-methylbarbituric acid with benzaldehyde to give 5-benzal-3-methylbarbituric acid, 
which following chromic acid oxidation gave N-methylalloxan in reasonable yield [144].
The 6,8-diazaflavin 4.9 was formed by heating a solution of the 
diaminopyrimidine 4.8, N-methylalloxan and boric acid at 60° for 30 minutes
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(Scheme 4-4b). The identity of the product was confirmed by n.m.r. spectroscopy, 
mass spectrometry and microanalysis.
The experimental details of the above syntheses (sections 4-2.1 and 4-2.2) are 
reported in section 7-2.
4-3 Physical properties
4-3.1 Nuclear magnetic resonance spectra
The lH n.m.r. data for this series of compounds is consistent with that obtained 
for the 3-methyl- 10-(substituted phenyl)flavins reported in section 2-3.2(i). The 
substituent location in ring-3 of the flavins was detected by both the absence of the 
positionally corresponding hydrogen atom peak and the new coupling pattem in the peaks 
of adjacent hydrogens.
For example, the 8-chloro flavin (4.2c) when compared to its 7,8,9-unsubstituted 
analogue (2.5o) has an H 7 doublet instead of a triplet and a H 9 singlet instead of a 
doublet and no signal for a corresponding H 8. The rest of the 7,8,9-substituted flavins 
presented in Table 4-1 are similarly consistent
The substituted chloro group has very little detectable effect on the shifts of the 
surrounding hydrogen atoms while the dimethyl substituents exerted a shielding effect of 
between 0.10-0.27 ppm on the two remaining hydrogen atoms in ring-3. The 9-Me 
hydrogen atoms in the 8,9-dimethyl isomer 4.3a were assigned to the peak at 1.58 ppm 
because of the shielded nature at the 9 position and by comparison with the unassigned 
methyl peaks in the 7,8-dimethyl isomers 4.2a and 4.2d.
Table 4-1: 1H rLm.r. spectral data (8)a for 7,8,9-substituted-3-methyl-10-
(substituted phenyl)flavins
a Chemical shifts reported as parts per million in CD3SOCD3 using a Varian XL 200 
spectrometer unless stated otherwise. Data are usually presented in the following form; 
chemical shift, multiplicity, coupling constants (where appropriate) and integration. The 
following abbreviations were used: s (singlet); d (doublet); t (triplet); com (complex); and 
in cases where the coupling constants are the same in a spin system it is presented lastly. 
b All peaks appear as singlets integrating for 3H. c All reported peaks integrate for 1H. 
d Spectral data taken from Tables 2-1 and 2-2 and included for comparison. e Peak 
obscured by hydrogen atom peaks of the 10-phenyl ring but detected by integration. 
f Spectrum recorded in CDCI3 using a Joel FX 90 spectrometer.
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Cmpd
no.
0 0 n X H 6 c H 7 c H 8 c H 9 c
2.5o d H a 8.24 d 8.0 Hz 7.64 t 8.0 Hz e 6.88 d 8.0 Hz
4 . 2 b 7-C1 Cl 8.39 s - e 6.89 d 8.6 Hz
4 . 2 c 8-C1 a 8.27 d 8.7 Hz 7.70 d 8.7 Hz - 6.85 s
4 . 3 b 9-C1 a 8.23 d 7.6 Hz e 7.89 d 
7.6 Hz
-
4 . 2 a 7,8-Me2 Cl 8.03 s - - 6.66 s
4 . 3 a 8,9-Me2 a 7.97 d 8.4 Hz 7.54 d 8.4 Hz - -
4 .2d  f 7,8-Me2 H 8.08 s - 6.65 s
Cmpd no. (Y)n X N M eb 10-substituted phenyl O 0 n b
2.5o d H a 3.25 7.48 d2 H , 7.81 d 3H 8.6 Hz
4 . 2 b 7-C1 a 3.25 7.47 d 2H, 7.81 d 3H 8.2 Hz
4 . 2 c 8 - 0 Cl 3.25 7.48 d 2 H , 7.81 d 2H 8 .1H z -
4 . 3 b 9-C1 Cl 3.24 7.44 d 2H, 7.66 d 3H 8.4 Hz
4 . 2a 7,8-Me2 a 3.22 7.46 d 2H, 7.79 d 2H 8.5 Hz 2.31, 2.38
4 . 3 a 8,9-Me2 Cl 3.22 7.46 d 2H, 7.68 d 2H 8.8 Hz 1.58, 2.38
4 .2d  f 7,8-Me2 H 3.47 7.27-7.66 com 5H 2.36, 2.42
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The n.m.r. spectrum of the 10-(4'-chlorophenyl)-3-methyl-6,8-diazaflavin 
(4.9) (obtained in CDCI3 on a Jeol FX 90 spectrometer) consisted of the following: 
a sharp singlet at 3.47 ppm assigned to the 3-N methyl group; a pair of symmetrical 
doublets (J2',3' = 8.6 Hz) at 7.34 and 7.70 ppm consistent with the 10-(4'-chlorophenyl) 
group; a singlet integrating for 1H at 8.64 ppm; and a singlet integrating for 1H at 9.35 
ppm. The unassigned peaks due to H 7 and H 9 appear considerably downfield 
undoubtedly due to the deshielding effect of the adjacent nitrogen atoms N-6 and N-8.
4-3.2 Mass spectra
The mass spectra (electron impact) of the three chloro isomers were nearly 
identical and offered no clear way of distinguishing between them. The spectra showed a 
molecular ion peak at m/z 372 and a closely associated but more intense peak at M-l.
Both these peaks had the associated +2 and 44 isotopic peaks characteristic of a 
compound containing two chlorine atoms. The expected ratio of these associated peaks 
was more pronounced for the M-l peak. The spectra also showed prominent peaks at 
m/z 315 (M-57) and 287 (M-85). These two peaks are consistent with the decomposition 
of the molecular ion by loss of CH3NCO (57) followed by further loss of CO (28). Such 
a fragmentation pattem is in accordance with that reported [133] for 3-methyl lumiflavin 
and that of the 3-substituted 10-(4'-chlorophenyl)flavins discussed in section 3-4.2.
The mass spectra (electron impact) of the 6,8-diaza compound (4.9) gave a peak 
corresponding to the molecular ion at m/z 340 which was associated with a more intense 
M-l peak at m/z 339 both of these peaks had an associated 42 peak typical of 
monochlorinated compounds. This spectrum is similar to those above for the flavins as it 
has prominent peaks at m/z 283 (M-57) and m/z 255 (M-85). It is interesting to note that 
chemical ionization with ammonia, which is usually associated with the formation of a 
quasi-molecular ion of M4l [145], gave a base peak of M43 and a M45 peak (37C1 
isotope peak) of approximately a third the intensity. This may indicate that the compound 
has become reduced during chemical ionization. Similar mass spectrometer reductions 
have been noted in the case of the benzoquinones [146].
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4-4 Results and discussion of in vivo testing
The compounds prepared in this chapter were tested for antimalarial activity 
against P. vinckei vinckei in mice. The results of this screen are presented in Table 4-2, 
the lead compound 10-(4'-chlorophenyl)-3-methylflavin has been included for 
comparison. The percentage cured, mean extension in lifespan and parasitemia on day 2 
were used to monitor activity. More details of this procedure are given in section 2-4.
Table 4-2: Antimalarial activity of 7,8,9-substituted-3-methyl-10- 
(substituted phenyl)flavins and 10-(4'-chlorophenyI)-3- 
methyl-6,8-diazaflavin against P. vinckei vinckei in mice a
Cmpd
no.
ring-3
subst.
10-phenyl
subst.
Per cent cured and increase in mean survival (days) 
at dose, mg/kg b
30 50 70 140
2.5o c - 4-C1 100 20 (-0.8) 0 (-1.0) -
4.2b 7-C1 4-C1 0(0) 0(-0.6)d 0 (-2.0) -
4.2c 8-C1 4-C1 0(0) - 0 (0.4) 0 (-1.0)
4.3b 9-C1 4-Cl - - 0 (0.5) e 0(0)
4.2a 7,8-Me2 4-C1 - - 0 (0.6) 0 (0 )e
4.3a 8,9-Me2 4-C1 - - 0(0) 0(0)
4.2d 7,8-Me2 H - - 0(0) 0 (-0.8)
4.9 6,8-diaza 4-C1 0(0) 0(0) 0 (-1.0) e
a See section 7-3.l(i) for experimental details. b Most groups consist of 4 to 6 animals. 
c Data taken from Table 2-5 and included for comparison. d Activity detected with day 
two blood smears. e Denotes a group of two mice.
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The rationale for introducing groups into ring-3 of the lead flavin compound are 
twofold.
Firstly, the introduction of 7,8-dimethyl substituents would produce a molecule 
that more closely resembles the natural flavin analogue riboflavin. If these compounds 
were inhibiting riboflavin metabolism a closer structural resemblance might be expected to 
improve their antagonism. Thus, the analogues produced and tested were the 10-phenyl 
and 10-(4'-chlorophenyl)-3,7,8-trimethylflavins as well as the incidentally produced 
10-(4'-chlorophenyl)-3,8,9-trimethylflavin. All of these flavins proved to be inactive 
over the same dose range in which their 7,8,9-unsubstituted analogues were active. 
Interestingly, their toxicity relative to their active analogue counterparts was reduced.
Flavins in many flavoproteins act as oxidizing agents for many biochemical 
reactions, some of these flavin enzymes include glucose oxidase, glycolate oxidase and 
amino acid oxidases. In all these cases, once the flavin is reduced it is reoxidized with 
molecular oxygen and hydrogen peroxide is produced. This ability for redox cycling is 
not exclusive to protein bound flavins. It has been shown that non-enzymatic oxidation 
of NADH by flavins occurs at moderate speeds in water at room temperature and that 
dihydroflavins are oxidized with molecular oxygen to form hydrogen peroxide [147]. 
This could create the possibility for a redox cycle as seen in Fig 4-1 to occur.
Fig 4-1 Flavin redox cycle
2 NAD + flavinH2
2 NADH flavin
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The malaria parasite is very susceptible to oxidative stress. The naturally 
occurring pyrimidine aglycones divicine and isouramil (shown in Fig 4-2) are known to 
undergo redox cycling in which hydrogen peroxide is formed. It is believed that these 
compounds function as antimalarials by exerting oxidant stress on the parasite [25].
Fig 4-2 Chemical structure of divicine and isouramil
O O
H
divicine isouramil
A possible mode of antimalarial action for the flavin analogues under investigation 
could therefore be oxidative damage to the parasite due to hydrogen peroxide produced by 
redox cycling of the flavin compounds. This hypothesis would seem to be supported by 
the observation of Divo et al. [148] that the antimalarial flavin analogue 8-methylamino-8- 
desmethyl riboflavin had enhanced activity in vitro in a high per cent oxygen atmosphere. 
Though this hypothesis was not investigated as such it did suggest the production of the 
7-, 8- and 9-chloroflavin isomers (4.2b, 4.2c, 4.3b) and the 6,8-diazaflavin (4.9) 
might be worthwhile. This is because introducing electron withdrawing groups into the 
flavin ring system increases the oxidizing activity of the flavin [140]. Thus, in light of 
the above hypothesis this might have been a way of increasing oxidative stress on the 
parasite and therefore increasing the biological activity of the flavins.
Of the three positional chloro isomers synthesised only the 7-chloro compound 
(4.2b) showed activity. Even here, however, the activity was at a lower level than the 
lead compound (2.5o). The 7-chloro flavin which produced an average 80% 
suppression in parasitemia of the surviving mice on day two after treatment, was toxic at 
the dose where activity was observed. The 8- and 9- chloro substituted flavins were not 
active in the dose range tested but were less toxic than 10-(4'-chlorophenyl)-3-
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methylflavin.
The 6,8-diaza flavin compounds produced by Yano et al. have not only been 
found to be the most active flavin mimics known for oxidation of thiols and nitroalkanes 
but also redox cycle in the present of oxygen [139,140]. The 6,8-diaza flavin (4.9) 
produced in this study should therefore have high oxidative activity and avoid any 
problems which might be associated with any increased steric hindrance that occurs when 
substituents are introduced into the ring-3 to increase oxidative activity (such as in the 
chloro series above). However, the 10-(4’-chlorophenyl)-3-methyl-6,8-diazaflavin was 
found to be inactive though less toxic in comparison to the lead compound.
Although no attempt was made to investigate the above two hypotheses it is clear 
from the paucity of activity in this series that it can be concluded on a purely S AR basis 
that substitution in ring-3 of the flavin is detrimental to in vivo activity.
4-5 Other biological testing
Compounds 4.2a-c and 4.3a,b were evaluated for in vitro anti-HIV activity by 
the National Cancer Institute as described in section 2-6.3 and classified as inactive.
CHAPTER 5
CHAPTER 5 Syntheses and antimalarial activity of some 6,7,8- 
substituted 3-methyIpteridine-2,4(3H ,8JT)-diones
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5-1 Introduction
In this chapter the synthesis of a series of 6,7,8-substituted 3-methylpteridine- 
2,4(3//,8/f)-diones (Scheme 5-1) and their in vitro and in vivo antimalarial activity are 
described. This work was undertaken in order to examine the role of the benzenoid ring 
(ring-3) of the flavins in antimalarial activity. An interesting historical precedent 
paralleling this was the removal of the 7-methoxy containing benzenoid ring of the 
antimalarial acridine, quinacrine, to give the superior antimalarial chloroquine (see Fig 
5-1) [15a]. The pteridinediones were also of interest as it has been reported [15b] that 
agents with the pteridine ring structure such as 2,4-diamino-6,7-diphenylpteridine shown 
in Fig 5-2 have antimalarial activity (these agents probably act as antifolates).
The substituents 4'-chloro and 3',5'-dimethyl, in the 8-phenyl ring of the 
pteridinediones (5.3a-f, Scheme 5-1), were selected because of their previously 
demonstrated beneficial effect on antimalarial activity in the 3-methyl- 10-(substituted 
phenyl)flavin series (see Table 2-5, pg46).
It was shown that ring-3 of the flavin series is necessary for in vivo activity. 
Additionally only the 6,7-unsubstituted pteridinediones (5 Ja, 5.3b) were active in the 
in vitro screen.
Fig 5-1 Chemical structures of quinacrine and chloroquine
Quinacrine Chloroquine
Z
 I
Scheme 5-1
2.2
2.4g (X=3,5-Me2)
5.1 and 5.2 (X)n
a 4-Cl
b 3,5-Me2
0
t
CH
5 .3 R (X)„
a H 4-C1
b H 3,5-Me2
c Me 4-C1
d Me 3,5-Me2
e Ph 4-C1
3 f Ph 3,5-Me2
5 .4
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Fig 5-2 2,4-D iam ino-6,7-diphenyIpteridine
5-2 Syntheses
The synthesis of the 6,7,8-substituted 3-methylpteridine-2,4(3//,8//)-diones is 
shown in Scheme 5-1. Nitrosation of the 6-(substituted anilino)-3-methyluracils (2.4o, 
2.4g; general synthesis discussed in section 2-2.4) in trifluoroacetic acid readily gave the 
corresponding 6-(substituted anilino)-3-methyl-5-nitrosouracils (5.1a, 5.1b) as 
trifluoroacetic acid salts (not characterized) which were easily reduced with sodium 
dithionite to the corresponding 5-amino-6-(substituted anilino)-3-methyluracils (5.2a, 
5.2b). In an attempt to purify 5-amino-6-(3,,5'-dimethylanilino)-3-methyluracil (5.2b) 
by recrystallization it was found that an unexpected product formed. The *H n.m.r. and 
mass spectra of this compound indicated that it w'as 3,6,8-trimethylbenzo[g]pteridine- 
2,4(l//,3//)-dione (5.4). This is in accordance with reports that compounds of similar 
structure to the 5-nitroso (5.1a, 5.1b) and 5-amino (5.2a, 5.2b) uracils easily 
convert, via ring closure involving the 5-nitroso/amino group and C-2' of the anilino 
substituent, into the corresponding benzo[g]pteridinediones or their N-oxides 
[58,68,149]. It's structure was confirmed by preparing it in a similar manner to that used 
by Goldner et al. [68] to prepare similar compounds, by briefly heating 6-(3',5'- 
dimethylanilino)-3-methyl-5-nitrosouracil (5.1b) in acetic acid. Care was therefore taken 
not to allow the 5-nitroso (5.1a, 5.1b) and 5-amino (5.2a, 5.2b) uracils to be heated 
during their preparation. The final synthetic step in the preparation of the 8- or 6,7,8- 
substituted 3-methylpteridine-2,4(3//,8//)-diones (5.3a-f) involved the Gabriel and 
Colman condensation of the 5-amino compounds (5.2a, 5.2b) with a-dicarbonyl
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reagents. This gave the 6,7,8-substituted 3-methylpteridine-2,4(3//,8//)-diones 
(5.3a-f) in reasonable yields.
Ram et al. [150] have made similar compounds using an alternate reaction 
sequence shown in Scheme 5-2; this scheme was deemed less convenient to that used 
because the 6-(substituted anilino)-3-methyluracils were already available from previous 
syntheses and the straightforward conditions used in going from the 5-nitroso group to 
the 5-amino group were preferable to the more laborious process used by Ram and 
colleagues in going from the 5-nitro to the 5-amino group.
Scheme 5-2
Zn
HC02H
X
Table 5-1: *H N.m.r. spectral data (5)a for the 6,7,8-substituted-3-
m ethyIp terid ine-2 ,4(3 i/,8H )-d iones
O
Cmpd
no.
R (X)n NMeb (X)nc R 8-Substituted
phenyl
5.3a d H 4-C1 3.21 - 8.20 d 1H,
8.41 d 1H 4.0 Hz
7.60 d 2H,
7.72 d 2H 8.9 Hz
5.3b d H 3,5-Me2 3.21 2.35 8.17 d 1 H,
8.37 d 1H 4.0 Hz
7.15 s 2H, 
7.24 s 1H
5 . 3 c Me 4-C1 3.41 - 2.26 s 3H, 
2.67 s 3H
7.19 d 2H,
7.60 d 2H 8.9 Hz
5 . 3 d Me 3,5-Me2 3.45 2.39 2.26 s 3H, 
2.67 s 3H
6.77 s 2H, 
7.18 s 1H
5 . 3 e Ph 4-C1 3.47 - 7.00-7.30 complex 14H
5 . 3 f Ph 3,5-Me2 3.50 2.19 6.68-7.30 complex 13H
a Chemical shifts reported as parts per million in CDCI3 using a Varian XL 200 
spectrometer unless stated otherwise. Data are usually presented in the following form; 
chemical shift, multiplicity, coupling constants (where appropriate) and integration. The 
following abbreviations were used: s (singlet); d (doublet); and in cases where the 
coupling constants are the same in a spin system it is presented lastly. b All peaks appear 
as singlets integrating for 3H. c All reported peaks are singlets integrating for 6H. d This 
spectrum was recorded in CD3SOCD3.
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5-3 Nuclear magnetic resonance spectra
The differences in solubility throughout the series of pteridine-2,4(3//,8//)-diones 
meant that dimethyl-d6 sulfoxide was the solvent of choice to obtain the spectra of the
6.7- unsubstituted compounds while the spectra of the 6,7-dimethyl and 6,7-diphenyl 
pteridinediones were best obtained in deuterochloroform. Table 5-1 shows the peak 
assignments, multiplicity and coupling constants of this series.
The signal due to the 3-N methyl group of this series appears as a singlet at 3.21 
ppm in dimethyl-d^ sulfoxide and between 3.41-3.50 ppm in deuterochloroform. This 
methyl peak appears downfield as expected due to the electron withdrawing effects of the 
neighbouring nitrogen and adjacent ß-carbonyl groups.
In the spectra of the 6,7-unsubstituted pteridinediones the 6 and 7 hydrogen atoms 
(not specifically assigned) appear as two doublets with a coupling constant of 4.0 Hz at 
8.20 and 8.41 ppm for 5.3a, and 8.17 and 8.37 ppm for 5.3b. This spin system 
appears and can be interpreted as a first order AX coupling system (A8/J >10). The 
signals of these hydrogen atoms are downfield due to the 7t-deficient nature of the 
pteridine ring system.
The spectra of the 8-(substituted phenyl) hydrogen atoms for the 6,7- 
unsubstituted and 6,7-dimethyl pteridinediones are in accordance with their 4'-chloro or 
3',5'-dimethyl substitution pattern. The spectra of the 4'-chloro substituted compounds 
have an AA'BB' quartet, characteristic of para disubstituted benzenes. The spectra of the 
3',5'-dimethyl substituted compounds have two singlets, the more upfield peak integrates 
for two hydrogens indicating it results from H 2' and H 6' while the downfield peak 
integrates for one hydrogen H 4'. The signals (not specifically assigned) for the 6- and 
7-methyl groups appear as singlets at 2.26 and 2.67 ppm for both 5.3c and 5.3d.
In the 6,7-diphenyl substituted compounds the aromatic resonances of the
6.7- diphenyl and the 8-substituted phenyl groups overlap to present complex spectra in 
the aromatic region. This disallows assignment of peaks or interpretation of splitting 
patterns, nevertheless, the integration and chemical shifts of the peaks in this region are 
consistent with the structures of these compounds.
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Fig 5-3 Growth suppression of P. falciparum  after 48 hr incubation with 
3-m eth yI-8-(sub stitu ted  p h en y l)p ter id in e -2 ,4 (3 /f ,8 //)-d io n es
O
5.3b (X=3\5'-diMe) 
2 .5 o a
[Antimalarial] (jiM)
a 10-(4'-Chlorophenyl)-3-methylflavin (2.5o) is included for comparison.
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The unexpected 3,6,8-trimethylbenzo[g]pteridine-2,4(l//,3//)-dione (5.4) 
presents a simple spectrum which agrees with its predicted structure. The spectrum was 
obtained using dimethyl-d^ sulfoxide (on a Varian XL 200 spectrometer) and consists of 
five singlets (integration shown in brackets) at 2.51 (3H), 2.70 (3H), 3.30 (3H) ,7.47 
(1H) and 7.51 (1H) ppm. The two downfield peaks, though not specifically assigned, 
are due to the aromatic hydrogen atoms H 7 and H 9, the peak at 3.30 ppm was assigned 
to the N-methyl group, while the remaining peaks correspond to the methyl groups at 
positions 6 and 8 (not specifically assigned).
5-4 Biological activity, results and discussion
The two antimalarial screens used for this series of compounds were inhibition of 
the human parasite P. falciparum in vitro (method 1) and inhibition of lethal P. vinckei 
vinckei in mice. These screens have been discussed in sections 2-4 and 2-5 and the 
experimental details are in section 7-3.1.
The compounds which were unsubstituted in positions 6 and 7 (5.3a, 5.3b) 
showed activity in the in vitro screen over the same concentration range as the original 
lead compound 10-(4'-chlorophenyl)-3-methylflavin (2.5o) (Fig 5-3). The apparent lack 
of increased activity of compound 5.3b at higher concentrations was due to its poor 
solubility in the testing medium. The other four pteridinediones (5.3c-f) containing 6,7- 
dimethyl or 6,7-diphenyl substituents failed to show any activity in the dose range tested. 
This suggests that the presence of bulky groups in both the 6 and 7 positions abolishes 
antimalarial activity in the 6,7,8-substituted 3-methylpteridine-2,4(3/7,8//)-diones.
The complete series of pteridinediones (5.3a-f) and 3,6,8-trimethyl- 
benzo[g]pteridine-2,4(l//,3//)-dione (5.4) were tested in vivo and found to be inactive 
in the same dose range (10-70 mg/kg) over which the 10-(4'-chlorophenyl)-3- 
methylflavin had shown activity. In light of their in vitro activity compounds 5.3a and 
5.3b were tested at the higher dose of 200 mg/kg in mice where still no activity was 
seen. This inactivity of the pteridinediones, when compared with the high activity of the 
3-methyl-10-(substituted phenyl)flavins such as some of those in Chapter 2, could
Fig 5-5 National Cancer Institute anti-HIV testing sheet
National Cancer Institute 
Developmental Therapeutics Program 
In-Vitro Testing Results
NSC: 627996-N/ 1 Plate: 2972 Lab: 9N Test Date: November 21,1989
Supplier Code: U50D QNS: MC: Report Date: January 12,1990
COMI: Cefl Line: CEM-6 ; Molecular Weight:
IN VITRO ANTI-HTV DRUG SCREENING RESULTS
100
75
50
25
0
0%, 50% Reference Line* Viral Cytopathtc Effect Infected Treated Culture Uninfected Treated Culture
SUMMARY DOSE INFECTED RESPONSE UNINFECTED RESPONSE
Index Concentration (Molar) Percent of Control Percent of Control
IC50 (Molar) >5.89 x 10‘5 1.87 x lO-* 38.21 105.40
EC50 (Molar) 5.92 x 10 35.40 11335
TI50(IC/EO 1.87 x 10'7 3438 105.72
Conclusion 5.91 x 10’7 31.01 10431
1.86 x 10-* 28.97 11323
iN ftP.TWE 5.90 x 10"* 24.43 118.87
1.86 x 10'5 3432 182.15
5.89 x 10*3 33.59 28938
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possibly be attributed to pharmacokinetic effects brought about by the absence of the 
3-benzenoid ring in the pteridine series. The results of the two types of antimalarial 
screens highlight the significance of this structure activity relationship.
As an aside, the 3,6,7-trimethyl-8-(substituted phenyl)pteridine-2,4(3//,8//)- 
diones are structural analogues of 6,7-dimethyl-8-(l'-D-ribityl) lumazine shown in 
Fig 5-4, which is the natural substrate of riboflavin synthase. As such this series 
represent an as yet untested group of potential riboflavin synthase inhibitors [151,152].
Fig 5-4 Chemical structure of 6,7-dimethyl-8-(l’-D-ribityI) lumazine
O
HC-OH
HC-OH
HC-OH
CH2OH
Compounds 5.3c and 5.3e were evaluated for in vitro anti-HIV activity by the 
National Cancer Institute as described in section 2-6.3 and classified as inactive. 
However, it is interesting to note that at higher doses compound 5.3e caused the number 
of uninfected drug treated control T4 lymphocytes (CEM-6 cell line) to increase relative to 
the uninfected and untreated control. The results of this screen are shown in Fig 5-5.
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CHAPTER 6 Antimalarial action of the flavins seems not to be due to the 
inhibition of glutathione reductase of host erythrocytes
6-1 Introduction
Reduced glutathione (GSH) plays an essential role in the anti-oxidant defence 
system of the red blood cell by the chemical reduction of hydrogen peroxide to water. 
Glutathione is maintained in its reduced form by the flavoenzyme, glutathione reductase 
(GR) which catalyses the reduction of oxidized glutathione (GSSG) at the expense of 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) as shown in Fig 6-1.
The malaria parasite is susceptible to oxidant stress. It has been postulated that 
increased oxidant stress in the cell caused by increasing the production of reactive oxygen 
species and/or the suppression of normal anti-oxidant defense systems is an effective way 
of inhibiting Plasmodium species [24,25,107]. Two examples implicating suppression 
of anti-oxidant capacity as a major factor in preventing malaria are:
1. The high frequency of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency in 
traditional malarial areas has been explained in terms of a positive selection pressure 
for this disorder because it confers protection against malaria [153]. This is thought 
to be the result of G-6-PD deficient individuals having a poor capacity to recycle 
glutathione. This impairment is a direct effect of their limited ability to produce the 
NADPH needed to reduce the GSSG to the important anti-oxidant GSH (Fig 6-1).
The G-6-PD deficient erythrocyte is known to be a less viable environment for the 
intraerythrocytic malaria parasite when levels of oxidant stress are increased [153]; and
2. The inhibition of malaria both in vivo and in vitro by the well known glutathione 
reductase inhibitors l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) and l-(2- 
chloroethyl)-3-(2-hydroxyethyl)-l-nitrosourea (HECNU) reported by Schirmer et al. 
[118-120]. In their in vitro P. falciparum experiments they were able to correlate the 
level of glutathione reductase activity to parasite growth. It was also shown that 
HECNU had a curative effect in rats infected with P. vinckei.
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When Thumham and co-workers [33,34] reported that riboflavin deficiency 
suppressed P. falciparum infection in humans and P. berghei infection in rats they 
highlighted the necessity of riboflavin for GR activity, the possibility of GR activity being 
essential to the parasite and that GSH plays an important role in protecting the parasite 
from oxidant stress.
Some of the flavins of the present study including the lead compound 10-(4’- 
chlorophenyl)-3-methylflavin have been shown to be good inhibitors of GR [41,107]. 
The above information lead a number of workers [41,107] to suggest that the possible 
antimalarial mode of action of these compounds was by the inhibition of glutathione 
reductase.
To investigate this possibility, the structure activity relationship of a series of 
3-substituted 10-(4'-chlorophenyl)flavins was examined (Table 6-1). These analogues 
exhibited considerable variation in their ability to inhibit human GR, which did not 
correlate with their inhibition of P. falciparum growth in vitro. These findings suggest 
that inhibition of human erythrocyte GR is probably not the primary mode of antimalarial 
action of this class of flavins.
GR inhibition assays of 3-methyl-10-phenylflavin analogues in which 
substituents on the 10-phenyl ring (Table 6-2) were varied were also conducted and 
revealed only small variations in activity amongst this series.
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6-2 Materials and methods 
6-2.1 Inhibitors
The preparation of the 3-substituted 10-(4'-chlorophenyl)flavins and the 
3-methyl-10-(substituted phenyl)flavins used are described in sections 3-2 and 2-2.4.
6-2.2 Glutathione reductase assay
Enzyme activity was measured essentially by the method of Krohne-Ehrich et al. 
[154]. The GR reaction was monitored with a Varian DMS 100 UV/visible 
spectrophotometer at 25° using the decrease in absorbance at 340 nm that occurs when 
NADPH is oxidised to NADP+. The assay mixture had a volume of 1 ml and a pH of 
7.0. It contained 50 mM potassium phosphate, 200 mM KCl, 1 mM EDTA, 1 mM 
GSSG, 0.1 mM NADPH and 3 nM GR purified from human erythrocytes (a generous 
gift from Dr Heiner Schirmer, Heidelberg, FRG). The assay mixture had been incubated 
with various concentrations of the inhibitor for 2 minutes and the reaction was initiated by 
addition of GSSG. Inhibitor stock solutions (1 mM) of the flavin compounds in dimethyl 
sulfoxide were used. Reaction rates were obtained at various inhibitor concentrations; 
control samples contained dimethyl sulfoxide without inhibitor.
6-2.3 In vitro inhibition of P. falciparum  growth
The inhibition of the growth of P. falciparum (FC-27, a Papua New Guinea strain 
maintained in vitro over several years) by the 3-substituted 10-(4'-chlorophenyl)flavins 
was determined by 3H-hypoxanthine incorporation over 48 hours incubation as described 
in section 2-5 and 7-3.1(ii) (method 1).
In
hi
bi
tio
n 
of
 G
R
 a
ct
iv
ity
 (
Fig 6-2 Inhibition of human glutathione reductase by 3-substituted
10-(4'-chlorophenyl)flavins
3.7b (R=H)
2.5o (R=Me) 
3.4b (R=Et)
3.4m (R=Propyl) 
3.4 n (R=Ph)
3.4o (R=Benzyl)
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6-3 Results
6-3.1 Flavin inhibition of glutathione reductase
Concentration-inhibition curves for 3-substituted 10-(4'-chlorophenyl)flavins 
were determined (Fig 6-2). The values presented are the means of three experiments; the 
experimental values deviated from the mean by less than 7%. Double reciprocal plots of 
GR inhibition against flavin concentration gave straight lines (r 2 > 0.97), which allowed 
the calculation of IC50 values (Table 6-1). Based on the IC50 values the best inhibitor, 
10-(4'-chlorophenyl)-3-methylflavin, (IC50 = 0.8 |4M), was 57 times more active than 
the worst inhibitor, 10-(4'-chlorophenyl)-3-phenylflavin, (IC50 = 46.2 jiM).
The 3-methyl-10-(substituted phenyl)flavins were tested in a single experiment at 
the concentrations of 1, 2.5, 5, 10 and 20 pM. Double reciprocal plots of the GR 
inhibition against flavin concentration gave straight lines (r 2 values given in Table 6-2). 
The IC50 values given in Table 6-2 range from 0.8 |iM for 10-(4'-chlorophenyl)-3- 
methylflavin to 4.1 jiM for 10-(3'-methoxyphenyl)-3-methylflavin.
6-3.2 Flavin inhibition of P. falciparum growth in vitro
Figure 6-3 shows inhibition of P. falciparum growth by the 3-substituted 10-(4'- 
chlorophenyl)flavins; it can be seen that all compounds inhibited to a similar extent The 
IC50 of all the flavins lie in the narrow range of 6 to 9 |iM. Results for the 3-benzyl 
compound 3.4o, at all concentrations, and the 3-propyl derivative 3.4m at 20 |4M could 
not be obtained due to their insolubility in the testing medium.
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Table 6-1: Effects of 3-substituted 10-(4’-chIorophenyI)flavins on
human erythrocyte glutathione reductase 
O
Cl
Compound number R IC50a ( |iM )
3.7b H 1.1
2 .5o Me 0.8
3.4b Et 4.3
3.4m Pr 19.0
3.4n Ph 46.2
3 .4o PhCH2 5.7
a Concentration required to inhibit 50% of GR activity.
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Table 6-2: Effects of 3-methyl-10-(substituted phenyl)flavins on
human erythrocyte glutathione reductase
Compound no. X IC50 a (l^M) r2
2.5o*> 4-C1 0.8 1.00
2.5h 2,6-(Me)2 1.4 1.00
2.5n 3-C1 1.5 0.99
2.5z 3-Br 1.5 1.00
2.5nn 3-SMe 1.9 0.99
2.5a H 2.1 0.99
2.5j 3-Et 2.1 0.95
2.5kk 3-CF3 2.2 1.00
2.5bb 3-F 2.5 0.99
2.5rr 4-CO2H 2.6 1.00
2,5c 3-Me 3.3 0.99
2.5ee 3-OMe 4.1 0.97
a Concentration required to inhibit 50% of GR activity. b Data taken from Table 6-1.
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Fig 6-3 Growth inhibition of P. falciparum in vitro by 
3-substituted 10-(4'-chlorophenyl)flavins
3.7b (R=H) .
2.5o (R=Me) ■ 
3.4b (R=Et) " 
3.4m (R=Pr) - 
3.4n (R=Ph) J
[ Antimalarial ] ( jiM )
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6-4 Discussion
The two series, 3-methyl-10-(substituted phenyl)flavins and 3-substituted 10-(4'- 
chlorophenyl)flavins were tested for their ability to inhibit human GR and found to be 
active. The 3-substituted 10-(4'-chlorophenyl)flavins demonstrated considerably greater 
variation in potency than the 3-methyl-10-(substituted phenyl)flavins, therefore it was 
decided that this series would be used to delineate the role for inhibition of host 
erythrocytic GR in the antimalarial activity of the flavin compounds.
This series of flavin analogues with its wide range of lipophilic, electronic and 
steric properties when tested against human GR demonstrated a substantial change in 
effectiveness across the series. On the other hand, in the P. falciparum assay, the 
compounds proved to be essentially equipotent throughout the series. This lack of 
correlation, throughout the series, between the two test systems suggests that inhibition 
of host erythrocytic GR is probably not the principal mode of antimalarial action of these 
agents. The possibility that the these compounds are metabolized within the erythrocyte 
or parasite to a common active metabolite which inhibits GR cannot, of course, be 
excluded though there is no evidence to support this proposition. These results also 
indicate the importance of the substituent in the 3-N position of 10-phenylflavins in terms 
of host red cell GR inhibition, a factor apparently not crucial in their antimalarial action 
against P. falciparum in culture.
In an effort to explain the antimalarial activity of 10-(4'-chlorophenyl)-3- 
methylflavin (2.5o), a number of erythrocytic enzymes have previously been 
investigated as possible targets by Becker et al. [107]. The enzymes in which no 
significant inhibition by compound 2.5o was noted include adenylate kinase, lactate 
dehydrogenase, pyruvate kinase, G-6-PD, hexokinase and adenylate kinase. They also 
showed that compound 2.5o does not affect pyrimidine or purine nucleotide biosynthesis 
or metabolism of the parasite or the erythrocyte. In that report, GR presented itself as the 
most likely drug target, however, they found that addition of GSH to parasite cultures did 
not block the antimalarial action of 10-(4'-chlorophenyl)-3-methylflavin against 
P . falciparum, an observation consistent with the present conclusion that inhibition of
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host erythrocytic GR is probably not the main site of antimalarial action for these drugs.
It should be noted that compound 2.5o has also been shown to be an inhibitor of the 
parasite’s GR [107] and the flavins could conceivably be exerting their antimalarial 
activity via this route.
The finding by Becker et al. [107] that compound 2.5o was not an inhibitor of its 
structural analogue, the cofactor flavin adenine dinucleotide (FAD), but that it 
competitively inhibited the binding of GSSG to GR, is of importance if further studies of 
flavins as GR inhibitors are to be undertaken.
In conclusion, the present work suggests that inhibition of human erythrocyte GR 
is probably not the primary mode of action of the 3-substituted 10-(4'-chlorophenyl)- 
flavin antimalarials. Additionally, substituents in the 3-N position of these compounds 
have a direct effect on their enzyme inhibitory activity, while the 10-phenyl substituted 
series showed only a small variation of 3.3 jiM over a wide range of substituents 
indicating that the enzyme is relatively insensitive to changes at this site in the molecule.
CHAPTER 7
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CHAPTER 7 Methods and materials
7-1 General
1. Melting points (mp) and decomposition points (dec) were taken with a Gallenkamp 
melting point apparatus and are uncorrected.
2. Analyses were performed by The Australian National University Analytical 
Services Unit, Canberra. All solids were dried for at least 3 hours under vacuum at 
appropriate temperatures prior to analysis.
3. *H Nuclear magnetic resonance spectra (*H n.m.r.) were recorded on either a Jeol 
FX 90, Varian XL 200 or Varian VXR 300 fourier-transform spectrometer. Data 
are presented in the following order: chemical shift (ppm); multiplicity; coupling 
constant (J) in Hz; and assignment (where possible). The following abbreviations 
were adopted: s (singlet); d (doublet); t (triplet); q (quartet); quint (quintet) and m 
(multiplet).
4. 13c  Nuclear magnetic resonance techniques were performed at 299.95 MHz on a 
Varian VXR 300 instrument at 25°.
5. Low resolution mass spectra (MS) were recorded on an Incos data system attached 
to a VG-Micromass 7070F double focusing mass spectrometer using electron 
impact (El) at 70 eV or chemical ionization (Cl) with ammonia. High resolution 
mass measurements were made by peak matching using perfluorokerosene as a 
reference. Data are presented in the following order, m/z value, relative intensity as 
a percentage of the base peak. The mass spectra in the following section are El 
unless stated otherwise.
6. Ultraviolet spectra were recorded on a Varian DMS 100 UV/visible 
spectrophotometer between 200-500 nm. Compounds were first dissolved in 
dimethyl sulfoxide and then diluted 1000 times with ethanol to a final concentration 
of 20 [iM.
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7. Analytical thin layer chromatography (t.l.c.) was performed on glass plates 
precoated with Merck Kieselgel 60 F254  of 0.25 mm thickness. Plates were 
visualized by both long and short wave ultraviolet light.
8 . Starting materials, unless stated otherwise, were obtained commercially, usually 
from the Aldrich Chemical Company.
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7-2 Synthetic experimental
Some of the 3-methyl-10-(substituted phenyl)flavins used in Chapter 2 were made 
by Dr W. B. Cowden. The description of the synthesis of those not reported in reference 
[42] has been included in this section.
The synthesis of some of the starting materials described below have been 
reported in the literature, however, conflicting results are often reported regarding 
reaction conditions, yields and characteristics for many of these. Thus, methods for their 
preparation are described herein.
N-Propylurea
Sodium cyanate (6.5 g, 0.1 mol) and «-propylamine hydrochloride (9.6 g,
0.1 mol) were dissolved in water (200 ml). The solution was brought to dryness on a 
steam-bath. The residue was recrystallized twice from the minimum amount of water to 
give white crystals which were dried over CaCl2 to give N-propylurea (3.6 g, 36%), 
mp 107° (lit mp 110° [155]).
N-Benzylurea
A solution of sodium cyanate (6.5 g, 0.1 mol) in water (200 ml) was added to a 
solution of benzylamine (10.7 g, 0.1 mol) in 5 M hydrochloric acid (20 ml) and stirred 
for 10 min. An exothermic reaction occurred after which the mixture was heated for an 
hour on a steam bath. An oil formed. The mixture was diluted with water (400 ml) and 
stirred overnight. Long needle-like crystals formed and were filtered off. The crystals 
were dried over CaCl2 to give N-benzylurea (90 g, 60%) mp 144-145° (lit mp 147-148° 
[155]).
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1-Ethylbarbituric acid (3.1a)
A mixture of carefully dried malonic acid (40.0 g, 0.4 mol) and N-ethylurea 
(30.0 g, 0.34 mol) in acetic acid (90 ml) was heated to 60° and stirred until the solids 
dissolved. Acetic anhydride (65 ml, 0.69 mol) was then added dropwise over 90 min. 
The temperature was then raised to 90° for three hours before the solution was cooled and 
concentrated under vacuum to a thick red syrup. The syrup was crystallized by dilution 
with ethanol (200 ml). Recrystallization from 90% ethanol gave 1-ethylbarbituric acid 
(3.1a) (29 g, 55%) mp 119-122° (lit mp 119-120° [155]).
1-Benzylbarbituric acid (3.1d)
Method 1
N-Benzylurea (synthesis described) (51 g, 0.34 mol) was treated as for 3.1a 
above. T.l.c. (ethanol) indicated the resulting crystals had a large amount of by-product 
present. Repeated recrystallizations from ethanol gave the title compound (3.Id) (0.7 g, 
6%) mp 146-151°. (Found: C, 60.4; H, 4.6; N, 12.6. C11H10N2O3 requires C, 60.6; 
H, 4.6; N, 12.8%).
The filtrates from the above recrystallizations were combined and reduced in 
volume under vacuum and the resulting crystals filtered off. By t.l.c. (ethanol) the 
crystals consisted mainly of the by-product. The crude by-product gave an ELMS 
molecular ion peak at 260. The unpurified by-product (44.2 g) in 5 M hydrochloric acid 
(700 ml) was refluxed for 11 hrs. The solution was brought to dryness under vacuum 
and the residue recrystallized from ethanol to give the title compound (3.1d) (9.3 g, 
13%) mp 147-151°. (Found: C, 60.5; H, 4.6; N, 12.9. C11H10N2O3 requires C, 60.6; 
H, 4.6; N, 12.8%).
Method 2
A mixture of phosphorous oxychloride (6 g, 40 mmol), malonic acid (2 g,
20 mmol) and N-benzylurea (synthesis described) (3 g, 20 mmol) in dry chloroform 
(20 ml) was heated under gentle reflux for 6 hrs. The chloroform was removed under 
vacuum, ice (2 g) was added and the mixture was allowed to stand for an hour before it
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was adjusted to pH 7.5 with saturated sodium bicarbonate solution. The solid was 
filtered off and recrystallized from ethanol to give N-benzylurea (1.5 g). On acidification 
of the filtrate with concentrated hydrochloric acid no precipitate formed, t.l.c. (ethanol) 
indicated the absence of 1-benzylbarbituric acid.
Method 3
A mixture of N-benzylurea (synthesis described) (3 g, 20 mmol), malonyl 
dichloride [156] (2.8 g, 20 mmol) and dry toluene (50 ml) was refluxed for 21 hrs. The 
solution was reduced to dryness under vacuum and the residue recrystallized from 90% 
ethanol. T.l.c. (ethanol) revealed two spots with close Rf values, one of which correlated 
to the Rf of 1-benzylbarbituric acid. Repeated recrystallization from ethanol and 90% 
ethanol failed to isolate the pure 1-benzylbarbituric acid.
Method 4
Sodium metal (0.85 g, 37.5 mmol) was dissolved in dry ethanol (20 ml) before 
diethyl malonate (5.0 g, 31 mmol) and N-benzylurea (synthesis described) (4.7 g,
31 mmol) were added to the stirred solution. The reaction mixture was refluxed for 
15 hrs. On cooling a precipitate formed. 2 M Hydrochloric acid (25 ml) was added to 
the reaction mixture with shaking. The solution was allowed to stand overnight before 
filtering off the precipitate, which after recrystallization from 90% ethanol gave 
1-benzylbarbituric acid (3.1d) (4.7 g, 69%) mp 145-147° (lit mp 148-150° [157]).
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3-Substituted 6-(substituted anilino)uracils (see Tables 7.1 and 7.2)
General method A
An intimate mixture of the appropriate 3-methyl (2.2) [63,66]; 3-ethyl (3.1a) 
[66]; 3-phenyl (3.1c) [124,66]; or 3-benzyl (3.1d) [66] -6-chlorouracil (10 mmol), the 
appropriate aniline (30 mmol) and acetic acid (0.5 ml) was heated in an oil bath at 180° for 
25 min, cooled briefly and poured into ethanol (ca 50 ml) and stirred for 15 min. The 
solid was filtered off, washed with ether (80 ml), recrystallized from acetic acid or 
methanol, and dried under vacuum. The compounds produced, their melting points and 
yields are found in Table 7-1 and microanalyses are presented in Table 7-2.
General method B
A mixture of the appropriate 3-methyl (2.2) [63,66]; 3-ethyl (3.1a) [66]; 
3-rt-propyl (3.1b) [123,158]; or 3-phenyl (3.1c) [66,124] -6-chlorouracil (10 mmol), 
the appropriate aniline (10 mmol; all except 2.3u [70] and 2.3w [69] were available 
from the Aldrich Chemical Company), N,N-diethylaniline (3 g, 3.2 ml, 20 mmol) and 
acetic acid (0.5 ml) was heated at 190° for 25 min, cooled briefly, poured into ethanol (ca 
50 ml) and stirred until crystallization was complete. The solid was filtered off, washed 
with ether and recrystallized from either methanol or acetic acid and then dried under 
vacuum. The compounds produced, their melting points and yields are found in 
Table 7-1 and microanalyses are presented in Table 7-2.
Attempted condensation of 2,6-dimethylaniIine and 6-chloro-3- 
methyluracil (2.2)
Using both general methods A and B above for 6-anilinouracil synthesis, the 
expected product was not formed as determined by t.l.c. (ethanol) and only starting 
materials were identified.
Table 7-1: Physical properties of 3-substituted 6-(substituted 
anilino)uraciIs produced by general methods A and B
a Literature mps are presented in brackets.b See reference [60]. c Synthesised by Dr W.B. Cowden. d See 
reference [159].e See reference [67].f See reference [160]. 8 See reference [161].h See reference [68].
Cmpd
no.
Substitutents 
R (X)n M elting point 
(°C) a
% yield Method
2.4a Me H 330 (336-338) b 91 B
2.4b Me 2-Me 237-239 67 B
2.4c Me 3-Me 273-274 (291) b 76 B
2 .4 d c Me 4-Me 311-313 (325) d 70 A
2.4e Me 2,4-M e2 290-292 59 B
2.4f Me 3,4-M c2 309-312 (309) e 88 B
2.4g Me 3,5-Me2 288 (275-277) f 87 B
2.4i Me 2-Et 223-226 22 B
2.4j c Me 3-Et 246-248 71 A
2.4k Me 4-Et 304-307 78 B
2.41 c Me 4-n-butyl 268-270 62 A
2.4o Me 4-C1 345-346 (297) b 49 B
2.4t Me 3-Cl,4-Me 299-300 88 B
2.4u Me 3-Cl,5-Me 303-304 60 B
2.4w Me 4-Cl,3-Me 334-335 76 B
2.4x Me 4-Cl,2-F 335-336 42 B
2.4y c Me 4-Cl,3-CF3 283-285 75 A
2.4dd Me 3,4-F2 333-337 71 B
2.4ee c Me 3-OMe 268-269 (276) e 69 A
2.4ff c Me 4-OMe 311 (290-292)8 75 A
2.4gg Me S ^-tO M e^ 298-299 88 B
2.4hh Me 4-OH 330-333 (>330) e 82 B
2.4jj Me 4-NMe2 dec 320 (>330)e 92 A
2.4kk Me 3-CF3 257-259 56 B
2.411 Me 4 -CF3 300-302 42 B
2.4mm c Me 3,5-(CF3)2 305-306 81 A
2.4nn Me 3-SMe 257-259 87 B
2.4oo Me 4-SMe 327-328 80 B
2.4qq Me 4-CN 353 (3 5 7 )b 30 B
3.3a Et H 328-329 91 B
3.3b Et 4-C1 267-268 65 A
3.3c Et 4-Br 292-294 55 B
3.3d Et 3-F 285-286 58 B
3.3e Et 4-F 284-285 72 B
3.3f Et 3,5-Cl2 285-287 40 B
3.3g Et 3,5-Me2 253-254 45 A
69 B
3.3h Et 3-CF3 250-251 41 B
3.3i Et 3-CN 292-294 52 B
3.3j Et 4-CN 318-320 37 B
3.3k Et 3-SMe 213-216 41 B
3.31 Et 4-SMe 316 71 B
3.3m Propyl 4-C1 263 46 B
3.3n Phenyl 4-C1 328-329 53 A
47 B
3.3o Benzyl 4-C1 279-280 45 A
3.3p Phenyl H 300 (308-310) h 41 B
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Table 7-2: Analytical data for the 3-substituted 6-(substituted
anilino)uracils
Cm pd
no.
Substitu  tents 
R  ( X ) n F orm ula
% calculated 
C H  N C
% found 
H N
2.4a M e H C i i H h N 3 0 2 60.8 5.1 19.3 60.8 5.4 19.6
2.4b M e 2-M e C i 2 H i 3 N 3 0 2 62.3 5.7 18.2 62.4 5.6 18.2
2.4c M e 3-M e " " tt tt 62.6 5.8 18.3
2.4d M e 4-M e tt tt tt tt 62.3 5.8 18.2
2.4e M e 2,4-M e2 C i 3 H i 5 N 3 0 2 63.7 6.2 17.1 63.9 6.3 17.2
2 .4 f M e 3,4-M e2 it
tt tt tt 63.4 6.3 17.2
2 .4g M e 3,5-M e2 it tt tt tt 63.7 6.3 17.2
2 .4 i M e 2-Et tt " tt tt 63.8 6.1 17.1
2.4j M e 3-Et tt " tt tt 63.7 6 .2 16.9
2 .4k M e 4-E t " tt tt tt 63.8 6.3 17.2
2.41 M e 4-n-butyl C i 5 H i 9 N 3 0 2 65.9 7.0 15.4 66.1 7.1 15.4
2 .4 t M e 3-C l,4-M e C i 2 H i 2 C 1 N 3 0 2 54.3 4 .6 15.8 54.6 4.8 16.1
2.4u M e 3-C l,5-M e " tt tt " 54.2 4.7 15.7
2.4w M e 4-C l,3-M e " tt tt tt 54.0 4.5 15.8
2 .4x M e 4-C1.2-F C h H 9 C 1 F N 3 0 2 49.0 3.4 15.6 48 .9 3.2 15.7
2.4y M e 4-C l,3 -C F 3 C i 2 H 9 C 1F 3 N 3 0 2 45.1 2.8 13.1 44.8 2.8 13.1
2.4dd M e 3 ,4-F 2 C h H 9 F 2 N 3 0 2 52.2 3.6 16.6 52.5 3.8 16.6
2.4ee M e 3-OM e C 12H 13N 3O 3 58.3 5.3 17.0 58.5 5.3 17.1
2.4ff M e 4-OM e tt tt tt tt 58.6 5.4 17.1
2.4gg M e 3,5-(O M e)2 C 12H 19N 3O 4 56.3 5.5 15.2 56.2 5.6 15.2
2.4hh M e 4-OH C 11H 11N 3O 3 56.7 4.8 18.0 57.0 4.7 18.1
2.4jj M e 4-N M e2 C i 3 H i 6 N 4 0 2 60.0 6.2 21.5 59.8 6.5 21.5
2 .4kk M e 3-C F 3 C i 2 H i o F 3 N 3 0 2 50.5 3.5 14.7 50.3 3.3 14.5
2.411 M e 4 -C F 3 tt " tt tt 50.6 3.5 14.4
2 .4m m  M e 3 ,5-(C F 3)2 C i 3 H 9 F ö N 3 0 2 44.2 2 .6 11.9 44 .4 2.3 11.8
2.4nn M e 3-SM e C i 2 H i 3 N 3 0 2 S 54.7 5.0 16.0 54.6 5.2 16.2
2 .4oo M e 4-SM e tt tt " tt 55.0 5.1 16.1
2.4qq M e 4-CN C i 2 H i o N 4 0 2 59.5 4 .2 23.1 59.2 4 .2 23.0
3.3a E t H C i2H i3N 30 2 62.3 5.7 18.2 62.3 5.8 18.2
3.3b E t 4-C1 C i 2 H i 2 C 1 N 3 0 2 54.3 4 .2 15.8 54.0 4.5 15.7
3.3c E t 4-Br C i2H i2BrN 302 46.5 3.9 13.6 46.1 3.8 13.4
3.3d E t 3-F C 12H 12F N 3O 2 57.8 4 .9 16.9 58.1 5.0 17.1
3.3e E t 4 -F " tt tt tt 58.2 4 .9 17.0
3 .3 f E t 3 ,5 -C l2 C 12H 11CI2N 3O 2 48.0 3.7 14.0 48.3 3.7 13.9
3.3g E t 3,5-M e2 C 14H 17N 3O 2 64.9 6.6 16.2 65.1 6.8 16.3
3.3h E t 3-C F 3 C 13H 12F 3N 3O 2 52.2 4 .0 14.0 52.5 4.1 14.1
3 .3 i E t 3-CN C 13H 12N 4 O 2 60.9 4 .7 21.9 60.9 4 .7 21.9
3.3j E t 4-CN tt tt tt tt 60.6 5.0 21.8
3.3k E t 3-SM e C 13H 12N 3O 2S 56.3 5.5 15.2 56.5 5.7 15.2
3.31 E t 4-SM e tt tt tt tt 56.6 5.5 15.1
3.3m Propyl 4-C1 C 13H 14C IN 3O 2 55.8 5.0 15.0 56.1 5.1 15.0
3.3n Phenyl 4-C1 C i 6 H i 2 C 1 N 3 0 2 61.3 3.9 13.4 61.5 3.9 13.4
3.3o Benzyl 4-C1 C 17H 14C 1N 3 0 2 62.3 4.3 12.8 62.6 4.3 12.8
3.3p Phenyl H C 16H 13N 3 0 2 68.8 4 .7 15.1 69.1 4.8 15.3
I l l
6 -(3 ,-Trifluorom ethylanilino)uracil (3.3s)
A mixture of 6-aminouracil (2.3 g, 18 mmol), 3-trifluoromethylaniline 
hydrochloride (4.1 g, 21 mmol), 3-trifluoromethylaniline (5.7 g, 36 mmol) and acetic 
acid (6 ml) were heated in an oil bath at 170° for 4 hrs. The melt was cooled and added to 
water (40 ml). The resulting solid was filtered off, washed with water and ethanol, and 
recrystallized from acetic acid to give the title compound (3.3s) (3.8 g, 78%) mp 325- 
327°. (Found: C, 48.8; H, 2.8; N, 15.5. C11H8F3N3O2 requires C, 48.7; H, 3.0; N, 
15.5%). n.m.r. (CD3SOCD3) 5 4.78, s, H 5; 7.50-7.58, m, H 2', 4’, 5’, 6’.
N-PhenyI-l,2-benzenediamine (3.6a)
To a solution of 2-nitro-N-phenylbenzenamine (4.3 g, 20 mmol) in acetic acid 
(100 ml) was added a solution of stannous chloride (22.6 g, 100 mmol) in concentrated 
hydrochloric acid (25 ml). The solution was warmed to 80° and stirred for 40 min. On 
cooling it was made strongly basic with 10 M sodium hydroxide solution, diluted with 
water (1 litre) and the residue was filtered off. The residue was washed with water 
(2 litres) and recrystallized from isopropanol to give the title compound (3.6a) (3.2 g, 
87%) mp 72° (tit mp 76° [155]).
N-(4'-Chlorophenyl)-l,2-benzenediamine (3.6b)
N-(4'-Chlorophenyl)-2-nitrobenzenamine [126] (4.3 g, 20 mmol) was treated as 
for 3.6a above. The product was recrystallized from a small amount of ethanol to give 
the title compound (3.6b) (3.5 g, 80%) mp 118° (tit mp 119° [126]).
10-PhenylfIavin (3.7a)
The title compound was prepared by a similar method to that of Kraus et al. [162]. 
The crude product was recrystallized from acetic acid to give the title compound (3.7a) 
(2.6 g, 77%) dec 330° (tit mp 250° [162]). (Found: C, 65.9; H, 3.4; N, 18.9. 
C16H10N4O2 requires C, 66.2; H, 3.5; N, 19.3%.). n.m.r. data are presented in 
Tables 3-1 (pg 70o) and 3-2 (pg 71). m/z (rel. int) 290 M (26), 289 (100), 246 (20), 
219 (51), 218 (75).
112
10-(4'-Chlorophenyl) flavin (3.7 b)
A mixture of N-(4'-chlorophenyl)-l,2-benzenediamine (3.6b) (2.5 g,
11.5 mmol), alloxan tetrahydrate (2.9 g, 13.7 mmol), boric acid (0.9 g, 14.6 mmol) and 
acetic acid (300 ml) was heated and stirred at 60° for 25 min. After crystallization was 
complete the solid was filtered off and recrystallized from acetic acid to give yellow 
crystals of the title compound (3.7b) (1.3 g, 36%) mp > 360° (lit mp >370° [42]). 
(Found: C, 59.5; H, 2.8; N, 17.4. C16H9CIN4O2 requires C, 59.2; H, 2.8; N, 17.3%).
n.m.r. and mass spectral data are presented in Tables 3-1 (pg 70o) and 3-2 (pg 71), 
and Table 3-3 (pg 126), respectively.
N, N-Dimethyl-N'-(2'-ni trophenyl)-ly4-benzenediamine  (3.6c)
A mixture of 2-chloronitrobenzene (25 g, 0.16 mol) and sodium acetate (25 g,
O. 3 mol) was heated with stirring at 170-180° under a nitrogen atmosphere while 
N,N-dimethyl-l,4-benzenediamine (22.0 g, 0.16 mol) was added portionwise over
7 hrs. The resulting black tar was solubilized with a small volume of ethanol and made 
acidic with 1 M hydrochloric acid. The solution was steam distilled for 2.5 hrs to 
remove unreacted 2-chloronitrobenzene. The residue was made basic with aqueous 
ammonia and the resulting oil separated The oil was washed with water (3 x 20 ml) and 
extracted several times with ether. The ether extracts were combined, dried (Na2SC>4), 
filtered and the volatiles removed under reduced pressure. The resulting oily residue was 
dissolved in a small volume of hot ethanol, treated with charcoal, filtered, reduced in 
volume and chilled to give red crystals of the title compound (3.6c) (2.1 g, 5.1%). An 
analytical sample was recrystallized from isopropanol, mp 97-98°. (Found: C, 65.5; H, 
5.9; N, 16.5. C14H15N3O2 requires C, 65.4; H, 5.9; N, 16.3%). m/z (rel. int.) 257 M 
(100), 223 (65), 209 (31), 167 (32), 136 (42).
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10-(4 ’-D im ethylam inophenyl)flavin  (3.7c)
N,N-Dimethyl-N'-(2'-nitrophenyl)-l,4-benzenediamine (3.6c) (1.2 g,
4.7 mmol) was added to a nitrogen saturated solution of stannous chloride (5.3 g,
23 mmol) in concentrated hydrochloric acid (10 ml) and acetic acid (50 ml) at 60° with 
stirring. A stream of nitrogen was passed through the solution continuously while 
stirring was continued for 1.3 hrs. The reaction was cooled, made basic with nitrogen 
saturated 10 M sodium hydroxide solution and diluted with nitrogen saturated water to 
dissolve the remaining tin salts. The resulting oil was extracted into chloroform, dried 
(Na2SC>4), the chloroform removed under reduced pressure and the oil (1.0 g, 4.5 mmol) 
dissolved in acetic acid (10 ml). To this solution was added alloxan tetrahydrate (1.0 g, 
4.5 mmol) and boric acid (0.3 g, 4.8 mmol) and the mixture heated at 60° for 1 hr under a 
nitrogen atmosphere. After evaporation to dryness the residue was washed with a small 
volume of water and ether, and recrystallized from methanol to give the title compound 
(3.7c) (0.4 g, 23%) dec 330°. (Found: C, 65.9; H, 3.4; N, 18.9. C16H10N4O2 
requires C, 66.2; H, 3.5; N, 19.3%). *H n.m.r. (CD3SOCD3) 5 3.02, s, N(CH3)2;
6.93, d, 7.17, d, J2\y  7.7 Hz, H 2’, 3', 5’, 6’, 9; 7.53-7.82, m, H 7, 8; 8.16, d, J6,7 
7.2 Hz, H 6. m/z (rel. int.) 334 (19), 333 M (95), 332 (71), 318 (17), 262 (54), 261 
(100), 247 (25).
10-(3'-Nitrophenyl)ßavin (3.9a)
To a solution of 10-phenylflavin [162] (1.5 g, 5 mmol) in concentrated sulfuric 
acid (10 ml) was added fuming nitric acid (d-1.5, 0.34 g, 5.5 mmol). The solution was 
heated to 130° for 1.5 hrs, allowed to cool, poured onto ice (100 g) and adjusted to pH 6 
with concentrated ammonia solution. The precipitate was filtered off, washed with 
ethanol and recrystallized from methanol to give the title compound (3.9a) (0.6 g, 34%) 
dec 253°. (Found: C, 57.2; H, 2.7; N, 20.6. C16H9N5O4 requires C, 57.3; H, 2.7; N, 
20.9%). *H n.m.r. (CD3SOCD3) 5 6.86, d, J8,9 8.0 Hz, H 9; 7.60-7.78, m, H 7, 8; 
7.92-8.08, m, H 5', 6’; 8.21, d, J6J 8.0 Hz, H 6; 8.42, s, H 2'; 8.53, d, J4',5* 8.0 Hz, 
H 4’. m/z (rel. int.) 335 M (34), 334 (100), 292 (16), 291 (22), 290 (21), 289 (76), 
264 (19), 263 (30).
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7-Nitro-10-(3'-nitrophenyl)flavin (3.8)
10-Phenylflavin [162] (1.5 g, 5 mmol) was added to a solution of fuming nitric 
acid (d-1.5, 12.5 ml) and concentrated sulfuric acid (25 ml) at 0°, and stirred at room 
temperature for 4 days. The solution was poured onto ice, adjusted to pH 3 with 
concentrated ammonia solution and filtered. The filtrate was allowed to stand for 4 days 
to ensure complete crystallization, the yellow solid was filtered off and recrystallized three 
times from ethanol to give the title compound (3.8) (0.2 g, 11%) dec 341°. (Found: C, 
50.9; H, 1.9; N, 21.8. Ci6H8N60 6 requires C, 50.5; H, 2.1; N, 22.1%). lH n.m.r. 
(CD3SOCD3) 5 7.08, d, J8,9 9.4 Hz, H 9; 7.92-8.13, m, H 5’, 6’; 8.40-8.45, m, H 8,
2'; 8.56, d, JyA< 8.0 Hz, H 4'; 8.96, s, H 6. m/z (rel. int.) 380 M (11), 379 (37), 336 
(11), 335 (24), 334 (70), 308 (11), 292 (15), 291 (22), 263 (28).
10-(3 '-Bromophenyl) f lav in  (3.9b)
A mixture of 10-phenylflavin [162] (1 g, 3.3 mmol), concentrated sulfuric acid 
(10 ml), water (1 ml), silver sulfate (1.1 g, 3.3 mmol) and bromine (0.53 g, 3.3 mmol) 
was mechanically shaken for 16 hrs. The reaction mixture was poured onto ice (100 g) 
and filtered. The filtrate was adjusted to pH 6 with concentrated ammonia solution and 
the resulting precipitate was filtered off and recrystallized from acetic acid to give the title 
compound (3.9b) (0.3 g, 25%) dec 248°. (Found: C, 52.0; H, 2.3; N, 15.0. 
Ci6H9BrN402 requires C, 52.0; H, 2.5; N, 15.2%). *H n.m.r. (CD3SOCD3) 6 6.82, 
d, J8,9 6.8 Hz, H 9; 7.44-7.95, complex, H 2\ 4’, 5’, 6', 7, 8; 8.21, d, J6j  7.4 Hz,
H 6.
Attempted dibromination of 10-phenylflavin 
Method 1
10-Phenylflavin [162] (1 g, 3.3 mmol) was treated as for 3.9b above except that 
twice the amount of bromine (1.06 g, 6.6 mmol) was used. The precipitate was 
recrystallized from acetic acid to give 10-(3'-bromophenyl)flavin (3.9b) (0.65 g, 51%) 
dec 248°. *H n.m.r. (CD3SOCD3) identical to that isolated above.
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Method 2
10-(3'-Bromophenyl)flavin (3.9b) (1.2 g, 3.3 mmol) was treated as for 3.9b 
above except that the reaction time was increased to 5 days. The black precipitate was 
taken up in acetic acid and filtered. T.l.c. (ethyl acetate) of the acetic acid solution 
showed no spots visible under long wavelength ultraviolet light. Attempts to isolate a 
product failed.
3-Substituted 10-(substituted phenyl)flavins (see Tables 7-3 and 7-4)
General method A - Condensation of 3-substituted 6-anilinouracils (2.4, 3.3) with 
nitrosobenzene.
The appropriate 3-substituted 6-(substituted anilino)uracil (2.4, 3.3) (10 mmol) 
and nitrosobenzene (3.2 g, 30 mmol) were refluxed in a mixture of acetic anhydride 
(16 ml) and acetic acid (6 ml) for 35 min. The volume of the reaction mixture was then 
reduced by approximately 50% under reduced pressure and ethanol (10 ml) added. After 
crystallization was complete the yellow solid was filtered off, washed with ethanol and 
ether, and recrystallized from methanol or acetic acid. The compounds produced, their 
melting points and yields are found in Table 7.3 and microanalyses are presented in 
Table 7-4. Some of the compounds' n.m.r. data are presented in Tables 2-1 (pg 32), 
2-2 (pg 36), 3-1 (pg 70o) and 3-2 (pg 71). The UV and EIMS data of some of these 
compounds are presented in Tables 2-4 (pg 43) and 3-3 (pg 72o), respectively.
Attempted condensation of 6-(4'-dimethylaminoanilino)-3-methyluracil 
(2.4jj) with nitrosobenzene
6-(4'-Dimethylaminoanilino)-3-methyluracil (2.4jj) (2.6 g, 10 mmol) was treated 
according to general method A for flavin synthesis above. The t.l.c. (ethyl acetate) of the 
reaction mixture compared with an authentic sample of 10-(4'-dimethylaminophenyl)-3- 
methylflavin (2.5jj) revealed the flavin not to be present in the reaction mixture.
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10-(4 ,-Carboxyphenyl)-3-m ethylßavin  (2 .5 rr)
10-(4'-Cyanophenyl)-3-methylflavin (2.5qq) (0.5 g, 1.6 mmol) was refluxed in 
a mixture of acetic acid (100 ml) and 70% sulfuric acid (100 ml) for 2 hrs. The cooled 
mixture was poured onto ice (200 g) and the product precipitated with solid sodium 
carbonate. The solid was filtered off, washed with water and recrystallized from acetic 
acid to give the title compound (2.5rr) (0.19 g, 34%) mp >360°. (Found: C, 61.8; H, 
3.7; N, 16.1. C18H12N4O4 requires C, 62.1; H, 3.5; N, 16.1%). UV and JH n.m.r. 
data are presented in Table 2-4 (pg 43), and Tables 2-1 (pg 32) and 2-2 (pg 36), 
respectively, m/z (rel. int.) 348 M (38), 347 (100), 291 (22), 290 (28), 263 (35), 262 
(30).
3-Methyl-10-(4*-methylsulfonylphenyl)flavin (2.5pp)
3-Methyl-10-(4'-methylthiophenyl)flavin (2.5oo) (0.2 g, 0.57 mmol) was 
dissolved in acetic acid (50 ml) and cooled to 5°. To this solution was added 30% w/v 
hydrogen peroxide (0.26 g, 2.3 mmol), dropwise, with stirring over 1 hr. The mixture 
was allowed to come to room temperature and stirred for an additional 18 hrs. The acetic 
acid was evaporated off under a steam of nitrogen in an evaporating dish and the solid 
recrystallized from methanol to give the title compound (2.5pp) (0.1 g, 45%) mp 334- 
335°. (Found: C, 56.4; H, 3.8; N, 14.5. C18H14N4O4S requires C, 56.5; H, 3.7; N, 
14.5%). UV and n.m.r. data are presented in Table 2-4 (pg 43), and Tables 2-1 
(pg 32) and 2-2 (pg 36), respectively. MSCI m/z (rel. int.) 383 M+l (7), 369 (38), 368 
(43), 367 (91), 366 (16), 365 (37), 354 (21), 353 (78), 352 (76), 351 (100).
3-Substituted 10-(substituted phenyl)ßavins (see Tables 7-3 and 7-4)
General method B - Alkylation of 10-(substituted phenyl)flavins
To a solution of the appropriate 10-(substituted phenyl)flavin (3.7a, 3.7c, 3.9a 
or 3.9b; 3.5 mmol) in dimethylformamide (250 ml) was added powdered potassium 
carbonate (4.7 g, 35 mmol) followed by the appropriate alkylating agent (methyl iodide, 
propyl iodide or benzyl bromide; 4.6 mmol). The mixture was heated and stirred at
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50-55° for 1 hr, cooled, filtered and the filtrate added to chloroform (400 ml). This was 
washed with water (5 x 200 ml), dried ( N & S O 4), filtered and evaporated to dryness 
under reduced pressure. The solid residue was washed with ether, and recrystallized 
from methanol. The compounds produced, their melting points and yields are found in 
Table 7-3 and microanalyses are presented in Table7-4. Some of the compounds' *H 
n.m.r. data are presented in Tables 2-1 (pg 32), 2-2 (pg 36), 3-1 (pg 70o) and 3-2 (pg 
71). The UV and EIMS data of some of these compounds are presented in Tables 2-4 
(pg 43) and 3-3 (pg 72o), respectively.
The mass spectral data for 2.5jj and 2.5z are as follows: 
10-(4'-dimethylaminophenyl)-3-methylflavin (2.5jj); m/z (rel. int.) 348 (21), 347 M 
(100), 346 (85), 332 (12), 290 (11), 262 (37), 261 (66); and 
10-(3'-bromophenyl)-3-methylflavin (2.5z); m/z (rel. int.) 384 (27), 383 (88), 382 M 
(29), 381 (82), 327 (14), 326 (17), 325 (13), 324 (14).
Table 7-3: Physical properties of 3-substituted 10-(substituted 
phenyl)flavins produced by general methods A and B
a Literature mps are presented in brackets.b See reference [60].c See reference [47]. d Synthesised by 
Dr W.B. Cowden. e See reference [77]. f See reference [42]. 8 See reference [161].h See reference [163].
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Cm pd
no.
Substitu tents 
R (X)n M elting po in t 
(°C) a
% yield Method
2.5a Me H >360 (>360) b 56 B
2.5b Me 2-Me >360 (372) c 50 A
2.5c Me 3-Me 341 ( 3 2 6 )b 91 A
2.5d d Me 4-M e 367-368 64 A
2.5e Me 2,4-M e2 333 56 A
2 .5 f Me 3,4-M e2 333-334 ( 3 4 7 ) b 47 A
2.5g Me 3,5-M e2 318-319 51 A
2.5 i Me 2-Et 270 (2 6 2 -2 6 3 )e 23 A
2 .5 j d Me 3-Et 277-279 42 A
2.5k Me 4-Et 318-319 51 A
2.51 d Me 4-n-butyl 298-300 42 A
2.5t Me 3 -Cl,4-M e >355 39 A
2.5u Me 3-Cl,5-M e 355 34 A
2.5w Me 4-Cl,3-M e >360 20 A
2.5x Me 4-C1.2-F 274 26 A
2.5y d Me 4-C l,3-C F3 >360 44 A
2.5z Me 3-Br 353 (3 5 1 -3 5 3 )f 69 B
2.5dd Me 3,4-F2 >360 35 A
2 .5 e e d Me 3-OMe 322-323 48 A
2 .5 f fd Me 4-OMe 355 (> 3 0 0 )§ 56 A
2.5gg Me S.S-COMeh 341 45 A
2.5hh Me 4-OH >360 (>300) g 24 A
2 .5 ii Me. 3 -N 0 2 >360 76 B
2-5 jj Me 4-NM e2 326 36 B
2 .5 k k d Me 3-CF3 346-348 38 A
2.511 Me 4 -CF3 >360 15 A
2.5m m  ‘1 Me 3,5-(CF3)2 >360 40 A
2.5nn Me 3-SM e 304-305 35 A
2.5oo Me 4-SM e >360 38 A
2.5qq Me 4-CN >355 (> 3 6 0 )b 21 A
3.4a Et H 341 61 A
3.4b Et 4-C1 330 15 A
3.4c Et 4-Br > 360 42 A
3.4d Et 3-F >360 33 A
3.4e Et 4-F 322 25 A
3.4 f Et 3,5-C l2 317 44 A
3.4g Et 3,5-M e2 276 36 A
3.4h Et 3-CF3 297-299 31 A
3.4 i Et 3-CN 349-350 12 A
3.4j Et 4-CN >360 23 A
3.4k Et 3-SM e 341 43 A
3.41 Et 4-SM e 265 26 A
3.4m Propyl 4-C1 >360 34 A
3.4n Phenyl 4-C1 >360 (>300) 32 A
3.4o Benzyl 4-C1 351 31 A
3.4q Propyl H 325 90 B
3.4p Phenyl H dec 280 (>330) 23 A
3.4r Benzyl H 327 (3 2 5 -3 3 0 )h 92 B
3.4s H 3-CF3 >360 45 A
Table 7-4 Analytical data for the 3-substituted 10-(substituted 
phenyl)flavins
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Cm pd
no.
Substitu ten ts 
R  ( X ) n Form ula
% calculated 
C H  N C
% found 
H N
2.5a M e H C n H i 2 N 4 0 2 67.1 4 .0 18.4 6 6 .8 3.8 18.4
2.5b M e 2-M e C i 8 H i 4 N 4 0 2 67.9 4 .4 17.6 68.3 4.3 17.8
2.5c M e 3-M e ft tt tt tt 68 .1 4.5 17.8
2.5d M e 4-M e " tt tt tt 67.7 4 .5 17.5
2.5e M e 2,4-M e2 C i 9 H i 6N 4 0 2 68.7 4.9 16.9 6 8 .8 4.9 17.0
2 .5 f M e 3,4-M e2 it
tt " tt 68 .8 5.1 16.9
2.5g M e 3,5-M e2 tt
tt tt tt 68.3 4 .8 16.7
2 .5 i M e 2-Et tt tt ” " 68.7 5.0 16.9
2.5j M e 3-Et tt tt tt tt 68.4 4 .9 17.1
2 .5k M e 4-E t tt tt tt tt 68.4 5.0 17.0
2.51 M e 4-n-butyl C 2 i H 2oN 4 0 2 70.0 5.6 15.6 69.7 5.7 15.3
2 .5 t M e 3-C l,4-M e C i 8H i 3c i n 4 o 2 61.3 3.7 15.9 61.0 3.6 15.8
2 .5u M e 3-C l,5-M e tt tt tt tt 61.1 3.9 16.2
2.5w M e 4-C l,3-M e tt " " tt 61.1 3.6 16.2
2.5x M e 4-C l,2-F C 1 7 H 1 0 C 1 F N 4 O O 57.2 2 .8 15.7 57.5 2 .8 15.9
2.5y M e 4-C l,3 -C F 3 C i 8H io C 1F 3N 4 0 2 53.2 2.5 13.8 53.2 2 .6 13.7
2.5z M e 3-Br C i7 H n B r N 4 0 2 53.3 2.9 14.6 53.0 2 .8 14.7
2.5dd M e 3.4-F2 C i 7H io F 2N 4 0 2 60.0 3.0 16.5 60.1 2.9 16.5
2.5ee M e 3-OM e C i 8 H i 4 N 4 0 3 64.7 4 .2 16.8 64.7 4.3 16.8
2.5ff M e 4-OM e tt tt tt tt 64.6 4 .4 16.8
2-5gg M e 3,5-(O M e)2 C 19H 16N 4 O 4 62.6 4 .4 15.4 62.3 4.3 15.4
2.5hh M e 4-OH C n H i 2 N 4 0 3 63.8 3.8 17.5 63.5 3.9 17.5
2 .5 ii M e 3 -N Q 2 C 17H 11N 5O 4 58.5 3 .2 2 0 .1 58.3 3.3 19.8
2.5jj M e 4-N M e2 C i 9 H i 7N 50 2 65.7 4 .9 2 0 .2 65.7 5.2 2 0 .2
2.5kk M e 3 -C F 3 C i 8H h F 3n 4 o 2 58.1 3 .0 15.1 57.8 3.1 15.2
2.511 M e 4 -C F 3 tt tt tt tt 58.2 3.1 14.8
2.5m m  M e 3,5-(C F3)2 C i9 H io F 6 N 4 0 2 50.5 2 .4 13.1 50.4 2 .1 12.7
2.5nn M e 3-SM e C i 8H i4 N 4 0 2S 61.7 4 .0 16.0 61.5 4.1 16.1
2.5oo M e 4-SM e tt tt tt tt 62.0 3.9 16.1
2.5qq M e 4-C N C i 8H n N 5 0 2 64.4 3.5 22 .1 64.6 3 .2 22 .1
3.4a E t H C i 8H 14N 4 0 2 67.9 4 .4 17.6 6 8 .0 4 .2 17.6
3.4b E t 4-C1 C i 8H i 3C1N4 0 2 61.3 3.7 15.9 61.1 3.6 15.8
3.4c E t 4-Br C i 8H i3 B rN 4 0 2 54.4 3.3 14.1 54.0 3.2 13.9
3.4d E t 3-F C i 8H i 3F N 40 2 64.3 3.9 16.7 64.1 3.9 16.7
3.4e E t 4-F tt " tt tt 64.6 3.8 16.7
3 .4f E t 3 ,5 -C l2 C i 8H i 2 C12N 40 2 55.8 3.1 14.5 56.1 3.1 14.6
3.4g E t 3,5-M e2 C 2oH i 8N 4 0 2 69.4 5.2 16.2 69.3 5.3 16.4
3.4h E t 3 -C F 3 C i9 H i3 F 3 N 4 0 2 59.1 3.4 14.5 59.3 3.4 14.5
3 .4i E t 3-CN C i9 H i3 N s 0 2 66.5 3.8 20.4 6 6 .6 3.9 2 0 .6
3.4j E t 4-C N " tt tt tt 6 6 .2 3.8 20.3
3.4k E t 3-SM e C i9 H i6 N 4 0 2S 62.6 4.4 15.4 62.3 4 .6 15.3
3.41 E t 4-SM e tt tt " tt 62.8 4 .5 15.5
3.4m P ropyl 4-C1 C i 9 H iö C 1N 402 62.2 4.1 15.3 62.1 4 .3 15.1
3.4n Phenyl 4-C1 c 22h 13c i n 4 o 2 65.9 3.3 14.0 65 .6 3 .2 13.8
3.4o Benzyl 4-C1 C 23H i 5C1N4 0 2 6 6 .6 3.7 13.5 66.7 3 .6 13.5
3.4q P ropyl H C i9 H i6 N 4 0 2 68.7 4 .9 16.9 6 8 .6 5.1 17.1
3.4p Phenyl H C 22 H i4 N 4 0 2 72.1 3.9 15.3 71.7 4 .2 14.9
3.4r Benzyl H C 2 3 H i6 N 4 0 2 72.6 4 .2 14.7 72.3 4 .3 15.0
3.4s H 3 -C F 3 C n H 9 F 3 N 4 0 2 57.0 2.5 15.6 56.6 2 .5 15.6
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Substituted nitrosobenzenes (4.1a-c)
Caro's acid - A paste of ground potassium persulfate (60 g, 0.22 mol) and 
concentrated sulfuric acid (60 ml) was well stirred for 1 hr at room temperature before 
being mixed with ice (1200 g). The solution was neutralized to a pH of 7 with solid 
potassium carbonate and acetic acid.
The Caro's acid solution from above was cooled to 0° before adding it to a cooled 
(0°) mixture of the appropriate aniline (60 mmol) in water (600 ml). The reaction mixture 
was allowed to stir for 5 hrs at 0°. The solution was filtered and the residue was then 
washed with water (2 litres), 1 M hydrochloric acid (800 ml) and water (500 ml). Steam 
distillation of the residue yielded the desired nitrosobenzene. Melting points of samples 
were determined on compounds recrystallization from ethanol: 4-chloronitrosobenzene 
(4.1c) mp 87° (lit mp 90°, prepared by the same method as above [137]); 3-chloro- 
nitrosobenzene (4.1b) mp 70° (lit mp 72° [164]); and 3,4-dimethylnitrosobenzene (4.1a) 
mp 44° (lit mp 44-45° [155]).
8- Chloro-10-(4'-chlorophenyl)-3-methylflavin (4.2c)
The title compound was prepared by a method similar to that of Yoneda et al.
[61]. The crude material was recrystallized from acetic acid to give the title compound 
(4.2c) (0.8 g, 37%) dec 346° (lit mp >360° [61]). (Found: C, 54.4; H, 2.6; N, 15.0. 
C17H 10CI2N4O2 requires C, 54.7; H, 2.7; N, 15.0%). m/z (rel. int.) 374 (18), 373 
(56), 372 M (27), 371 (83), 315 (18), 287 (25). *H n.m.r. spectral data are presented in 
Table 4-1 (pg 83).
9-  Chloro-10-(4'’Chlorophenyl)-3-methylflavin (4.3b)
A solution of 3-chloronitrosobenzene (4.1b) (2.6 g, 18 mmol) and 6-(4'- 
chloroanilino)-3-methyluracil (2.4o) (1.5 g, 6 mmol) in acetic anhydride (12 ml) and 
acetic acid (4 ml) was refluxed for 35 min. After crystallization was complete the solid 
was filtered off, washed with ether and recrystallization from acetic acid. The *H n.m.r. 
spectrum of the recrystallized material indicated it to be a mixture of the 7- and 9- chloro 
isomers. The mixture was twice recrystallized from dimethylformamide to give the title
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compound (4.3b) (0.4 g, 18%) mp >360°. (Found: C, 54.7; H, 2.8; N, 15.1. 
C17H10CI2N4O2 requires C, 54.7; H, 2.7; N, 15.0%). The above recrystallization 
filtrates were combined and retained for use below, m/z (rel. int.) 374 (18), 373 (29),
372 M (20), 371 (41), 315 (9), 287 (33). *H n.m.r. data are presented in Table 4.1 
(pg 83).
7-Chloro-10-(4,-chlorophenyl)-3-methylflavin (4.2b)
The filtrate from above was diluted with ether and the resulting solid was filtered 
off and recrystallized from acetic acid to give the title compound (4.2b) (0.25 g, 11%) 
dec 335°. (Found: C, 54.7; H, 2.8; N, 15.1. C17H10CI2N4O2 requires C, 54.7; H,
2.7; N, 15.0%). m/z (rel. int.) 374 (15), 373 (41), 372 M (20), 371 (64), 315 (14), 287 
(25). *H n.m.r. data are presented in Table 4.1 (pg 83).
10-(4'-Chlorophenyl)-3,8,9-trim ethyl flavin  (4.3a)
3,4-Dimethylnitrosobenzene (4.1a) (2.4 g, 18 mmol) was treated as for 4.3b 
above. The *H n.m.r. spectrum of the recrystallized material indicated it to be a mixture 
of the 7,8- and 8,9- dimethyl isomers. The mixture was recrystallized twice from acetic 
acid and then dimethylformamide to give the title compound (4.3a) (0.5 g, 23%) dec 
304°. (Found: C, 62.0; H, 4.0; N, 15.1. C19H15CIN4O2 requires C, 62.2; H, 4.1; N 
15.3%). n.m.r. data are presented in Table 4.1 (pg 83).
5-Bromo-6-(4,-chloroanilino)’3-methyluracil  (4.4b)
To a suspension of 6-(4'-chloroanilino)-3-methyluracil (2.4o) (3.8 g, 15 mmol) 
in methanol (50 ml), bromine (0.9 ml, 2.4 g, 18 mmol) was added and the mixture stirred 
for 1.5 hrs at room temperature. The resulting crystals were filtered off and recrystallized 
from acetic acid to give the title compound (4.4b) (3.2 g, 64%) mp 236°. (Found:
C, 39.9; H, 2.7; N, 12.7. C nH 9BrClN302 requires C, 40.0; H, 2.7; N, 12.7%.)
*H n.m.r. (CD3SOCD3) 5 3.14, s, CH3N; 7.16, d, 7.38, d, J2’,3’ 8.8 Hz, H 2’, 3’, 5’, 
6'; 8.72, s, NH.
6-(4 f-C hloroanilino)-5-(3”,4 ',-dim ethylanilino)-3-m ethyluracil (4.5b)
A mixture of 5-bromo-6-(4'-chloroanilino)-3-methyluracil (4.4b) (1.7 g,
5 mmol) and 3,4-dime thy laniline (6.1 g, 50 mmol) in dimethyl sulfoxide (20 ml) was 
stirred at room temperature for 17 hrs. The resulting crystals were filtered off and 
recrystallized from acetic acid to give the title compound (4.5b) (1.2 g, 65%) dec 250°. 
(Found: C, 62.0; H, 4.1; N, 15.4. C19H19CIN4O2 requires C, 62.2; H, 4.1; N,
15.3%). *H n.m.r. (CD3SOCD3) 5 2.06, s (CH3)2C6H3; 3.10, s, CH3N; 6.12, s, NH; 
6.18-6.82, complex, (CH3)2C6H3; 7.11, d, 7.31, d, J2’,3’ 8.5 Hz, C6H4CI; 8.47, s,
NH.
6-A nilino-5-brom o-3-m ethyluracil (4.4a)
A solution of 6-anilino-3-methyluracil (2.4a) (2.0 g, 9.2 mmol) in methanol and 
acetic acid (1:4, 1500 ml) was cooled to -7° in an ice salt/ethanol bath. A solution of 
bromine (1.8 g, 11 mmol) in acetic acid (30 ml) was added at once to the cold solution 
and stirred for 20 min. The reaction mixture was allowed to come to room temperature 
over 2 hrs and the solution was evaporated to dryness under vacuum. The residue was 
recrystallized from ethanol to give the title compound (4.4a) (1.9 g, 69%) mp 243°. 
(Found: C, 44.9; H, 3.5; N, 14.1. C n H i0BrN3O2 requires C, 44.6; H, 3.4; N, 
14.2%). !H n.m.r. (CD3SOCD3) 8 3.13, s, CH3N; 7.20-7.34, m, C6H5; 8.63, s, NH.
5 -Brom o-6-(4'-brom oanilino)-3-m ethyluracil (4.4c)
When 6-anilino-3-methyluracil (2.4a) (1.8 g, 8.3 mmol) was treated as for 4.4a 
above, except that the reaction was kept at 0°, the crude product was seen (*H n.m.r.) to 
contain a mixture of starting material (2.4a), 6-anilino-5-bromo-3-methyluracil (4.4a) 
and the title compound (4.4c). Recrystallization of this crude material from ethanol gave 
the title compound (4.4c) (0.5 g, 16%) mp 222°. (Found: C, 35.1; H, 2.6; N, 10.9. 
C iiH 9Br2N302 requires C, 35.2; H, 2.4; N, 11.2%). *H n.m.r. (CD3SOCD3) 5 3.13, 
s, CH3N; 7.09, d, 7.50, d, J2’,3' 9 Hz, H 2’, 3’, 5’, 6 '; 8.71, s, NH.
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6-A n ilino -5 -(3 ',4 ,-d im ethylanilino)-3-m ethyluracil (4.5a)
A mixture of 6-anilino-5-bromo-3-methyluracil (4.4a) (1.0 g, 3.4 mmol) and 
3,4-dime thy laniline (4.1 g, 34 mmol) in dimethyl sulfoxide (20 ml) was stirred at room 
temperature for 17 hrs. The solution was poured into cold 0.5 M hydrochloric acid 
(100 ml) and stirred for 20 min. The crystalline mass was filtered off, washed with ether 
(200 ml) and recrystallized from ethanol to give the title compound (4.5a) (1.0 g, 84%) 
mp 228°. (Found: C, 67.6; H, 6.0; N, 16.5. C19H20N4O2 requires C, 67.8; H, 6.0; N, 
16.7%). *H n.m.r. (CD3SOCD3) 5 2.06, s, (CH3)2C6H3; 3.10, s, CH3N; 6.12, s, NH; 
6.28-6.83, complex, (CH3)2CöH3; 7.14-7.40, m, C6H5; 8.35, s, NH.
3,7,8-Trimethyl-10-phenyIflavin (4.2d)
The title compound was prepared by a similar method to that of Sako et al. [62]. 
The *H n.m.r. spectrum of the crude material indicated the presence of only the 7,8- 
dimethyl isomer. The crude material (0.79 g) was recrystallized from acetic acid to give 
the title compound (4.2d) (0.52 g, 37%) dec 330° (lit mp >300° [62]). (Found: C, 69.0; 
H, 4.6; N, 16.7. C19H 16N4O2 requires C, 68.7; H, 4.9; N 16.9%). *H n.m.r. data are 
presented in Table 4-1 (pg 83).
10-(4 '-C hlorophenyl)-3,7,8‘trim ethylflavin  (4.2a)
A solution of 6-(4'-chloroanilino)-5-(3",4"-dimethylanilino)-3-methyluracil 
(4.5b) (1.1 g, 3 mmol) in dimethylformamide (30 ml) was heated at 120° for 2 hrs under 
oxygen. The solution was cooled and diluted with ether (100 ml) and the resulting 
yellow crystals were filtered off. The *H n.m.r. spectrum of the crude material indicated 
the presence of both the 7,8-dimethyl and 8,9-dimethyl isomers. The crude material 
(0.3 g) was recrystallized from acetic acid and then dimethylformamide to give the title 
compound (4.2a) (0.1 g, 9%) dec 330°. (Found: C 62.0; H, 4.1; N, 15.4. 
C19H15CIN4O2 requires C, 62.2; H, 4.1; N, 15.3%). n.m.r. data are presented in 
Table 4-1 (pg 83).
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7-(4f-Chlorophenyl)purine  (4.7)
A solution of 4'-chloroanilinoacetonitrile [142,143] (3.3 g, 20 mmol), 
formamidine acetate [165] (15.6 g, 150 mmol) and 1-butanol (20 ml) was refluxed for 
5 hrs. The butanol was distilled off under reduced pressure and the residue taken up in a 
mixture of chloroform (50 ml) and water (50 ml). The aqueous fraction was separated 
and extracted with chloroform (2 x 20 ml). The chloroform extracts were combined, 
dried (Na2S04), filtered and evaporated to dryness. The residue was washed with ether 
(100 ml) and allowed to air dry. The dry residue was sublimed at 220-240° (1 mm Hg) to 
give white crystals of the title compound (4.7) (2.4 g, 52%) mp 223°. (Found: C, 56.9; 
H, 3.0; N, 24.1. C11H7CIN4 requires C, 57.3; H, 3.1; N, 24.3%). lK  n.m.r. (CDCI3)
5 7.49, d, 7.65, d, J2->3- 8.8 Hz, H 2’, 3', 5’, 6'; 8.44, s, 9.04, s, 9.22, s, H 2, 6, 8.
4-Amino-5-(4,-chloroanilino)pyrimidine (4.8)
A suspension of 7-(4'-chlorophenyl)purine (4.7) (2 g, 8.7 mmol) in 0.5 M 
sodium hydroxide (80 ml) was refluxed for 10 min. The precipitate was filtered off and 
recrystallized from ether to give the title compound (4.8) (1.7 g, 89%) mp 204°. (Found: 
C, 54.7; H, 4.1; N, 25.4. C10H9CIN4 requires C, 54.4; H, 4.1; N, 25.4%). lH n.m.r. 
(CD3SOCD3) 5 6.70, d, 7.18, d, J2’,3’ 8.8 Hz, H 2\ 3’, 5', 6’; 7.40, s, NH; 8.00, s, 
8.18, s, H 2, 6.
10-(4r-Chlorophenyl)-3-methyl-6,8-diazaflavin  (4.9)
A mixture of 4-amino-5-(4'-chloroanilino)pyrimidine (4.8) (1.7 g, 7.7 mmol), 
N-methylalloxan [144] (1.5 g, 7.8 mmol), boric acid (0.6 g, 9.7 mmol) and acetic acid 
(130 ml) was heated and stirred at 60° for 30 min. After cooling, the solvent was 
removed under vacuum to give a dark syrup. The syrup was redissolved in acetic acid 
(20 ml) and diluted with ether (50 ml), the resulting precipitate was filtered off and 
recrystallized from isopropanol to give the title compound (4.9) (0.4 g, 15%) dec 298°. 
(Found: C, 53.3; H, 3.1; N, 24.3. C i5H9C1N60 2 requires C, 52.9; H, 2.7; N, 24.7%). 
m/z (rel. int.) 342 (15), 341 (26), 340 M (27), 339 (67), 283 (18), 255 (56). MSC1 m/z
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(rel. int.) 345 (36), 344 (25), 343 (100), 342 (26), 231 (24). *H n.m.r. (CDC13) 5 3.47, 
s, CH3N; 7.34, d, 7.70, d, J2',3' 8.6 Hz, H 2’, 3', 5’, 6’; 8.64, s, 9.35, s, H 7, 9.
5-Amino-6-(4f-chloroanilino)-3-methyluracil (5.2 a)
To a stirred cooled solution of 6-(4'-chloroanilino)-3-methyluracil (2.4o) (7.7 g, 
30 mmol) in trifluoroacetic acid (50 ml) was added a sodium nitrite solution (3.2 g,
46 mmol) in water (20 ml) dropwise over 15 min. After stirring for an additional 10 min 
the resulting 6-(4'-chloroanilino)-3-methyl-5-nitrosouracil trifluoroacetic acid salt was 
filtered off, washed with ether, dried, pulverized and suspended in a solution of 1 M 
sodium hydroxide and methanol (4:1, 250 ml). Sodium dithionite was added with 
stirring until the suspension's red colour disappeared. The product was filtered off, 
washed with water and ether, and recrystallized from methanol to give the title compound 
(5.2a) as a white powder (4.6 g, 56%) mp 230-232°. (Found: C, 49.6; H, 4.2; N,
20.9. C11H11C1N40 2 requires C, 49.5; H, 4.2; N, 21.0%). m/z (rel. int.) 268 (32),
267 (15), 266 M (100), 154 (16), 138 (26). *H n.m.r. (CD3SOCD3) 5 3.15, s, CH3N; 
6.80, d, 7.25, d, J2-,3’ 8.9 Hz, H 2’, 3', 5’, 6'.
5-Amino-6-(3,,5'-dimethylanilino)-3‘methyluracil (5.2b)
6-(3',5'-Dimethylanilino)-3-methyluracil (2.4g) (7.35 g, 30 mmol) was treated 
as for 5.2a above to give the title compound (5.2b) (5.2 g, crude yield 67%).
3,6,8-T rim ethylbenzo[g]pteridine-2,4(l/7 ,3/0-dione (5.4)
(A) Recrystallization of crude 5-amino-6-(3',5'-dimethylanilino)-3-methyluracil 
(5.2b) (0.5 g, 2 mmol) from methanol gave 3,6,8-trimethylbenzo[g]pteridine- 
2,4(l//,3//)-dione (5.4) (0.3 g, 60%) mp 310-312° (lit mp 295-298° [160]). (Found:
C, 61.2; H, 5.0; N, 21.9. C13H12N40 2 requires C, 60.9; H, 4.7; N, 21.9%). m/z (rel. 
int.) 257 (15), 256 M (100), 199 (20), 171 (40), 156 (19). *H n.m.r. (CD3SOCD3)
5 2.51, s, 2.70, s, 6-, 8-CH3; 3.30, s, CH3N; 7.47, s, 7.51, s, H 7, 9.
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(B) Sodium nitrite solution (1.7 g, 25 mmol) in water (10 ml) was added to a hot 
(100°) stirred solution of 6-(3',5'-dimethylanilino)-3-methyluracil (2.4g) (1.2 g,
5 mmol) in acetic acid (50 ml); the mixture went fleetingly red before becoming yellow. 
On cooling crystals formed, which were filtered off, and washed with water and 
methanol. Recrystallization from acetic acid gave light yellow crystals of the title 
compound (5.4) (0.9 g, 70%) identical with the compound from (A) above by mp, mass 
spectrum and *H n.m.r. comparison (Found: C, 60.8; H, 5.0; N, 21.8).
8-(4 '-C hlorophenyl)-3-m ethylpteridine-2,4(3¥L,8H )-dione  (5.3a)
A glyoxal solution (1 g of 30% glyoxal solution, 5.6 mmol) in methanol (10 ml) 
was added to a suspension of 5-amino-6-(4'-chloroanilino)-3-methyluracil (5.2a) (1.5 g, 
5.6 mmol) in water (50 ml); after briefly stirring at room temperature the mixture was 
refluxed for 30 min. After crystallization was complete the solid was filtered off, washed 
with ether, and recrystallized from acetic acid to give yellow crystals of the title 
compound (5.3a) (0.75 g, 46%) dec 333°. (Found: C, 54.1; H, 3.2; N, 19.3. 
C13H9C1N40 2 requires C, 54.1; H, 3.1; N, 19.4%). m/z (rel. int.) 289 (9), 288 M (35),
287 (28), 286 (100), 230 (34), 202 (27). ^  n.m.r. data are presented in Table 5-1 
(pg 92o).
8 -(3 r,5 '-D im ethylphenyl)-3-m ethylp terid ine-2 ,4(3H ,8K )-d ione  (5 .3b)
5-Amino-6-(3',5,-dimethylanilino)-3-methyluracil (5.2b) (1.5 g, 5.6 mmol) was 
treated as for 5.3a above. The product was recrystallized from 70% ethanol to give 
brown orange crystals of the title compound (5.3b) (0.25 g, 16%) dec 280°. (Found:
C, 64.1; H, 5.0; N, 20.1. C15H 14N40 2 requires C, 63.8; H, 5.0; N, 19.9%). m/z (rel.
int.) 282 M (53), 281 (100), 267 (73), 225 (46), 224 (54), 210 (50), 197 (43), 196 (55). 
*H n.m.r. data are presented in Table 5-1 (pg 92o).
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8-(4 f-Chlorophenyl)-3,6,7-trimethylpteridine-2,4(3ll,8l l)-dione  (5.3c) 
Biacetyl (0.5 g, 5.6 mmol) in methanol (10 ml) was added to a suspension of 
5-amino-6-(4'-chloroanilino)-3-methyluracil (5.2a) (1.5 g, 5.6 mmol) in water (50 ml) 
and was refluxed for 1 hr. After crystallization was complete the solid was filtered off, 
washed with water and then ether, and recrystallized from methanol to give yellow 
crystals of the title compound (5.3c) (0.5 g, 28%) dec 261-263°. (Found: C, 56.6; H, 
4.1; N, 17.6. C15H13C1N40 2 requires C, 56.9; H, 4.1; N, 17.7%). m/z (rel. int.) 318
(18), 317 (39), 316 M (59), 315 (100), 258 (18), 231 (23). n.m.r. data are presented 
in Table 5-1 (pg 92o).
8-(3', 5 f-Dimethylphenyl)-3,6,7-trimethylpteridine-2,4(3H,8YL)- 
dione  (5 .3d )
5-Amino-6-(3',5'-dimethylanilino)-3-methyluracil (5.2b) (1.5 g, 5.6 mmol) was 
treated as for 5.3c above. The product was recrystallized from 70% ethanol to give 
brown orange crystals of the title compound (5.3d) (0.3 g, 17%) dec 280°. (Found: C, 
65.8; H, 6.0; N, 18.3. C17HlgN40 2 requires C, 65.8; H, 5.9; N, 18.1%). m/z (rel.
int.) 310 M (88), 309 (100), 295 (36), 253 (15), 252 (16), 238 (10), 225 (17), 224 (21). 
!H n.m.r. data are presented in Table 5-1 (pg 92o).
8-(4'-Chlorophenyl)-3-methyl-6,7-diphenylpteridine-2,4(3l{,8l{)-  
dione (5.3e)
A solution of benzil (1.3 g, 6 mmol) in methanol (30 ml) was added to 
5-amino-6-(4'-chloroanilino)-3-methyluracil (5.2a) (1.5 g, 5.6 mmol) in 50% 
acetic acid (50 ml), and refluxed for 2 hrs. After crystallization was complete the 
solid was filtered off, washed with water and then ether, and recrystallized from 
70% ethanol to give bright yellow crystals of the title compound (5.3e) (1.3 g,
49%) mp 313-314°. (Found: C, 67.9; H, 3.9; N, 12.8. C25H17C1N40 2 requires
C, 68.1; H, 3.9; N, 12.7%). m/z (rel. int.) 441 (16), 440 M (43), 439 (51), 438 
(100), 353 (24). lH n.m.r. data are presented in Table 5-1 (pg 92o).
8-(3' , 5 ’-Dimethylphenyl)-3-methyl-6,7-diphenylpteridine-  
2,4(3H,8H)-dione  (5.3f)
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5-Amino-6-(3',5’-dimethylanilino)-3-methyluracil (5.2b) (1.6 g, 6 mmol) was 
treated as for 5.3e above. The product was recrystallized from 70% ethanol to give 
bright yellow crystals of the title compound (5.3f) (0.6 g, 24%) mp 331-333°. (Found: 
C, 75.0; H, 5.1; N, 12.8. requires C, 74.6; H, 5.1; N, 12.9%). m/z (rel.
int.) 434 M (65), 433 (100), 419 (21), 349 (11), 348 (33). *H n.m.r. data are presented 
in Table 5-1 (pg 92o).
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7-3 Biological activity experimental
7-3.1 Biological evaluation of antimalarial activity
(i) Antimalarial activity in vivo testing
Experimental animals
Female CBA/CaH mice (6-8 weeks old) were used in all experiments. These 
were bred and maintained in the John Curtin School of Medical Research Animal 
Breeding Establishment (under specific pathogen free conditions) and fed normal 
laboratory diet pellets and tap water ad libitum. Mice were usually put into groups of 4 to 
6 animals in which the weight range was no greater than 1 g.
Parasite
Plasmodium vinckei subsp. vinckei (originally from Dr D. Walliker, Institute of 
Animal Genetics, Edinburgh) was stored frozen in liquid nitrogen and had been passaged 
several times before experimental use in CBA/CaH mice. All infections were initiated by 
intraperitoneal injection of 1 x 106 or 1 x 105 parasitized erythrocytes in sterile saline to 
provide infected mice (15-35% parasitemia) in 5 or 6 days time, respectively. The 
percentage parasitemia was monitored by thin blood smears taken from the tail vein and 
stained with Diff-Quik stain (Australian Hospital Supply, Sydney) and examined under 
oil immersion microscopy. Counts of parasitized red blood cells were determined in 
microscopic fields with approximately 200 cells per field in which there were few 
overlapping erythrocytes.
Drug treatment
Purified drugs were ground to a fine powder using an agate mortar and pestle. If 
the compound failed to give a well separated fine powder at this stage it was put through a 
sieve (0.15 mm screen).
The doses given were calculated on the average weight of the group (when the 
weight range of the group was less than 1 g, otherwise the dose was based on the weight 
of individual mice). Test compounds were then evenly suspended in olive oil using a
130
vortex mixer immediately prior to injection. Compounds were administered as a single 
100 (il (or 200 |il in cases where the dose was greater than 70 mg/kg) intraperitoneal 
injection when parasitemias were between 15 and 35%. Glass syringes (1 ml) and 23 
gauge needles were used to prevent clogging of the suspension during injection.
In control mice treated with olive oil alone, parasitemias rose to 40-60% one day 
post treatment and to 70-90% after 2 days. Death inevitably occurred on day 3.
The efficacy of the compounds tested was determined by the percentage of the 
animals in the group cured, the mean extension in lifespan and the percentage parasitemia 
two days after treatment (or 1 day after treatment if death occurred before day 2).
(ii) In vitro inhibition of P. falciparum  growth
(a) Method 1
This method was used in collaboration with Dr G. A. Butcher. It was similar to 
that quoted in reference [41]. A brief description of the method including differences 
from the referenced method are outlined below.
Parasites
A Papua New Guinea strain of P. falciparum (FC-27) isolated at the Walter and 
Eliza Hall Institute, Melbourne, and maintained in continuous culture by Dr G. A. 
Butcher [41,166] (Department of Pure and Applied Biology, Imperial College, Prince 
Consort Rd, London, SW7 2BB) was used. Parasites were maintained using group O 
erythrocytes at a hematocrit of 5%.
Media
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Complete medium: The complete medium was RPMI 1640 supplemented with 
25 mM HEPES (N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]), 26 mM 
sodium bicarbonate and 100 ng/ml gentamicin.
Culturing medium: Complete medium was supplemented with 10% (v/v) heat- 
inactivated human group O blood semm to produce normal culturing medium.
Drug preparation
The insolubility of the flavins required that they were first dissolved in dimethyl 
sulfoxide to obtain a stock solution which was diluted with complete medium 
supplemented with 40% (v/v) group O blood serum (the high serum concentration 
facilitated the solubilization of the drugs). A four fold dilution with complete medium 
gave culturing media with the highest drug concentration. Dilution of this with normal 
culturing medium gave the range of drug concentrations required for the assay.
Drug preparation was always carried out on the same day as the assay was begun. 
All drug treated culturing media were passed through millipore filters (0.22 pm) for 
sterilization and to ensure that all the test compounds were in solution.
Preparation and processing of microtiter plates
The drug treated culturing medium (100 p.1) was added in triplicate to the flat 
bottom wells of 96-well microtiter plates (Nunc). Control wells consisted of 100 pi of 
culturing medium containing equivalent volumes of dimethyl sulfoxide (max 0.25% v/v). 
This was followed by the addition of 1 p.1 of parasitized erythrocytes (0.5% - 5% 
parasitemia, asynchronous parasites) and 20 p.1 of 3H-hydroxanthine (1:100 dilution of 
1 mCi/ml, 2.8 Ci/mmol, Amersham, Australia) in RPMI as a combined mixture (21 p.1) to 
all wells. The final drug concentration range in the wells was 1-20 p.M.
The microtiter plates were incubated for 48 hours in the gas mixture 5% CO2,
5% 0 2, 90% N2 at 37°.
At the end of incubation the cells were harvested onto filters with a semi- 
automated cell harvester using distilled water as the washing fluid. The filters were then
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counted by liquid scintillation to determine the incorporation of 3H-hypoxanthine into the 
nucleic acid of the parasites.
(b) Method 2
This method, used by Dr K. A. Rockett, is similar to that quoted in reference 
[167]. A brief description of the method and the differences from the referenced method 
are outlined below.
Parasites
The strains of P. falciparum used were FC-27 as in method 1 and the multi-drug 
resistant K-l strain (a generous gift from Dr K. H. Rieckmann, Army Malaria Research 
Unit, Milpo, Inglebum, NSW, 2174, Australia) isolated in Bangkok, Thailand, and 
originating from Kanchanaburi, Thailand [168]. Parasites were maintained using 
group A+ erythrocytes at a hematocrit of 5%.
Media
As in method 1.
Drug preparation
Flavins were made up as stock solutions in dimethyl sulfoxide. Dilution of the 
stock solution followed by serial dilution with culturing media gave the desired 
concentrations of drug treated culturing media.
The antimalarials, chloroquine, pyrimethamine and quinine were dissolved in 
culturing media to the appropriate dilution and likewise serially diluted.
Preparation and processing of microtiter plates
To triplicate wells in 96-well microtiter plates were added 50 jil of each dilution of 
the drug treated culturing medium followed by the addition of another 50 pil culturing 
medium containing synchronized parasitized cells (at ring stage) adjusted to a parasitemia
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of between 0.5 and 1.0% at a hematocrit of 5%. The concentration range tested for 
flavins against the FC-27 strain was 0.756-48.4 jiM (in 4-fold dilution intervals) and 
against the K-l strain was 0.756-96.8 fiM (in 2-fold dilution intervals). The other 
antimalarials were tested in the concentration range 0.001 to 100 (iM. Controls consisted 
of wells treated with normal culturing medium and infected erythrocytes (100% control) 
or with normal culturing medium and non-infected erythrocytes (0% control). It had been 
previously shown that dimethyl sulfoxide at the concentration (max 0.2% v/v) used had 
no effect on parasite growth.
The plates were incubated under the same conditions as in method 1 for 24 hrs 
when 3H-hypoxanthine (0.4 p.Ci per well) was added to each well. After a further 24 hrs 
of incubation, the plates were treated as in method 1.
7-3.2 Antibabesial screen in mice
Experimental animals
The same as used in section 7-3. l(i).
Parasite
Babesia microti (King strain originally from Dr F. E. G. Cox, King’s College, 
London) was stored frozen in liquid nitrogen and had been passaged several times in 
CB A/CaH mice before experimental use. Infections were initiated by intraperitoneal 
injection of 1 x 107 parasitized erythrocytes in sterile saline and became patent 3 days 
later. The percentage parasitemia was monitored by tail vein thin blood smears stained 
with Giemsa's stain and examined under oil immersion microscopy. Parasitemias were 
expressed as the percentage of erythrocytes infected.
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Drug treatment
The test compounds were prepared and injected as described in section 7-3.1 (i). 
Four groups of mice were treated as follows:
Control group - Olive oil (100 pil) was injected daily for 5 days starting on day 3 after 
inoculation;
Group 1-15 Mg/kg of 10-(3',5’-dichlorophenyl)-3-methylflavin (2.5s) in olive oil 
(100 |il) was injected daily for 5 days starting on day 3 after inoculation;
Group 2 - 5  Mg/kg of 10-(3',5'-dichlorophenyl)-3-methylflavin (2.5s) in olive oil
(100 fil) was injected daily for 5 days starting on day 3 after inoculation; and 
Group 3 - 1 0  Mg/kg of 10-(4'-chlorophenyl)-3-methylflavin (2.5o) in olive oil (100 |il) 
was injected daily for 4 days starting on day 3 after inoculation. Only four 
injections were given to this group as signs of toxicity were noted after the 
fourth injection.
The course of the disease was monitored by daily blood smears for 10 days after 
the first injections.
7-3.3 Anticoccidial screen in mice
The testing of 3-ethyl-10-(3'-trifluoromethylphenyl)flavin (3.4h) against the 
Coccidia species, Eimeria vermiformis, a species of rodent Eimeria, was kindly carried 
out by Mr C. Reiger and Dr K. Ovington (Department of Zoology, The Australian 
National University, Canberra, ACT, 2601, Australia). Female C57/BL6 mice weighting 
approximately 18 g were infected orally with 1 x 103 oocysts. The infection was 
monitored by daily determinations of the numbers of oocysts present in the total faecal 
output of individual mice. Methods used for routine maintenance of the parasite, 
infection with oocysts and counting of oocysts were the same as those described by 
Rose, Owen and Hesketh [169]. Infections became patent on the seventh day after 
infection and continued for a further seven days.
To test for anticoccidial activity eight mice were fed a daily ration of 3 g of 
laboratory diet pellets into which the test compound was incorporated at a level of
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150 ppm. Treatment began on the day of infection and continued until day 14, excepting 
days 9 and 13 on which the mice were fed untreated food because of apparent signs of 
toxicity. The control group of 6 mice were also fed a daily ration of 3 g laboratory diet 
pellets, identical to the treated pellets except for the incorporated test compound. Both 
groups were given tap water ad libitum.
At the end of the experiment animals were kept for 7 days during which time no 
adverse effects were noted.
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